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Abstract 
 
This thesis critically evaluates the measurement of outcomes in economic evaluations of drug 
misuse interventions. Three different aspects of measuring outcomes are examined: one 
focusing on non-monetary outcomes at the individual patient level; one focusing on monetary 
outcomes within studies using individual patient level data; and one focusing on long-term 
outcomes, both monetary and non-monetary. The many limitations of measuring these 
outcomes in existing economic evaluations of drug misuse interventions are exposed and the 
problems with conducting such studies are identified. The importance of this thesis is thus in 
providing an overview and methodological critique of the extant economic evaluations of 
drug misuse interventions. In addition a decision analytic model for a drug testing in schools 
programme is developed to illustrate how the limitations highlighted in the methodological 
critique might be addressed by future research.  
 
The findings of the thesis reveal the problems with using EQ-5D as a generic outcome 
measure for economic evaluations of drug misuse interventions, as is recommended by NICE 
in the UK. The nature of drug misuse problems requires that a wide range of different 
measures, including drug misuse specific measures, must be taken into account when 
evaluating drug misuse interventions. Similarly, the limitations with existing studies that 
attempt to estimate the monetary outcome of drug misuse interventions are exposed, as many 
studies fail to take into account all of the costs that will determine the monetary impact of an 
intervention for society. The thesis stresses the complexity of drug misuse and the need to 
measure the long-term outcomes of interventions, which may be best achieved by developing 
drug misuse modelling studies. However, these models are then revealed to be themselves 
limited, in part due to the lack of real-world data available to set their parameters. 
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Chapter 1 Introduction 
 
1.1 Outcomes of drug misuse interventions 
 
Over the last few centuries, drug misuse has affected both individuals and society. For 
instance, problems related to opium addiction have been recorded in Europe, Africa, and 
Asia since the sixteenth century (Brownstein, 1993). Heroin smoking began in Shanghai in 
the 1920s and gradually spread through Asia and Europe in the 1960s and 1970s (Strang et al, 
1997).  
 
In many countries drug misuse is criminalised, such as in America where it has been 
considered as a criminal offence since the Harrison Act of 1914 (King, 1953). However, 
more recent developments in the drug misuse policies of some countries, like Portugal, have 
resulted in drug misuse being considered as a chronic health condition and therefore, instead 
of being met with criminal proceedings, drug users are referred to related treatments (van het 
Loo, van Beusekom and Kahan, 2002).  
 
Regardless of whether or not drug misuse is illegal, it involves a complex of problems which 
are related to the patients, their family and friends, as well as other people in society. Drug 
misuse is more complex than other chronic diseases and the evaluation of drug misuse 
interventions usually includes multi-dimensional outcomes.  
 
In the review by Rehm and colleagues (2000), the effectiveness of drug misuse treatment is 
categorised in 3 major dimensions: the continuation of drug misuse; improvement of medical 
condition; and social integration. Similarly, the review by Connock and colleagues (2007) 
also includes a wide range of outcomes among the opioid dependent patients: drug use, 
health of drug user, social effects and crime. The drug use outcome covers areas like changes 
in illicit drug use, concordance and retention in treatment, while the health of drug user 
outcome covers drug related mortality and morbidity, health related quality of life, use of 
health care systems and the major adverse effects of treatment. The social effects outcome 
covers problems related to employment and the family, and the crime outcome covers crime 
rates and recidivism (Connock et al, 2007). Another review of the treatment among the 
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opioid addicts includes categories like retention in treatment, use of primary substance, 
follow-up completion rate, compliance, craving, psychiatric symptoms, quality of life and 
severity of dependence (Amato et al, 2008).  
 
In many countries economic evaluations are central to the decision making process for policy 
makers. The study by Ross (1995) shows that decision makers in Australia are highly aware 
of economic evaluations and some have taken these into consideration during the decision 
making process. Similarly, one study shows that economic evaluations have increasing 
potential use for decision makers in the UK (Drummond, Cooke, and Walley, 1997; 
Drummond, Jonsson and Rutten, 1997). Furthermore, in the UK, the guideline of NICE 
(National Institute for Clinical Excellence) requires that technology assessments include 
analysis of the cost-effectiveness of the health interventions (NICE, 2008; Claxton, Sculpher 
and Drummond, 2002). 
 
In an economic evaluation there are a number of different methods that may be used to 
evaluate the interventions. The outcomes of the intervention may be measured in the form of 
a natural unit like reduction of blood pressure in a cost-effectiveness analysis, or a measure 
of health related utility, such as quality-adjusted life years (QALYs) in a cost-utility analysis. 
The outcomes can also be measured in the monetary unit of a cost-benefit analysis, such as 
willingness-to-pay (Drummond, M.F. et al, 2005), and there are more general outcomes 
measured in monetary terms that apply to all types of economic evaluations such as the 
savings in social resources following the intervention. 
 
When carrying out economic evaluations certain choices have to be made about which 
outcomes are measured and this depends on the perspective from which the research is 
carried out. The decision regarding which outcomes to include usually depends on the 
interests of those undertaking the research, or the funding body, or the policy makers. For 
policy makers, the decision regarding which outcomes to include in an economic evaluation 
depends on their perspective. Claxton and colleagues (2010) have shown that policy makers 
in different countries have adopted different perspectives when making health policy. In the 
UK, health policies are based on the NHS perspective and are mainly determined by the 
effects on individuals’ health after receiving treatment (Claxton et al, 2010). The new 
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guidelines of NICE require that QALYs should be the main health outcome measured in 
economic evaluations and EQ-5D is their preferred quality-of life questionnaire (NICE, 
2008).  
 
Following the guidelines set out by NICE, the policy makers for drug misuse interventions 
within the NHS in the UK would focus on the economic evaluation of the health related 
outcome when making decisions. However, reviews of outcomes of drug misuse 
interventions show that drug misuse is a problem related to multi-dimensional outcomes 
(Rehm, Guggenbuhl and Uchtenhagen, 2000; Connock et al, 2007; Amato et al, 2008). By 
only using EQ-5D to estimate the outcomes of drug misuse interventions, as NICE suggests, 
policy makers could misjudge the effectiveness of the interventions. There is very little 
literature and research that examines the relationship between EQ-5D and other non-
monetary outcomes in drug misuse interventions, and analyses whether or not there are 
problems with only using EQ-5D as the single measure in economic evaluations of drug 
misuse interventions. The first part of this thesis will therefore analyse the relationship 
between EQ-5D and other non-monetary outcomes in economic evaluations of drug misuse 
interventions. 
 
The non-monetary outcome is only one aspect of the economic evaluation of drug misuse 
interventions. It is also important to consider the monetary outcome and to know which 
dimensions of this outcome should be measured. In a report to the NHS Health Development 
Agency, Kelly and colleagues (2005) suggest that the monetary outcome can be presented as 
the difference of the resources used or of the resources saved. The difference of the resources 
used shows the cost of the resources that the patient have used as a result of the intervention, 
whereas the difference of resources saved estimates the savings to society from the patient 
having received the intervention. 
 
It is especially important to estimate the societal cost of drug misuse interventions given that 
drug misuse is usually regarded as being closely related to the social resource use, 
particularly with respect to the criminal justice system and the health burden of hepatitis and 
HIV (Cartwright, 1998; Cartwright, 2008; Garfein et al, 1996; Godfrey, 2006; Hser and 
Anglin, 1991; Joseph, 1988; Mark et al, 2001; Masson et al, 2002; Neale et al, 2006; 
 16 
Sweeney et al, 2009; Wiessing et al, 2004). Although different outcome categories have been 
developed (Godfrey, 2006; Simoens et al, 2006; McCollister and French, 2003), there are 
only a few common methods for estimating the monetary benefit within these categories. 
 
Another issue related to the monetary outcome is that it is usually presented as the sum of the 
different resources used. However, it may be that certain types of patients have higher costs 
with respect to one resource (such as health cost) and less with respect to another (such as the 
cost of crime committed). By only presenting the sum of the resource used this information is 
lost, yet identifying the specific relationship between the types of drug users and the 
resources they use may help policy makers to make decisions about the allocation of 
resources. However, very few studies have analysed these relationships. The second part of 
the thesis therefore reviews the dimensions of the monetary outcome considered in existing 
drug misuse intervention studies and explores the relationship between specific drug user 
characteristics and the different dimensions of the monetary outcome. 
 
One of the problems with clinical trials is that they usually only last for a limited period of 
time and the follow-up period of the intervention is rarely longer than 2 years. When 
comparing the different interventions, NICE has recommended that the appropriate time 
horizon should reflect the period when the participants are expected to experience the main 
differences arising from the intervention. Accordingly, if the intervention has long-term 
effects, it may be necessary to consider the different outcomes over the course of the 
patients’ lifetimes (NICE, 2008). However, the time and resources required to do this are 
usually unavailable for clinical trials. 
 
An alternative approach for considering the long-term outcomes of drug misuse interventions 
is by using decision analytic models, which are developed to synthesize the costs and the 
outcomes of the interventions (Buxton et al, 1997). However, only a few economic 
evaluation studies have developed modelling methods to estimate the simulation of lifetime 
costs and outcomes for drug misuse patients (French and Drummond, 2005; Zarkin et al, 
2005). The third part of this thesis will therefore compare the current modelling methods for 
drug misuse and develop a new model for evaluating a drug misuse intervention. 
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1.2 Purpose and objectives of the research  
 
The aim of this thesis is to explore the problems with measuring outcomes in economic 
evaluations of drug misuse interventions and the implications for policy makers. In doing so 
the thesis provides an overview of current economic evaluations in drug misuse research and 
an agenda for related studies in the future. There are 3 primary objectives of the research. 
The first is to explore the relationship between EQ-5D (a measure of QALYs) and other non-
monetary outcome measures. This involves examining whether or not the outcome of EQ-5D 
reflects the trends of the outcomes in other drug misuse specific measures, and considering 
whether EQ-5D covers the same content as the other measures. 
 
The second objective is to evaluate the dimensions of the monetary outcome that have been 
considered in existing drug misuse intervention studies. This involves examining whether or 
not previous economic evaluations have measured all of the relevant dimensions of the 
monetary outcome and whether specific relationships can be identified between patient 
characteristics and associated dimensions of the monetary outcome. While the first two 
objectives examine the individual patient level outcomes, the third objective is to explore the 
use of modelling studies for the economic evaluation of drug misuse interventions. This 
involves reviewing the existing models to reveal their limitations and building a new model 
that attempts to overcome many of the problems with existing studies identified throughout 
the thesis. 
 
This thesis will demonstrate that the complexity of drug misuse problems demands that a 
wide range of both monetary and non-monetary outcomes should be considered to provide a 
comprehensive evaluation of drug misuse interventions from the societal perspective. 
Furthermore, it will be maintained that these outcomes need to be measured over long time 
periods to estimate the overall societal impact of drug misuse interventions. By exposing the 
limitations with existing economic evaluation studies, the problems that policy makers need 
to be aware of and that future researchers need to address will be elucidated.    
 
1.3 Structure of thesis 
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1.3.1 Non-monetary outcome measures 
 
To meet these 3 objectives, the thesis consists of 6 interrelated chapters, with 2 chapters 
dedicated to each objective. As NICE (2008) in the UK recommends using EQ-5D as a 
generic outcome measure for economic evaluations of health interventions, the first 2 
chapters analyse the adequacy of this measure for drug misuse interventions through a 
systematic review and then a secondary data analysis of existing studies. Chapter 2 first 
identifies the existing drug misuse intervention studies that have considered both EQ-5D and 
another non-monetary outcome and then evaluates whether or not the outcome of EQ-5D 
reflects the trends of the outcomes of the other measures. If EQ-5D adequately reflects the 
trends of other measures then it may be appropriate to use it as a generic measure in 
economic evaluations, without considering drug misuse specific measures. This would be 
advantageous for policy makers as drug misuse interventions could then be evaluated using 
the same measure that is recommended more generally for all economic evaluations of health 
interventions. However, if EQ-5D does not have the same trends as other measures, then 
using it as the only measure may lead to policy makers misjudging the effects of a given drug 
misuse intervention. 
 
It is not only the trends of the outcomes between EQ-5D and other measures that needs to be 
considered, however, as it is also important to know whether EQ-5D and other non-monetary 
outcome measures cover the same concepts. That is, whether or not the questionnaires used 
in other outcome measures cover similar content to that of EQ-5D. Chapter 3 thus conducts a 
content comparison of the drug intervention studies that consider both EQ-5D and other 
outcome measures. If they cover similar concepts then it may be appropriate to use EQ-5D as 
a single outcome measure for drug misuse intervention studies, however, if this is not the 
case then a wider range of measures should be taken into account. 
 
1.3.2 Dimensions of the monetary outcome 
 
Chapters 4 and 5 evaluate the dimensions of the monetary outcome measured in existing drug 
misuse intervention studies, again through a systematic review and then an empirical analysis. 
Chapter 4 reviews existing drug misuse intervention studies that have measured dimensions 
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of the monetary outcome. The chapter follows Godfrey (2006) in categorising the dimensions 
that it is important to consider into 2 domains and then examining whether the studies that 
claim to provide a societal perspective actually consider all the relevant dimensions of these 
domains. Given that drug misuse is associated with a range of social problems it is important 
to know whether existing economic evaluations actually consider all the monetary 
dimensions that would influence the societal impact of an intervention. 
 
Chapter 5 proceeds to examine whether or not a profile can be developed of different types of 
drug misuse patient. If relationships could be identified between patient characteristics and 
the monetary dimensions that specific patients use then policy makers could take this into 
consideration and direct different interventions at different groups of drug misuse patients. 
To attempt to develop this profile the chapter uses an existing data sample, RESULT 
(Raistrick et al, 2007). The data is clustered into groups, which are then analysed to try to 
identify relationships between patient characteristics and different dimensions of the 
monetary outcome, or even just between different monetary dimensions. 
 
1.3.3 Modelling studies 
 
Chapters 6 and 7 focus on modelling studies in the economic evaluation of drug misuse 
interventions, which can potentially provide long-term estimates of the costs and outcomes of 
interventions. A modelling study is an analytical approach which provides a structural 
framework for decision making under conditions of uncertainty. It provides the full structure 
of the possible prognoses of the individual, brings together the relevant evidence from 
different resources, and translates this evidence into estimates of cost and effectiveness to 
predict outcomes in the long-term. Chapter 6 reviews the limited number of economic 
evaluation models that have previously been developed for drug misuse interventions. Using 
the checklist of good practice developed by Phillips and colleagues (2004), the quality of 
these models is examined to assess their limitations. 
 
Chapter 7 attempts to develop a new decision analytic model to evaluate the introduction of a 
drug testing in schools programme. The aim of developing this model is to try to overcome 
the limitations that have been identified in existing economic evaluations of drug misuse 
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interventions. In particular, the model attempts to take into consideration a range of both 
monetary and non-monetary outcomes in the long-term to provide a comprehensive 
evaluation of the intervention from the societal perspective. Chapter 7 thus explores the 
possibilities and limitations of trying to address the problems highlighted throughout the 
thesis within a single study. The extent to which the model is able to address previously 
identified problems is examined and the implications for policy makers and future 
researchers are elucidated.  
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Chapter 2 Using EQ-5D as an outcome measure in the economic evaluation 
of drug misuse interventions: a systematic review 
 
2.1 Background 
 
When calculating the cost-utility or cost-effectiveness ratios in economic evaluations only 
one outcome measure can be considered. For policy makers it is useful if generic outcomes 
are measured as this allows them to compare interventions across different fields and 
provides standard criteria to inform their decisions about whether or not to adopt a given 
intervention. In a recent review by Claxton and colleagues (2010) quality-adjusted life years 
(QALYs) were identified as the preferred generic outcome measure for health policy makers 
in countries such as Australia, Canada and the UK. Indeed in the UK the NICE guideline 
(2008) formally requires that QALYs are used to measure health outcomes. QALYs are a 
measure of an individual’s life years that are adjusted to take into account health-related 
quality of life (Drummond, M.F. et al, 2005).  
 
There are a number of different instruments that may be used to estimate QALYs and the 
NICE guideline (2008) recommends the use of the EQ-5D instrument with UK population 
values for this purpose. The use of EQ-5D and its sensitivity to change has been established 
for a range of conditions including chronic conditions and mental health illnesses (Almond et 
al, 2004; Brazier et al, 2004; Byford et al, 2003; Haro et al, 2003; Jerant, Chapman and 
Franks, 2008; Lamers et al, 2006; Myers and Wilks, 1998; Sobocki et al, 2007). In economic 
evaluations of drug misuse, however, a large range of naturalistic outcome measures have 
been used and EQ-5D has not been widely tested. 
 
It is important for policy makers to know whether or not using the EQ-5D measure leads to 
similar results as those estimated by other outcome measures, including measures that are 
specifically designed for drug misuse. The problem is further complicated as there is no 
“gold standard” outcome measure for drug misuse, therefore to determine whether or not EQ-
5D is an adequate measure it needs to be compared with a range of drug misuse specific 
outcome measures. If there are similar trends between EQ-5D and other drug misuse specific 
outcome measures then EQ-5D may prove to be an adequate generic outcome measure in this 
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field. However, if there are no such similar trends, it would suggest that policy makers cannot 
rely on EQ-5D alone to estimate the outcomes of drug misuse interventions.  
 
2.2 Objectives 
 
The aim of this chapter is to review drug misuse studies that have evaluated EQ-5D and other 
outcome measures to determine whether or not EQ-5D is an adequate outcome measure for 
drug misuse interventions. The first objective is descriptive and involves identifying how 
many studies of drug misuse interventions have included EQ-5D as an outcome measure and 
which other outcomes measures they include along with it. The second objective is to 
examine the trends between EQ-5D and other outcome measures. In order to do this the 
outcomes scores identified in the studies reviewed are first standardised so that the outcome 
measures can be compared with one another. 
 
2.3 Methods 
 
2.3.1 Inclusion Criteria for this review 
 
Type of studies: Economic evaluation studies that measure EQ-5D along with clinical 
outcomes for drug misuse interventions will be included. Only studies collecting individual 
patient level data will be included. Studies only measuring intervention costs or only 
measuring clinical effectiveness will not be included. 
 
Type of intervention: Studies of interventions primarily aimed at reducing drug misuse 
problems will be included. All types of intervention delivered to the individual drug user or 
potential drug users will be considered. Studies of interventions delivered solely to the drug 
users’ family/ partner will not be included as the focus here is only on the outcome of the 
individual drug users. 
 
Type of participants: People who misuse substances, including any type of illegal substance. 
Studies of people with alcohol addictions or smoking problems only will be excluded.  
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Comparison: Studies considering at least one intervention will be included. Studies that 
measured outcomes either at one point of time, at different points of time, or the changes 
between points of time will be included. 
 
2.3.2 Data sources and search strategy 
 
Both electronic and manual searches are undertaken to identify studies. 
Search strategy: 
The search was performed in July 2010. Studies which meet the inclusion criteria are 
identified from the following sources. The beginning of the search is 1990, when EQ-5D was 
developed and discussed in the published literature. There is no language restriction.  
 
Econlit  
EMBASE  
MEDLINE  
PsycINFO  
CRD (Centre for Reviews and Dissemination) databases 
The Cochrane Library 
The Cochrane Central Register of Controlled Trials (CENTRAL) 
Current Controlled Trials Register 
 
Example of searching strategy: MEDLINE; 1990 – to July 2010:  
(drug misuse or drug dependen* or substance misuse or substance abuse or substance 
dependen* or addict* or illegal drug* or illicit drug* or inject* drug* or methadone or heroin 
or opiat* or opium or cocaine or crack cocaine or ecstasy or LSD or magic mushroom* or 
amphetamine or cannabis or marijuana or ketamine) and (EQ-5D or EuroQoL or QALY*) 
 
2.3.3 Analysis of the extracted data 
 
The extracted data from the identified studies must first be standardised before the results can 
be compared and trends can be identified. There are sophisticated statistical techniques to 
standardise data that would be applicable if the individual patient scores were available, such 
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as the Z score, which considers the variance of the individual scores within the sample. 
However, as the individual patient scores were not available, more simplified techniques 
based on the mean score of the outcome measure for the study sample are used to standardise 
the data, as detailed below. In addition, for 3 of the studies, the HEPC trial (Abou-Saleh et al, 
2003; Abou-Saleh et al, 2008), the study by Carpentier and colleagues (2009) and the 
UKCBTMM trial (Drummond et al, 2004; Drummond, C. et al, 2005), the standard deviation 
of the mean score for each measure can be extracted from the reports to indicate the variance 
of the mean score.   
 
Standard mean score 
 
Different measures use different scales to estimate the outcomes. For example, in EQ-5D the 
self-reported health state scores range from -0.594 to 1 when applying the UK population 
value, where 1 represents the best health state (Dolan, 1997; Dolan et al, 1995; EuroQol 
group, 1990; Kind, Hardman and Macran, 1999). By contrast, the scores of another outcome 
measure, SF-12, are usually presented as 2 composite scores: MCS (mental component 
summary) and PCS (physical component summary). In each case the scores range from 0 to 
100, where 100 represents the best state of either the individual’s mental or physical health 
(Ware, Kosinski and Keller, 1995 and 1996). In order to compare the relative changes from 
the different outcome measures, standard mean scores are established, using the following 
formula which provides a standardised score ranging from 0 to 100: 
 
Standard mean score = mean score/ score range * 100 
 
For instance, at the baseline of the UKCBTMM trial (Drummond et al, 2004; Drummond, C. 
et al, 2005), the actual mean score of EQ-5D is 0.6875 and the SF-12 physical health score 
(PCS) is 38.89 within the whole trial sample. Both of the scores are converted into the 
standard mean score as follows: 
 
EQ-5D standard score = 0.6875/ 1.594*100 = 43.13 
SF-12 PCS standard score = 38.89/100*100 = 38.89 
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Reversed score 
 
Another problem with comparing outcome measures is that in some measures the highest 
score represents the worst outcome. For example, the score range of SDS (Severity of 
Dependence Scale) is between 0 and 15, where 15 represents the worst outcome as it 
indicates the greatest dependence severity (Gossop et al, 1995). There is, therefore, an initial 
difficulty when comparing the results of SDS with the results other outcome measures such 
as EQ-5D because the highest score of SDS represents the worst outcome whereas the 
highest score of EQ-5D represents the best outcome. However, when the scores are reversed 
for SDS 0 represents the worst outcome and 15 represents the best outcome, so it can easily 
be compared with EQ-5D. The following formula is thus used to calculate the reversed mean 
score when the highest score originally represents the worst outcome: 
  
Reversed mean score = Highest score – actual mean score  
 
Using SDS in the UKCBTMM trial (Drummond et al, 2004; Drummond, C. et al, 2005) as an 
example, the actual SDS mean score is 9.78 in a range from 0 to 15. The reversed mean score 
is therefore calculated as 5.22 (=15-9.78), which can then be converted into the standard 
mean score of 34.8 (=5.22/15*100). The reversed standard mean score still represents 
individuals’ dependence severity, however, the higher score now represents a lower 
dependence severity and may therefore be compared with other outcome measures like EQ-
5D. 
 
Percentage of score change 
 
Having standardised the scores, the percentage of score change is calculated using the 
following formula: 
 
Percentage of score change = (follow-up standard mean score – baseline standard mean score) 
/ baseline standard mean score*100% 
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The percentage of score change shows the score change in the outcome measured taken as a 
percentage of the standardised baseline score. If the outcome change is above 0, this reflects 
an improvement in the outcome measured at the follow up period, whereas if it is below 0, 
this reflects deterioration in the outcome measured. The degree of change in the different 
outcome measures may be related to the sensitivity of the measures when evaluating the 
outcomes among drug misuse patients. 
 
2.4 Results 
 
2.4.1 Description of included studies and outcome measures included 
 
The first objective of the review was to identify studies that measured EQ-5D and at least one 
other outcome measure. The review identified 81 studies in total, of which only 8 were drug 
misuse intervention studies. Most of the excluded studies were related to opiate use for 
cancer patients. Within the 8 included studies, 5 studies were controlled trials, 2 were cross-
sectional studies, and 1 was an on-going randomised controlled trial. This ongoing trial is not 
scheduled to be completed until September 2010 and published results will not be available 
for this thesis. 
 
The interventions used in the included studies ranged from counselling sessions to prescribed 
heroin or methadone treatment. These included 2 types of HIV prevention counselling, 
prescribed buprenorphine, methadone maintenance treatment, prescribed heroin, and 
cognitive behaviour therapy. 
 
The duration of the trials ranged from 3 months to 12 months. The follow-up periods were 
between 2 and 14 months. The participants were all adult drug users and the number of 
participants ranged from between 21 to 2,414. All of the included studies were conducted in 
Europe, including 3 UK studies, 2 Dutch studies, 1 Spanish study, 1 German study and 1 
Danish study. Details of each included study are listed in Table 2.4.1.  
 
The review identified 31 other outcome measures that were considered along with EQ-5D in 
the relevant studies, which are also listed in Table 2.4.1. Of these 31 measures, only 16 were 
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directly related to drug misuse. Rehm and colleagues (2000) recommend that different 
outcome measures can be categorised into 3 dimensions: continuation of illegal substance use 
and abuse; improvement of medical conditions (somatic and mental); and social integration 
(criminal behaviour, work, housing, personal relations). The 16 relevant outcome measures 
are categorised in these 3 dimensions in Table 2.4.2, and each measure can be categorised in 
more than one dimension depending on the problems with which it is concerned. For 
example, the Severity of Dependence Scale (SDS) is only concerned with problems relating 
to individuals’ dependence severity and is therefore only categorised in the first dimension, 
illegal substance use and abuse. By contrast, the European Addiction Severity Index 
(EuropASI) is concerned with problems related to individuals’ drug misuse, medical and 
psychological health, work satisfaction and family and other relationships, and is therefore 
included in all 3 dimensions. The full details of each outcome measure are listed in Appendix 
1. All of the 8 studies have considered outcome measures in each of the 3 dimensions, which 
indicates that all the studies consider that it is important to take into account all of the 
dimensions to provide a comprehensive evaluation of drug misuse interventions. 
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Table 2.4.1 Description of included studies 
Study Population Intervention Follow-up period Clinical outcome measure 
Abou-Saleh et al, 2003; 
Abou-Saleh et al, 2008 
(HEPC), UK 
33 injecting drug users, 
recruited from drug 
treatment centres 
Trial enhanced HIV 
prevention counselling 
intervention: Stay Safe 
Therapy (SST; 4 sessions) 
versus Simple Educational 
Counselling (SEC; 1 session) 
6 months -Alcohol Use Disorders 
Identification Test; AUDIT 
-Drug Injecting Confidence 
Questionnaire; DICQ, adopted 
from DTCQ 
- European addiction severity 
index; EuropASI 
-Hepatitis-C Knowledge 
Questionnaire; HCV-K 
-HIV Risk-Taking Behaviour 
Scale; RTBS 
-Injecting Risk Questionnaire; 
IRQ 
-Readiness to Change 
Questionnaire; RCQ 
Carpentier et al, 2009, 
Netherlands 
193 opiate addicts, 
recruited from existing 
methadone maintenance 
programme 
Methadone maintenance 
programme 
N/A -EuropASI 
- WHO’s Composite 
International Diagnostic 
Interview; CIDI(illegal 
substance section only) 
-Social Conformism Scale; SCS 
Castillo, 2008, Spain 100 opiate addicts, 
recruited from existing 
methadone maintenance 
programme 
Methadone maintenance 
programme 
N/A -IDUQoL(score not presented) 
-SF-36(score not presented) 
Dijkgraaf et al, 2005; 
van den Brink et al, 
2003, Netherlands 
430 heroin addicts, the sub-
sample from 549 heroin 
addicts recruited from 
existing methadone 
maintenance programmes 
 
 
methadone versus heroin 
prescribed over 
12 months 
 
 
EQ-5D data: 2, 6, 
10, 12 months 
(treatment 
continues through 
follow-up periods) 
Clinical outcome: 
12 and 14 month  
- EuropASI 
-CIDI 
-Maudsley Addiction Profile 
(MAP-HSS; health symptoms 
section only) (not presented in 
analysis of sub-sample) 
-Symptom Checklist-90; SCL-
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90 (not presented in analysis 
of sub-sample) 
Drummond et al, 2004; 
Drummond, C. et al, 
2005 (UKCBTMM), UK 
60 opiate addicts, recruited 
from 10 community based 
clinics 
Cognitive behaviour therapy 
(CBT) plus methadone 
maintenance treatment 
(MMT) versus MMT alone 
6 and 12 months -Brief symptom inventory; BSI 
-Coping responses inventory; 
CRI 
-Drug taking confidence 
questionnaire; DTCQ-8 
- EuropASI 
-Severity of dependence scale; 
SDS  
-SF-12 
-Stage of change readiness and 
treatment eagerness scale; 
SOCRATES  
-Timeline follow back; TLFB 
for heroin, methadone and 
alcohol 
Hjorthoj et al, 2008 
(CapOpus), ongoing trial 
lasts from March 2007 to 
September 2010, 
Denmark 
Aim to recruit between 120 
and 140 young patients 
(Aged 18-35) with cannabis 
abuse and psychosis 
Specialized addiction 
treatment (CapOpus) plus 
treatment as usual versus 
treatment as usual over 6 
months 
6, 10 months -Brief Assessment of Cognition 
in Schizophrenia; BACS 
-Client Satisfaction 
Questionnaire; CSQ 
-Continuous Performance Test, 
Identical Pairs version; CPT-
IP 
-Danish Adult Reading Test; 
DART 
-Hopkins Verbal Learning Test; 
HVLT 
-Manchester Short Assessment 
of Quality of Life; MANSA  
-Neuropsychological 
Assessment Battery; NAB 
-Positive and Negative 
Syndrome Scale for psychosis 
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symptom; PANSS  
- TLFB for cannabis 
-12 item interviewer 
administrated version of 
WHO’s Disability Assessment 
Schedules; WHODAS-II 
Lintzeris et al, 2006; 
Strang et al, 2010, 
(RIOTT), UK 
127 heroin dependents 
recruited from supervised 
injecting clinics 
Injected methadone treatment 
versus injected heroin 
treatment versus optimized 
oral methadone treatment 
over 6 months 
13 and 26 weeks 
(treatment 
continues through 
follow-up periods) 
-Hospital Anxiety and 
Depression Scale; HADS 
-Injecting Risk Questionnaire 
-Maudsley Addiction Profile 
(crime Section only) 
-Opiate Treatment Index; OTI 
(drug use, crime and 
psychological health sections 
only) 
-SF-36 
-Treatment Perception 
Questionnaire; TPQ 
Schafer et al, 2009 
(COBRA), Germany 
2,414 opiate addicts, 
recruited from 233 opiate 
substitution doctors/centres 
Antiviral interferon (IFN) 
treatment on opiate addicts 
with and without hepatitis C 
virus (HCV) infection 
12 months -BSI 
- EuropASI 
-CIDI 
 
 31 
Table 2.4.2 List of outcome measure categories in the included studies, using dimensions suggested by Rehm and colleagues (2000) 
 Continuation of illegal substance use 
and misuse 
Improvement of medical 
condition 
Social 
integration 
Abou-Saleh et al, 2003; Abou-Saleh et al, 2008 
(HEPC) a 
EuropASI, IRQ, RTBS EuropASI EuropASI 
Carpentier et al, 2009 EuropASI, CIDI EuropASI EuropASI 
Castillo, 2008 IDUQoL IDUQoL, SF-36 IDUQoL 
Dijkgraaf et al, 2005; van den Brink et al, 2003 EuropASI MAP-HSS, SCL-90 EuropASI 
Drummond et al, 2004; Drummond, C. et al, 2005 
(UKCBTMM) b 
EuropASI, SDS, TLFB BSI, EuropASI, SF-12 EuropASI 
Hjorthoj et al, 2008 (CapOpus) c TLFB MANSA, WHODAS II MANSA 
Lintzeris et al, 2006; Strang et al, 2010, (RIOTT) d IRQ, OTI HADS, OTI, SF-36 MAP-crime, 
OTI 
Schafer et al, 2009 (COBRA) EuropASI, CIDI BSI, EuropASI EuropASI, 
CIDI 
a: AUDIT from HEPC is excluded in the analysis because it measures consumption of alcohol, not illegal substances. HCV-K, DICQ and RCQ 
from HEPC are also excluded because they are the process measures for drug misuse problems. 
b: The TLFB section related to alcohol problems from UKCBTMM is excluded in the analysis because it is not a measure of illegal substance 
use. CRI, DTCQ-8, and SOCRATES from UKCBTMM are also excluded because they are the process measures for drug misuse problems. 
c: BACS, CPI-IP, DART, HVLT, NAB, and PANSS from CapOpus are excluded in the analysis, because they are specific assessment for 
psychosis patients. CSQ is also excluded because it is an assessment of patients’ satisfaction and is not directly related to the effectiveness of 
the intervention. 
d: TPQ from RIOTT is excluded in the analysis because it assesses patients’ satisfaction and is not related to the effectiveness of the 
intervention. 
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2.4.2 Outcome comparison of the included studies 
 
The second objective of the review is to compare the trends between EQ-5D and other 
outcome measures. Although there are 8 drug misuse intervention studies that have 
considered EQ-5D and at least one other outcome measure, only 5 of these reported the 
scores for both EQ-5D and the other measures. To compare the trends between EQ-5D and 
other outcome measures these scores are required, therefore only 5 studies are examined: the 
HEPC trial (Abou-Saleh et al, 2003; Abou-Saleh et al, 2008), the study by Carpentier and 
colleagues (2009), the Dutch prescribed heroin trial (Dijkgraaf et al, 2005; van den Brink et 
al, 2003), the UKCBTMM trial (Drummond et al, 2004; Drummond, C. et al, 2005) and the 
COBRA trial (Schafer et al, 2009). The outcome measures from these trials can be compared 
with EQ-5D, in each case by each of the 3 dimension in turn. In some cases the outcome 
measures are broken down into subscales, such as EuropASI, so more measure are examined 
in the results than the original 16 outcome measures identified in the review. 
 
HEPC trial 
 
The HEPC trial (Abou-Saleh et al, 2003; Abou-Saleh et al, 2008) recorded scores at baseline 
and 6 month follow-up periods, and the change between these two time points. Table 2.4.3 
presents the original scores extracted from the study, the standardised mean scores and 
percentage score change for all of the outcome measures or the subscales of outcome 
measures in the HEPC trial. 
 
In the first dimension, continuation of illegal substance use and abuse, the standardised mean 
scores at baseline and the follow-up period reveal that EQ-5D only has relatively similar 
scores to 1 of the 3 other measures (EuropASI Drug): at baseline the EQ-5D score was 51.6 
and the EuropASI Drug score was 60.1 and at the follow-up period the EQ-5D score was 
57.9 and the EuropASI Drug score was 65.2. The 2 measures also have similar percentage 
score changes: 8.49% for EuropASI Drug and 12.5% for EQ-5D. 1 of the other measures 
(RTBS) also records a similar percentage of score change of 10.46%, however the scores in 
RTBS are consistently higher than in EQ-5D. EQ-5D does not reflect the trends of the other 
measure (IRQ) at all, which records a percentage score change of 100%. These results show 
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that within the first dimension, EQ-5D only describes patients’ outcomes similarly to 1 of the 
3 measures at different points of time, but records similar proportional changes to 2 of the 3 
measures over the period of time. 
 
In the second dimension, improvement of medical condition, neither of the 2 measures record 
similar results to EQ-5D. Both measures have scores of consistently more than 30 units of the 
standard mean score higher than EQ-5D at both baseline and the follow-up period. However, 
both measures do show that, like EQ-5D, the patients’ scores have improved over the follow-
up period, recording percentage score changes of 4.74% (EuropASI Medical) and 6.35% 
(EuropASI Psychiatric), even though this is lower than the 12.5% score change of EQ-5D. In 
the third dimension, social integration, EQ-5D has considerably lower scores at baseline and 
the follow-up period than all of the 5 measures with the exception of EuropASI Economic, 
which EQ-5D has considerably higher scores than. However, EQ-5D does record very 
similar percentage score changes to 2 of the other measures: EuropASI Other relationship, 
which has 10.22% change, and EuropASI Work satisfaction, which has 13.54% change. EQ-
5D also has quite similar percentage score changes to 2 of the other measures but not to 
EuropASI Economic, which is the only measure in the HEPC trial where the patient score 
decreased over the follow-up period, recording a -29.65% score change. 
 
Taking all of the dimensions together, as illustrated in Figure 2.4.1, EQ-5D only describes 
patients’ outcomes at different points of time similarly to EuropASI Drug, and generally 
records lower scores than most other measures, which indicates that the patients’ health 
related quality of life outcome is generally lower than other outcomes. All of the measures 
except one recorded improved scores over the 6 month follow-up period, and EQ-5D 
reflected very similar trends of change to 4 other measures and quite similar trends to another 
4 of the measures, as is illustrated by Figure 2.4.2.  
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Table 2.4.3 Result of included studies: HEPC 
n=33 Baseline 6 month follow-up Change at 6 month 
Outcome measure Standard mean score; 
A (S.D.) 
Original mean score; 
A’ (S.D.) 
Standard mean score; 
B (S.D.) 
Original mean score; 
B’ (S.D.) 
% of score change;  
(B-A)/A 
EQ-5D a 51.6 (12.4) 0.823 (0.198) 57.9 (13.9) 0.923 (0.221) 12.2 
Continuation of illegal substance use and abuse 
EuropASI Drug b 60.1 (15.3) 0.399 (0.153) 65.2 (19.6) 0.348 (0.196) 8.5 
IRQ c 39.4 60.6 78.8 21.2 100.0 
RTBS d 79.5 (15.1) 11.3 (8.3) 87.8 (11.3) 6.7 (6.2) 10.5 
Improvement of medical condition 
EuropASI Medical b 88.6 (27.1) 0.114 (0.271) 92.8 (19.5) 0.072 (0.195) 4.7 
EuropASI Psychiatric b 83.5 (22.1) 0.165 (0.221) 88.8 (18.3) 0.112 (0.183) 6.3 
Social integration 
EuropASI Economics b 31.7 (42.8) 0.683 (0.428) 22.3 (39.4) 0.777 (0.394) -29.7 
EuropASI Family 
relationship b 
87.2 (18.8) 0.128 (0.188) 92.4 (13.8) 0.076 (0.138) 6.0 
EuropASI Legal b 87.8 (18.2) 0.122 (0.182) 92.2 (13.3) 0.078 (0.133) 5.0 
EuropASI Other 
relationship b 
87.1 (17.3) 0.129 (0.173) 96.0 (9.8) 0.040 (0.098) 10.2 
EuropASI Work 
satisfaction b 
68.7 (29.6) 0.313 (0.296) 78.0 (29.5) 0.220 (0.295) 13.5 
a: The original score range of EQ-5D is between -0.594 and 1 using the UK social tariff, where 1 means that individuals have the best heath 
state (Dolan, 1997; Dolan et al, 1995; EuroQol group, 1990; Kind, Hardman and Macran, 1999). 
b: The score range of each subscale of EuropASI (European Addiction Severity Index) is between 0 and 1, where 1 means that individuals have 
the most problems or greatest severity in each subscale (Koeter and Hartgers, 1997; Kokkevi and Hartgers, 1995). The extracted scores are 
reversed in all subscales of EuropASI. 
c: The IRQ (Injecting Risk Questionnaire) results from the HEPC trial is presented as percentage of individuals who shared any IV equipment 
in last month. The extracted IRQ results are reversed. The standard deviation of IRQ is not reported in the HEPC trial report. 
d: The score range of RTBS (HIV Risk-Taking Behaviour Scale) is between 0 and 55, where 55 means that the individual has a higher 
incidence of HIV-related risk behaviour (Darke et al,1991a). The extracted RTBS score is reversed. 
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Figure 2.4.1 Standard mean scores and SEM (Standard Error of mean=SD/√n) bar of outcome measures at baseline and 6 month follow-up 
period in the HEPC trial 
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Figure 2.4.2 Percentage of score change of outcome measures between baseline and 6 month 
follow-up period in the HEPC trial 
 
Carpentier et al, 2009 
 
The study by Carpentier and colleagues (2009) is a cross-sectional study that only recorded 
scores at one point in time. Table 2.4.4 presents both the original scores extracted from the 
study and the standardised mean scores for all of the outcome measures or the subscales of 
outcome measures in the study. The study only considered EQ-5D, subscales of EuropASI, 
and CIDI, however, the CIDI scores were not reported. 
 
The only measure in the first dimension was EuropASI Drug, which had a standardised mean 
score of 42.2 compared with the EQ-5D score of 41.4. There were 2 EuropASI subscales in 
the second dimension, with scores of 53.3 and 70.0. In the third dimension there were 3 
EuropASI subscales with scores ranging between 50 and 59. As shown in Figure 2.4.3, it is 
only EuropASI Drug that EQ-5D has a very similar score to, which supports the findings 
from the HEPC trial, where this was the only other measure that had similar scores to EQ-5D 
at different points in time. 
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Table 2.4.4 Result of included studies: Carpentier et al 2009 
n=193 
 
Standard mean score; A 
(S.D.) 
Original mean score; A’ 
(S.D.) 
EQ-5D a 41.4 (19.4) 0.66 (0.31) 
Continuation of illegal substance use and abuse 
EuropASI Drug b 42.2 (16.7) 5.2 (1.5) 
Improvement of medical condition 
EuropASI Medical b 70.0 (24.4) 2.7 (2.2) 
EuropASI Psychiatric b 53.3 (24.4) 4.2 (2.2) 
Social integration 
EuropASI Family/other 
relationship b 
58.9 (20.0) 3.7 (1.8) 
EuropASI Legal b 57.8 (25.6) 3.8 (2.3) 
EuropASI Employment/support b 50.0 (20.0) 4.5 (1.8) 
a: This study uses the UK social tariff for EQ-5D scores, hence, the original score range of 
EQ-5D is between -0.594 and 1, where 1 means that individuals have the best heath state 
(Dolan, 1997; Dolan et al, 1995; EuroQol group, 1990; Kind, Hardman and Macran, 1999). 
b: The score range of each subscale of EuropASI (European Addiction Severity Index) is 
between 0 and 9, where 9 means that individuals have the most problems or greatest severity 
in each subscale (Koeter and Hartgers, 1997; Kokkevi and Hartgers, 1995). The extracted 
scores are reversed in all subscales of EuropASI. 
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Figure 2.4.3 Standard mean scores and SEM bars of outcome measures in the study by 
Carpentier and colleagues (2009) 
 
Dutch prescribed heroin trial 
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The Dutch prescribed heroin trial (Dijkgraaf et al, 2005; van den Brink et al, 2003) recorded 
scores at baseline, the 12 month follow-up period and the change between these time points. 
Table 2.4.5 presents the original scores, the standardised mean scores and the percentage 
score change for the measures in the trial. Although the trial has a sample of 433 heroin 
addicts at baseline, the report only presented scores for the subgroup of 193 patients who 
received methadone and prescribed heroin. Although the trial considered 3 different outcome 
measures (EuropASI, MAP-HSS and SCL-90) across the 3 dimensions, scores were only 
reported for 2 measures, both of which were in the second dimension, improvement of 
medical condition. 
 
At baseline EQ-5D had a standardised mean score of 46.4, which is considerably lower than 
both the other measures, which scored 71.5 (MAP-HSS) and 80.0 (SCL-90). At the follow-up 
period the EQ-5D score was 51.0 which was very similar to MAP-HSS (59.3), but not to 
SCL-90 (72.8), as illustrated in Figure 2.4.4. However, more significantly, both of the other 
measures recorded negative percentage score changes over the follow-up period: -17.1% for 
MAP-HSS and -9.0% for SCL-90. By contrast, as shown in Figure 2.4.5, EQ-5D was the 
only measure to record improved scores with a 9.9% score change. EQ-5D does not therefore 
adequately reflect the trends of either of the other 2 measures in the trial. 
 
Table 2.4.5 Result of included studies: Dutch prescribed heroin trial (sub-sample of patients 
received methadone maintenance treatment plus prescribed heroin) 
n=193 Baseline 12 month follow-up Change at 12 
month 
Outcome 
measure 
standard mean 
score; A 
mean 
score; A’ 
Standard mean 
score; B 
mean 
score; B’ 
% of score 
change;  (B-A)/A 
EQ-5D a 46.4 0.740 51.0 0.813 9.9 
Improvement of medical condition 
MAP-HSS b 71.5 11.4 59.3 16.3 -17.1 
SCL-90 b 80.0 71.9 72.8 97.8 -9.0 
a: The social tariff of EQ-5D is not stated in the trial. In a related study by van der Zanden 
and colleagues (2006), they have stated that they use the UK social tariff for EQ-5D scores. 
Assuming they also used the UK social tariff for this trial, the original score range of EQ-5D 
is between -0.594 and 1, where 1 means that individuals have the best heath state (Dolan, 
1997; Dolan et al, 1995; EuroQol group, 1990; Kind, Hardman and Macran, 1999). 
b: The score range of MAP-HSS (health symptoms scale of Maudsley Addiction Profile) is 
between 0 and 40, where 40 means that individuals have the worst health state (Marsden et al 
1998). The extracted MAP-HSS score is reversed. 
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c: The score range of SCL-90 (Symptom Checklist-90) is between 0 and 360, where 360 
means that individuals have the worst psychological health state (Derogatis and Cleary, 
1977). The extracted SCL-90 score is reversed. 
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Figure 2.4.4 Standard mean scores of outcome measures at baseline and 12 month follow-up 
period in the Dutch prescribed heroin trial 
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Figure 2.4.5 Percentage of score change of outcome measures between baseline and 12 
month follow-up period in the Dutch prescribed heroin trial 
 
UKCBTMM trial 
 
The UKCBTMM trial (Drummond et al, 2004; Drummond, C. et al, 2005) recorded scores at 
baseline, 6 month and 12 follow-up periods, and the change between these 3 time points. 
Table 2.4.6 presents the original scores, standardised mean scores and the percentage score 
change for all of the measures in the trial. 
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In the first dimension, although EQ-5D has similar scores at different points in time to 3 of 
the other 4 measures, as illustrated in Figure 2.4.6, this is not consistent. EQ-5D also has very 
different percentage score change trends to all of the other measures at both 6 month and 12 
month follow-up periods, as illustrated by Figure 2.4.7 and Figure 2.4.8. One of these 4 
measures is EuropASI Drug, which it is worth noting since these results contrast with the 
findings of both the HEPC trial (Abou-Saleh et al, 2003; Abou-Saleh et al, 2008) and the 
study by Carpentier and colleagues (2009), where EQ-5D and EuropASI Drug had similar 
trends. 
 
In the second dimension EQ-5D has similar scores at different points in time to 2 of the 5 
measures, which are both subscales of SF-12 and measure health-related quality of life like 
EQ-5D. Of the 2 subscales, SF-12 MCS is the most similar to EQ-5D, with scores of 39.3 at 
baseline, 41.3 at the 6 month follow-up and 43.7 at the 12 month follow-up, compared with 
scores of 43.1, 47.3 and 47.0 respectively at these points in time for EQ-5D. SF-12 MCS also 
has a similar percentage score changes over the period, recording an 11.2% change over the 
12 month follow-up period compared to 9.2% for EQ-5D. BSI also had a similar trend of 
proportional change to EQ-5D, with a 10.2% score change over the 6 month follow-up period 
and an 11.3% change over the 12 month follow-up period, compared with 9.8% and 9.2% 
respectively for EQ-5D. However, as illustrated in Figure 2.4.6, the BSI scores were 
consistently much higher than those of EQ-5D. The third dimension only includes subscales 
of EuropASI. Figure 2.4.6 shows that the scores of all 5 measures were much higher than 
EQ-5D at each point of time. Only 1 measure (EuropASI Work satisfaction) had a similar 
percentage score change at both 6 and 12 month follow-up periods, as shown in Figure 2.4.7 
and Figure 2.4.8, with scores of 6.5% and 13.7% respectively. 
 
As shown in Figure 2.4.7 and Figure 2.4.8, EQ-5D only consistently reflects the trends for 3 
of the 15 measures (BSI, SF-12, and EuropASI Work satisfaction) over both the 6 and 12 
month follow-up periods. However, it is worth stressing that there is a large diversity of 
scores and trends in the different measures examined in the UKCBTMM trial and it would 
therefore be impossible for any single outcome measure, such as EQ-5D, to reflect all of 
these divergent trends. 
 41 
Table 2.4.6 Result of included studies: UKCBTMM 
n=60 Baseline 6 month follow-up Change at 6 
month 
12 month follow-up Change at 
12 month 
Outcome 
measure 
Standard 
mean score; 
A (S.D.) 
Original 
mean score; 
A’ (S.D.) 
Standard 
mean score; 
B (S.D.) 
Original 
mean score; 
B’ (S.D.) 
% of score 
change;  (B-
A)/A 
Standard 
mean score; 
C (S.D.) 
Original 
mean score; 
C’ (S.D.) 
% of score 
change;  (C-
A)/A 
EQ-5Da 43.1 (21.7) 0.687 (0.346) 47.3 (17.8) 0.754 (0.283) 9.8 47.1 (19.5) 0.750 (0.311) 9.2 
Continuation of illegal substance use and abuse 
EuropASI Drug 
b 
70.4 (13.6) 0.296 (0.136) 69.9 (12.6) 0.301 (0.126) -0.7 72.8 (14.4) 0.272 (0.144) 3.4 
SDS c 34.8 (25.3) 9.78 (3.80) 50.8 (27.9) 7.38 (4.19) 46.0 55.5 (32.3) 6.67 (4.84) 59.6 
TLFB of heroin 
PDA d 
46.3 (34.3) 46.28 (34.31) 59.2 (37.0) 59.21 (37.01) 27.9 69.3 (38.4) 69.31 (38.39) 49.8 
TLFB of 
methadone 
PDA d 
32.3 (27.8) 32.26 (27.76) 25.2 (36.3) 25.23 (36.25) -21.8 36.7 (44.8) 36.65 (44.79) 13.6 
Improvement of medical condition 
BSI e 68.5 (22.3) 1.26 (0.89) 75.5 (19.8) 0.98 (0.79) 10.2 76.3 (22.5) 0.95 (0.90) 11.3 
EuropASI 
Medical b 
75.3 (34.1) 0.247 (0.341) 80.4 (30.0) 0.196 (0.300) 6.8 77.1 (30.1) 0.229 (0.301) 2.4 
EuropASI 
Psychiatric b 
78.5 (21.2) 0.215 (0.212) 74.6 (26.6) 0.254 (0.266) -5.0 77.6 (24.5) 0.224 (0.245) -1.1 
SF-12 MCS f 39.3 (11.3) 39.32 (11.29) 41.3 (13.0) 41.25 (12.99) 4.9 43.7 (11.7) 43.74 (11.68) 11.2 
SF-12 PCS f 38.9 (6.3) 38.90 (6.28) 39.9 (5.7) 39.90 (5.68) 2.6 39.3 (5.5) 39.34 (5.46) 1.1 
Social integration 
EuropASI 
Economics b 
16.5 (35.7) 0.835 (0.357) 30.0 (42.1) 0.700 (0.421) 81.8 29.7 (42.2) 0.703 (0.422) 80.0 
EuropASI 
Family 
relationship b 
82.8 (23.8) 0.172 (0.238) 82.5 (22.5) 0.175 (0.225) -0.4 86.3 (20.1) 0.137 (0.201) 4.2 
EuropASI Legal 87.3 (20.1) 0.127 (0.201) 82.2 (26.1) 0.178 (0.261) -5.8 91.0 (17.0) 0.090 (0.170) 4.2 
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b 
EuropASI Other 
relationship b 
83.6 (20.7) 0.164 (0.207) 88.9 (16.6) 0.111 (0.166) 6.3 86.7 (18.6) 0.133 (0.186) 3.7 
EuropASI Work 
satisfaction b 
70.6 (36.3) 0.294 (0.363) 76.6 (30.8) 0.234 (0.308) 8.5 80.3 (26.7) 0.197 (0.267) 13.7 
a: The original score range of EQ-5D is between -0.594 and 1 using the UK social tariff, where 1 means that individuals have the best heath 
state (Dolan, 1997; Dolan et al, 1995; EuroQol group, 1990; Kind, Hardman and Macran, 1999). 
b: The score range of each subscale of EuropASI (European Addiction Severity Index) is between 0 and 1, where 1 means that individuals have 
the most problems or greatest severity in each subscale (Koeter and Hartgers, 1997; Kokkevi and Hartgers, 1995). The extracted scores are 
reversed in all subscales of EuropASI. 
c: The score range of SDS (Severity of Dependence Scale) is between 0 and 15, where 15 means that individual has the highest level of 
dependence severity (Gossop et al,1995). The extracted SDS score is reversed. 
d: The score TLFB (Timeline follow back) is presented as PDA (percentage of days abstinent) and ranges from 0 to 100, where 100 means that 
individual has not used the specific substance for the entire recorded period (Sobell and Sobell 1996; Sobell et al 1996). 
e: The score range of BSI (Brief Symptom Inventory) is between 0 and 4, where 4 means that individual has the worst psychological health 
state (Derogatis and Melisaratos, 1983). The extracted BSI score is reversed. 
f: The score of SF-12 is presented as two composite scores: MCS (mental component summary) and PCS (physical component summary). 
Both PCS and MCS ranges between 0 and 100, where 100 means individual has the best heath state (Ware, Kosinski and Keller, 1995 and 
1996). 
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Figure 2.4.6 Standard mean scores of outcome measures and SEM bars at baseline, 6 and 12 month follow-up in the UKCBTMM trial 
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Figure 2.4.7 Percentage of score change of outcome measures between baseline and 6 month 
follow-up period for the UKCBTMM trial 
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Figure 2.4.8 Percentage of score change of outcome measures between baseline and 12 
month follow-up period for the UKCBTMM trial 
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COBRA trial 
 
The COBRA trial (Schafer et al, 2009) recorded scores at baseline, the 12 month follow-
up period and the change between these 2 time points. Table 2.4.7 presents the original 
scores extracted from the study, the standardised mean scores and the percentage score 
change for all of the measures in the trial. Although the COBRA trial examined subscales 
of EuropASI, CIDI and BSI, it only presented scores for BSI. 
 
BSI is only a measure of the second dimension, improvement of medical condition. At 
baseline the BSI standardised mean score was 83.6, compared with 59.7 for EQ-5D. At 
the 12 month follow-up period the BSI score was 84.5, compared with 59.9 for EQ-5D, 
and the percentage score change was 1% for BSI compared with 0.4% for EQ-5D. These 
results show that although BSI is consistently higher, EQ-5D reflects similar trends of 
percentage score change, which supports the relationship between EQ-5D and BSI 
identified in the UKCBTMM trial. The similar trends are illustrated in Figure 2.4.9.  
 
Table 2.4.7 Result of included studies: COBRA  
n=2,414 Baseline 12 month follow-up Change at 12 
month 
Outcome 
measure 
standard mean 
score; A 
mean 
score; A’ 
standard mean 
score; B 
mean 
score; B’ 
% of score 
change;  (B-A)/A 
EQ-5D a 59.7 0.720 59.9 0.723 0.4 
Improvement of medical condition 
BSI b 83.6 0.655 84.5 0.622 1.0 
a: The social tariff of EQ-5D is not stated. As this trial was conducted in Germany, it is 
assumed that the social tariff of Germany was adopted. Therefore, the original score range 
of EQ-5D is between -0.207 and 1 using the social tariff of Germany, where 1 means that 
individuals have the best heath state (EuroQol group, 1990; Szende, Oppe and Devlin ed., 
2007).  
b: The score range of BSI (Brief Symptom Inventory) is between 0 and 4, where 4 means 
that the individual has the worst psychological health state (Derogatis and Melisaratos, 
1983). The extracted BSI score is reversed. 
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Figure 2.4.9 Standard mean scores of outcome measures at baseline and 12 month follow-
up period in the COBRA trial 
 
2.5 Conclusions and Discussion 
 
The first objective of this chapter was simply to identify the drug intervention studies that 
have evaluated EQ-5D and other outcome measures. Although only 8 studies were 
identified, between them they covered 16 outcome measures in addition to EQ-5D. These 
measures have been categorised into 3 dimensions as recommended by Rehm and 
colleagues (2000): continuation of illegal substance use and abuse, improvement of 
medical conditions, and social integration. All of the 8 studies considered outcome 
measures in each of the 3 dimensions. This reveals that current researchers consider it 
important to take into account a wide range of outcome measures when evaluating drug 
misuse interventions and that for a comprehensive analysis measures from all 3 
dimensions should be considered. This suggests that if only a single outcome measure is 
considered in economic evaluations, such as EQ-5D, other important measures may be 
neglected. 
 
The second and most important objective of the chapter was to determine whether or not 
EQ-5D is an adequate generic outcome measure for evaluating drug misuse interventions. 
Of the 5 studies that were reviewed, EQ-5D only reflected the trends of percentage score 
change of the majority of measures in the HEPC trial, where it has very or quite similar 
trends to 8 of the 10 other measures. Across the other studies, however, EQ-5D only 
adequately reflected the trends of a few other measures. Both the UKCBTMM trial and 
the COBRA trial indicated that EQ-5D has similar trends to BSI. The UKCBTMM trial 
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also revealed that EQ-5D has similar trends to both the subscales of the SF-12 measure, 
which is probably due to it also being a health related quality of life measure, like EQ-5D. 
In general EQ-5D did not have similar standardised mean scores to most of the other 
measures, with one exception. Both the HEPC trial and the study by Carpentier and 
colleagues (2009) revealed EQ-5D to have similar scores to the EuropASI Drug subscale, 
although the UKCBTMM trial provided contrasting results.  
 
Although EQ-5D has similar trends to a few different individual measures across the 
different dimensions, more generally the results indicate that EQ-5D does not adequately 
reflect the majority of measures in any of the 3 dimensions. One of the problems of using 
EQ-5D as a generic outcome measure is that there was a wide divergence of trends among 
the different measures considered in the studies. Where these trends differ from one 
another it would be impossible for any single measure, such as EQ-5D, to reflect this 
divergence. These results indicate not only that it is important to consider measures from 
all 3 of the dimensions in drug misuse intervention studies, but that it may also be 
important to consider a range of measures from each dimension to reflect the diversity of 
the scores and trends. 
 
These results reveal the problems with using any single outcome measure to provide a 
comprehensive evaluation of drug misuse interventions. Policy makers need to be aware 
that any single outcome measure will be unable to reflect all the diverse trends of the 
outcome measures across all 3 of the dimensions reviewed in this chapter. This is not a 
problem specifically related to EQ-5D, but rather with using one outcome measure to 
reflect the complexity of drug misuse. 
 
It is important to stress that these conclusions are only tentative, as there are some 
limitations with using the scores extracted from the studies reviewed in this chapter. The 
most significant of these is that the studies all presented mean average scores but 
individual patient scores were not available, which would be required to calculate the 
variance at the individual patient level. To know whether the results are statistically 
significant it would be necessary to take into account the variance by using more 
sophisticated statistical analyses, such as the Z score. From the scores extracted from the 
studies, it is impossible to know whether they are statistically significant, which is a 
major limitation when comparing EQ-5D with other outcome measures. This limitation 
may account for some of the divergent results between the studies highlighted above. 
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The problem of knowing whether the scores are statistically significant is especially 
important given that some of the sample sizes in the studies are quite small, only 
considering between 30 and 60 patients. Given this any outlying scores are more likely to 
distort the mean score and it would be useful to know the variance within these studies. 
To this extent the studies by Carpentier and colleagues (2009), the COBRA trial (Schafer 
et al, 2009) and the Dutch prescribed heroin trial (Dijkgraaf et al, 2005; van den Brink et 
al, 2003) may be more reliable as the sample sizes were all over 290, with the COBRA 
trial having a sample of over 2000 participants.  
 
This chapter has only considered the results of the different measures. However, it is not 
only the results but also the content of the measures that can be compared to evaluate 
whether or not EQ-5D adequately reflects the other outcome measures. To complete the 
evaluation of EQ-5D as an outcome measure for drug misuse intervention studies it is 
therefore necessary to compare the content of the measures identified in this chapter, 
which provides the focus for the next chapter. 
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Chapter 3 Content comparison of EQ-5D and other outcome measures 
 
3.1 Background 
 
In the UK the NICE guideline (2008) requires that QALYs are used to measure health 
outcomes and to do so it recommends using the EQ-5D instrument with UK population 
values. The previous chapter has discussed the importance of establishing whether or not 
EQ-5D is an adequate generic outcome measure for drug misuse interventions and 
explored the trends between EQ-5D and other drug misuse specific measures. However, 
although some trends were identified the conclusions drawn from the results were 
tentative at best. In large part this was due to the limitations of the scores extracted from 
the studies reviewed, which provided no indication of statistical significance. 
 
This chapter explores the same problem as the previous chapter but adopts a different 
approach. Where the previous chapter examined the trends between the results of EQ-5D 
and other outcome measures, this chapter focuses on a content comparison of the different 
measures. These measures rely on questionnaires to evaluate drug misuse interventions. 
However, there are a wide range of questionnaires used in the studies identified in the 
previous chapter. It is important to know how similar these questionnaires are to one 
another, as if a content comparison reveals that they are very similar then it may not be 
necessary to use so many questionnaires. Indeed if EQ-5D addresses the same questions 
as the other outcome measures then policy makers may be justified in using it as the only 
outcome measure for economic evaluations of drug misuse interventions, as 
recommended by NICE. 
 
A content comparison shows whether or not questionnaires cover similar concepts to each 
other. The concept is the general concern that a given question aims to address, for 
example, a question asking whether or not the patient has experienced problems with 
washing or dressing themselves covers the concept of self-care. This chapter uses the 
WHO’s content comparison technique, which was developed to provide a clear and 
comprehensive framework for examining individuals’ well-being. The WHO’s ICF 
(International Classification of Functioning, Disability and Health) is not an instrument, 
but a common reference framework for functioning in outcome research (Cieza et al, 
2005).  
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ICF has been used as the content comparison technique in a wide range of studies, such as 
outcome measures for patients suffering with pain (Borchers et al, 2005; Prodinger et al, 
2008), stroke patients (Geyh et al, 2007), head and neck cancer patients (Tschiesner et al, 
2008), and patients who received occupational and physical therapies (Stamm et al, 2004; 
Stamm et al, 2006). In the study by Cieza and Stucki (2005) the ICF content comparison 
technique has been used to compare health related quality of life measures such as EQ-5D 
and SF-36. However, the ICF content comparison technique has not yet been used in drug 
misuse studies. The advantages of using ICF in drug misuse studies have been discussed 
by Broekman and colleagues (2004). For example ICF can point out the areas that are 
ignored or poorly developed in addiction outcome measures and can facilitate the 
communication in universally understandable terms between drug misuse research and 
other health care fields (Broekman et al, 2004). In general, using ICF allows policy 
makers to evaluate how EQ-5D and other outcome measures fit into the WHO’s 
framework. 
 
3.2 Objectives 
 
The aim of this chapter is to use the ICF content comparison technique to evaluate the 
relationship between EQ-5D and other outcome measures used in drug misuse studies. As 
ICF has not previously been used for drug misuse studies, the first objective is to use ICF 
to map the concepts of EQ-5D and the other outcome measures identified in the previous 
chapters. The mapping is used to examine the extent to which EQ-5D adequately covers 
the same concepts as other measures and the amount of agreement at different levels of 
the ICF code between EQ-5D and other measures. 
 
Although it is important to know whether EQ-5D covers the same concepts as other 
outcome measures, a further consideration is whether or not patients respond to questions 
covering the same concept in the same way across different measures. The second 
objective is therefore to examine whether or not patients respond to questions covering 
one concept in the same way as they respond to other questions covering that same 
concept, by examining one study where the individual patient responses are available. If 
patients respond differently to questions covering the same concept then it would suggest 
that it is insufficient to only consider whether or not the same concepts are covered in 
different measures, as there may be other factors determining how patients respond to any 
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given question. This information is therefore important for evaluating the relationship 
between EQ-5D and other outcome measures used in drug misuse studies. 
 
3.3 Methods 
 
3.3.1 Content comparison using ICF concepts 
 
To meet the first objective, this chapter uses the outcome measures identified in the 
previous chapter as the basis for the content comparison in order to examine the extent to 
which EQ-5D covers the same concepts as other outcome measures used in drug misuse 
studies. In addition to EQ-5D, there are 16 other outcome measures that are mapped using 
the ICF framework. The first stage of content comparison is to identify the keyword for 
each question in each outcome measure. This is then mapped on to the ICF framework 
using linking rules detailed below. ICF is a classification system for outcomes related to 
individuals’ well-being, which provides letter codes for different concepts. Each keyword 
is mapped onto the most appropriate ICF concept (where possible) and by doing this for 
each question within an outcome measure, a profile of the concepts covered in that 
measure is developed. 
 
The ICF framework covers 4 major components: body functions (b), body structure (s), 
activities and participation (d), and environmental factors (e) (WHO, 2001). The linking 
rules of ICF have been developed (Cieza et al, 2002; Cieza et al, 2005). The component 
letter code is followed by a numeric code. The first digit of the numeric code is the 
chapter number in each component, the following 2 digits represent the second level of 
the description of each functioning, and the next 2 digits represent the third and fourth 
levels of functioning detail (WHO, 2001; Cieza et al, 2002). Taking ICF code b28010 as 
an example: the letter b represents the body functions component, and 2 indicates that this 
code is from chapter 2, sensory functions and pain. In chapter 2, the codes from b280 to 
b289 are all related to pain and b280 is the specific code for the sensation of pain. The 
code b2801 represents pain in one body part and the final digit represents the body part 
where the pain occurs, so b28010 means a specific pain in the head and neck. There is a 
detailed description for each ICF code (WHO, 2001).  
 
Each question may be linked to an ICF code, however, in some cases it is not only the 
question but also the different responses that need to be linked to the ICF code. If the 
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question or the response options cover more than one concept then they need to be linked 
to more than one code (Cieza et al, 2002; Cieza et al, 2005). For example, the second 
question in EQ-5D is about self-care, which is linked to the ICF code, d5 (self-care). 
There are 3 response options for this specific EQ-5D question: (1) I have no problems 
with self care, (2) I have some problems washing or dressing myself, and (3) I am unable 
to wash or dress myself. The concepts of washing myself is linked to the ICF code d510 
(washing oneself) and the concept of dressing myself is linked to d540 (dressing), so 
option 2 is linked to both d510 and d540. ICF does not differentiate between the degrees 
of the functioning, so there is no difference between the codes for options 2 and 3.  
 
Based on the updated linking rules (Cieza et al 2005), if the concepts cannot be linked to 
a specific ICF code then 4 options are available: nd (not definable), nc (not covered by 
ICF), hc (health condition, such as a diagnosis), or pf (personal factors, such as gender). 
As recommended in the linking rules (Cieza et al 2002; Cieza et al 2005), the ICF linkage 
is carried out independently by 2 health professionals with ICF training (one is a drug 
misuse researcher and the other is a social worker in mental health). When there is 
disagreement regarding specific linkage results, a third person is consulted to resolve the 
disagreement. Using SPSS software, Kappa statistics are then used to assess the inter-
observer agreement between the 2 people who carry out the linking process. 
 
3.3.2 Correlation between questions covered by the same concepts 
 
The second objective of the chapter is to examine whether or not patients respond to 
questions covering one concept in the same way as they respond to other questions 
covering that same concept. To examine this it is necessary to have the individual patient 
responses to the question in each measure. However, none of the drug misuse intervention 
studies reviewed in the previous chapter provided the individual patient responses.  
 
As individual patient responses are not usually published, to examine the relationship 
between them it is necessary to use a study where they are available. For this reason the 
data from RESULT (Raistrick et al, 2008) are used in this chapter, which provides a 
sample of 401 patients at baseline and 268 patients at the 6 month follow-up period. 
RESULT is an economic evaluation study of treatment-as-usual drug misuse policies in 
the UK, which covers both EQ-5D and 4 other outcome measures: LDQ (Leeds 
Dependence Questionnaire), SSQ (Social Satisfaction Questionnaire), CORE (Clinical 
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Outcome in Routine Evaluation), and SCL (Symptom Checklist). The RESULT study can 
therefore be used to examine the relationship between different questions and concepts 
even though it is not a drug misuse intervention study. 
 
The concepts from the RESULT questionnaires are first mapped into ICF code, using the 
method outlined above, and the overlapping concepts between EQ-5D and the other 
outcome measures are identified. The specific questions in the overlapping concepts are 
then examined to identify whether or not patients respond to different questions in the 
same concept in the same way. Spearman’s correlation is designed to test the correlation 
for ordinal data and as this is how the responses to the questions are presented in the 
outcome measures, this correlation technique is used to calculate the correlation 
coefficient and identify the extent of the correlation between the questions in EQ-5D and 
other measures. 
 
3.4 Results 
 
3.4.1 Content comparison results 
 
The ICF mapping for EQ-5D and the other outcome measures was conducted 
independently by 2 health professionals with ICF training and the Kappa coefficient was 
calculated to show the inter-observer agreement. The Kappa coefficient ranges between 1 
and -1 and is based on the difference between the actual agreement and the expected 
agreement between health professionals (Viera and Garrett, 2005; Cohen, 1960). If Kappa 
equals 1 there is perfect agreement. If Kappa ranges from 0.61 to 0.80 there is considered 
to be substantial agreement and from 0.41 to 0.60 is considered to be moderate agreement. 
If Kappa is under 0.20 there is considered to be poor agreement (Viera and Garrett, 2005; 
Altman, 1991). 
 
The ICF updated linking rules (Cieza et al, 2005) recommend that the Kappa coefficient 
should be given for the mapping results. The Kappa coefficient was calculated for each 
outcome measure in the studies at the different levels of the ICF code and the full details 
are in Appendix 2.1, however, the overall Kappa coefficient for each level is presented in 
Table 3.4.1. The table shows that at every level of ICF code there was substantial 
agreement overall, even though there was not substantial agreement for every individual 
measure at every ICF level. This reveals that the 2 health professionals who conducted the 
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ICF mapping shared similar interpretations of how the individual questions should be 
mapped onto the ICF concepts. It should be noted that this is the first time that ICF 
mapping for most of the outcome measures (all except EQ-5D and SF-36) has been 
conducted and therefore there are no other results to check the mapping against.  
 
The high level of agreement between the 2 health professionals indicates that the mapping 
results are potentially reliable, and where there was disagreement a third professional 
confirmed which code should be used. These mapping results provide the basis for 
comparing the content of EQ-5D and the other outcome measures. 
 
Table 3.4.1 Kappa coefficient of inter-observer agreement 
ICF Kappa coefficient overall 
component 0.75** 
Chapter 1st level 0.89** 
2nd level 0.91** 
3rd level 0.97** 
4th level 1.00** 
*: p < 0.05; **: p< 0.001 
 
The mapping was conducted for the 8 drug misuse intervention studies identified by the 
review in the previous chapter. In total the studies included 24 different outcome 
measures or subscales of outcome measures in addition to EQ-5D. These measures 
covered 196 concepts in total: 51 in ICF component b, 92 in ICF component d, 21 in ICF 
component e and 32 that could not be mapped onto ICF concepts. The measures covered 
no concepts in ICF component s. EQ-5D only covered 2 concepts in ICF component b, 12 
in component d and did not cover any other concepts. Of the 196 concepts covered in 
total there were 182 that were covered by other outcome measures and not by EQ-5D, and 
only 14 covered by both EQ-5D and other measures. Full details of the concepts covered 
by each measure are in Appendix 3, however, Table 3.4.2 shows the frequency of 
overlapping concepts between EQ-5D and the other measures. In addition, it shows the 
frequency of agreement between different measures at both the component and the first 
level of the ICF chapter. This thus reveals the extent to which EQ-5D covered similar 
concepts as other outcome measures, even when it did not cover exactly the same concept, 
which further indicates the extent of the similarity between the content of EQ-5D and the 
other measures in components b and d. 
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Table 3.4.2 shows that of the measures that covered concepts in component b (body 
functions), there was a large extent of agreement between EQ-5D and the other measures 
at the first level of the ICF chapter. At the first level most of these measures were in 
complete agreement with EQ-5D; the measure that had the least agreement, MAP-HSS, 
still had 6 of 10 concepts in component b in agreement at the first level. The first level for 
component b represents the chapter that the concepts are in, such as the mental functions 
or sensory functions and pain. Where there is agreement at the first level of the ICF 
chapter it thus reveals that the questions were concerned with the same general content. 
 
Table 3.4.2 reveals that it was only at the second level of the ICF chapter that EQ-5D did 
not generally map the same concepts as other measures. In some cases there was a 
considerable amount of overlapping concepts, for example of the 14 concepts that SF-36 
covered in component b, 9 were overlapped, and of the 5 concepts that EuropASI 
Family/Other covered 3 were overlapped. 4 of the measures had just under half of the 
concepts in component b overlapped with EQ-5D (BSI, MAP-HSS, SCL-90, and SDS), 
however the other 10 measures that covered concepts in component b had few or no 
overlapping concepts at the second level of the ICF chapter. The second level of the ICF 
chapter categorises the concepts in a greater level of detail. For example within mental 
functions (b1), options include emotional functions (b152), perceptual functions (b156) or 
thought functions (b160). This indicates that within component b, EQ-5D does not cover 
exactly the same concepts as other measures when they are considered in detail, however, 
EQ-5D does cover similar concepts as shown by the high level of agreement between the 
measures at the first level of the ICF chapter. 
 
Turning to component d (activities and participation), Table 3.4.2 shows that there was a 
large extent of agreement between EQ-5D and the other measures at the first level of the 
ICF chapter. Most of the measures were in complete agreement with EQ-5D and even 
BSI, the measure that had the least agreement, had 8 of 10 concepts in component d in 
agreement at the first level. The chapters for component d include mobility (d4) and self-
care (d5), and the high level of agreement between EQ-5D and the other measures 
indicates that they were concerned with the same general content and covered similar 
concepts. 
 
Again, it was only at the second level of the ICF chapter that EQ-5D did not map the 
same concepts as other measures in component d. Table 3.4.2. shows that the only 
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measures that had considerable overlapping concepts with EQ-5D at the second level 
were SF-12, which had 9 of 13 concepts overlapped, and SF-36, which had 21 of 31 
concepts overlapped. The other 20 measures that included concepts in component d all 
had under half of the concepts at the second level of the ICF chapter overlapped with EQ-
5D. This means that EQ-5D does not generally cover exactly the same concepts as the 
other measures, such as lifting and carrying objects (d430) or using transportation (d470), 
but that there is general agreement between the measures regarding the content that 
should be considered. 
 
The first objective of this chapter has been to compare the content of EQ-5D and the other 
outcome measures. The general agreement between EQ-5D and the other measures at the 
first level of the ICF chapter for components b and d, reveals that even though there are a 
lot of specific concepts that EQ-5D does not cover that are covered in the other measures, 
this does not simply indicate that the measures have no common content. Indeed they are 
largely in agreement about the general content and cover similar concepts if not exactly 
the same concepts. However, it is worth stressing that this is only the case within 
components b and d. It is also important to recognise how many concepts EQ-5D does not 
cover that are additionally covered by other measures. This is revealed by examining the 
‘Other concepts not in EQ-5D’ column in Table 3.4.2. This takes into account all of the 
concepts from component e (environmental factor), under the chapters of products and 
technology (e1), support and relationships (e3), and services, systems and policies (e5), as 
well as all the concepts that could not be mapped onto the ICF code, such as suicide. 
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Table 3.4.2 Content comparison results 
ICF category  Component b Component d  
 Total 
number of 
concept 
Agreement at 
component 
Agreement at 
chapter 1st 
level 
Overlapping 
concepts at 
chapter 2nd level 
Agreement at 
component 
Agreement at 
chapter 1st 
level 
Overlapping 
concepts at 
chapter 2nd level 
Other 
concepts not 
in EQ-5D 
EQ-5D* 15 2 - - 13 - - - 
BSI 57 44 40 19 10 8 0 3 
CIDI 128 16 16 3 29 24 15 83 
EuropASI 262 34 34 9 79 79 24 149 
EuropASI Drug 64 5 5 1 4 4 0 55 
EuropASI 
Employment 
36 2 2 0 27 27 8 7 
EuropASI 
Family/Other 
73 5 5 3 39 39 16 29 
EuropASI Legal 30 2 2 0 7 7 0 21 
EuropASI 
Medical 
24 2 2 0 0 0 0 22 
EuropASI 
Psychiatric 
37 18 18 5 2 2 0 15 
HADS 18 15 14 5 2 2 1 1 
IDUQoL 31 1 1 0 21 20 7 9 
IRQ 21 0 0 0 18 18 0 3 
MANSA 26 0 0 0 15 15 6 11 
MAP-crime 11 0 0 0 1 1 0 10 
MAP-HSS 10 10 6 4 0 0 0 0 
OTI 107 19 18 5 9 8 1 79 
OTI-crime 9 0 0 0 3 3 0 6 
OTI-drug 66 0 0 0 0 0 0 66 
OTI- 32 19 18 5 6 5 1 7 
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psychological 
health 
RTBS 14 0 0 0 14 14 0 0 
SCL-90 108 78 66 32 25 23 1 5 
SDS 8 5 5 2 0 0 0 3 
SF-12 22 6 6 5 13 12 9 3 
SF-36 56 14 14 9 31 31 21 11 
TLFB-cannabis 4 0 0 0 1 1 0 3 
TLFB-heroin, 
methadone 
9 0 0 0 2 2 0 7 
WHODASII 35 6 6 2 23 22 12 6 
* EQ-5D is mapped onto the following concepts: b152 (emotional functions), b280 (sensation of pain), d230 (carrying out daily routine), d4 (mobility), 
d450 (walking), d498 (mobility, other specified-confined to bed), d5 (self-care), d510 (washing oneself), d540 (dressing), d640 (doing housework), d760 
(family relationship), d839 (education, other specified-study), d850 (remunerative employment), and d920 (recreation and leisure).
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3.4.2 Results of correlation between questions in overlapping concepts 
 
In addition to knowing whether or not EQ-5D covers the same concepts as other measures, 
it is also important to know whether or not patients respond to different questions 
covering one concept in the same way as they respond to other questions covering that 
same concept across the different measures. The RESULT study (Raistrick et al, 2008) 
was used to examine the correlation between the questions. The Kappa coefficient was 
calculated for each outcome measure and the overall results are show in Table 3.4.3, with 
the full details in Appendix 2.2. Overall there was substantial agreement between the 2 
health professionals who conducted the ICF mapping. 
 
Table 3.4.4 shows the overlapping concepts between the outcome measures and EQ-5D in 
the RESULT study. In this section it is only necessary to consider the overlapping 
concepts; unlike in the previous section the concepts that EQ-5D did not cover do not 
need to be examined. Of the 4 other outcome measures in the RESULT study, 2 had 
overlapping concepts with EQ-5D in ICF component b (CORE and SCL) and 2 in 
component d (LDQ and SSQ). The overlapping concepts in component b are covered by 2 
separate EQ-5D questions, whereas the overlapping concepts in component d are all 
covered by a single EQ-5D question. The results for the correlation are considered in turn 
by each EQ-5D question and are given at both the baseline and the 6 month follow-up 
period.  
 
Table 3.4.3 Kappa coefficient of inter-observer agreement in RESULT 
ICF Kappa coefficient overall 
component 0.61** 
Chapter 1st level 0.90** 
2nd level 0.81** 
3rd level 0.80** 
4th level 1.00* 
*: p < 0.05; **: p< 0.001 
 
Table 3.4.4 Overlapping concepts covered by the outcome measures in RESULT 
ICF 
category 
Overlapped with EQ-
5D in component b 
Overlapped with EQ-
5D in component d 
LDQ 0 2 
SSQ 0 7 
CORE 12 0 
SCL  4 0 
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The responses from EQ-5D and the other 4 outcome measures all use different response 
ranges. EQ-5D responses range from 1 to 3, where 1 means ‘no problem’. CORE and 
SCL responses range from 0 to 4, where 0 means ‘not at all’ or ‘never’. LDQ responses 
range from 0 to 3 where 0 means ‘never’. SSQ responses also range from 0 to 3 where 0 
means ‘very dissatisfied’. The correlation coefficient was calculated using Spearman’s 
correlation, which ranges from -1 to 1, where -1 represents strong negative correlation 
and 1 represents strong positive correlation. If the coefficient is between 0.10 and 0.29 
there is a weak correlation, between 0.30 and 0.49 there is medium correlation, and above 
0.50 there is strong correlation (Field, 2005). 
 
Table 3.4.5 shows the correlation between EQ-5D and all of the other questions covering 
ICF concept b152 (emotional functions) at both baseline and the follow-up period. Most 
of the results have either medium or strong correlation, although 2 questions have weak 
correlation (Q12 and Q33 at baseline). 7 of the 11 questions have strong correlation at the 
follow-up period, however only one of these (Q2) also has strong correlation at baseline. 
Q2 is the only question that has a coefficient of over 0.6, which reflects that this question 
(I have felt tense, anxious or nervous), was closest to EQ-5D Q5 (anxiety/ depression). If 
the different questions within the same concept were very similar to one another then 
strong correlation would be expected. However, the results suggest that even though there 
is some strong correlation, in most cases this is not consistent between the 2 time points 
considered.  
 
Table 3.4.6 shows the correlation between EQ-5D and the other questions covering ICF 
concept b280 (sensation of pain) at baseline and the follow-up period. None of the 
questions have strong correlation, and the highest is CORE Q8, which has coefficients of 
0.47 at baseline and 0.45 at the follow-up period. The other coefficients are all lower, 
which is probably because EQ-5D Q4 is a general question about pain/ discomfort, 
whereas the other SCL questions all ask about pain in a specific body part. 
 
Table 3.4.7 shows the correlation between EQ-5D and the other questions covering ICF 
concepts d230 (carrying out daily routine), d760 (family relationships), d850 
(remunerative employment) and d920 (recreation and leisure) at both baseline and the 
follow-up period. There are only a limited number of statistically significant correlation 
coefficients, all of which have weak correlation. The reason for this is that EQ-5D Q3 is a 
general question regarding the patients’ usual activities, whereas the LDQ and SSQ 
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questions all refer to very specific activities or relationships. For example SSQ Q5 asks 
how satisfied patients are with the amount of time they are able to go out, and there is 
only small correlation with EQ5D Q3 at the follow-up period. 
 
Having examined the correlation between EQ-5D and the other measures that ask 
questions that cover the same concepts, it is clear that in most cases the patients do not 
necessarily respond to different questions covering the same concept in the same way. If 
they did, strong correlation would be expected between the questions, however there was 
only any strong correlation with 1 of the 3 EQ-5D questions for which there were 
overlapping concepts, and even for that question (EQ-5D Q5) the strong correlation was 
inconsistent. The results therefore indicate that it cannot be expected that patients will 
respond to different questions covering the same concepts in the same way. It should be 
noted that this is a tentative conclusion as the correlation has only been calculated for the 
limited number of overlapping concepts within the one study where individual patient 
responses were available. To indicate whether these results apply more widely, it would 
be necessary to have more individual patient responses across a range of outcome 
measures, especially from drug misuse intervention studies. 
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Table 3.4.5 Correlation between EQ-5D and CORE questions which cover the same 
concept (ICF b152 Emotional functions) at baseline and follow-up 
n=401 at baseline, n=268 at 
6 month follow-up 
EQ-5D Q5 Anxiety/Depression 
(range 1-3; 1 is ‘no problem’) at 
baseline 
EQ-5D Q5 
Anxiety/Depression 6 
month 
CORE Q1 I have felt 
terribly alone and isolated 
(range 0-4; 0 is ‘not at all’) 
0.48** 0.47** 
CORE Q2 I have felt tense, 
anxious or nervous 
0.63** 0.62** 
CORE Q9 I have thought of 
hurting myself 
0.36** 0.41** 
CORE Q11 Tension and 
anxiety have prevented me 
doing important things 
0.47** 0.50** 
CORE Q12 I have been 
happy with the things I have 
done 
0.21** 0.26** 
CORE Q14 I have felt like 
crying 
0.44** 0.56** 
CORE Q15 I have felt panic 
or terror 
0.48** 0.56** 
CORE Q17 I have felt 
overwhelmed by my 
problems 
0.45** 0.56** 
CORE Q27 I have felt 
unhappy 
0.49** 0.55** 
CORE Q28 Unwanted 
images or memories have 
been distressing me 
0.41** 0.49** 
CORE Q33 I have felt 
humiliated or shamed by 
other people 
0.29** 0.37** 
**: p< 0.001 
 
Table 3.4.6 Correlation between EQ-5D, CORE and SCL questions which cover the same 
concept (ICF b280 Sensation of pain) at baseline and follow-up 
 EQ-5D Q4 
Pain/Discomfort at 
baseline 
EQ-5D Q4 
Pain/Discomfort at 6 
month 
CORE Q8 I have been troubled by 
aches, pains or other physical 
problems (range 0-4; 0 is ‘not at all’) 
0.47** 0.45** 
SCL Q4 Stomach pains (range 0-4; 0 
is ‘never’) 
0.23** 0.32** 
SCL Q6 Chest pains 0.26** 0.30** 
SCL Q7 Joint/bone pains 0.41** 0.29** 
SCL Q8 Muscle pain 0.38** 0.33** 
**: p< 0.001 
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Table 3.4.7 Correlation between EQ-5D, LDQ and SSQ questions which cover the same 
concepts (ICF d230 Carrying out daily routine, d760 Family relationships, d850 
Remunerative employment, d920 Recreation and leisure) at baseline and follow-up 
ICF 
concept 
 EQ-5D Usual Activities 
(eg. work, study, 
housework, family or 
leisure activities) at 
baseline 
EQ-5D Usual 
Activities  at 
6 month 
d230 LDQ Q2 Is drinking or taking 
drugs more important than anything 
else you might do during the day? 
(range 0-3; 0 is ‘never’) 
0.15* 0.14* 
d230 LDQ Q4 Do you plan your days 
around getting and taking drink or 
drugs? 
0.13* 0.15* 
d760 SSQ Q7 7. How satisfied are you 
with your closest relationship in 
life (eg. spouse, partner, lover, 
parent, best friend)? (range 0-3; 0 is 
‘very dissatisfied’) 
-0.03 -0.08 
d760 SSQ Q8 How satisfied are you with 
your relationship with your family 
(include children and other 
relatives)? 
-0.02 -0.12 
d850 SSQ Q3 How satisfied are you with 
your employment situation?  
(Please answer this question even if 
you are unemployed or a full-time 
homemaker) 
-0.06 0.04 
d920 SSQ Q5 How satisfied are you with 
the amount of time you are able to 
go out? 
-0.07 -0.19** 
d920 SSQ Q6 How satisfied are you with 
the amount of time you see your 
friends? 
-0.10 -0.15* 
*: p < 0.05; **: p< 0.001 
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3.5 Conclusions and Discussion 
 
The aim of this chapter has been to evaluate the content of EQ-5D by comparing it with 
other outcome measures. This has been achieved first by using ICF, the content 
comparison technique developed by the WHO (2001), to examine whether or not EQ-5D 
covers the same concepts as other outcome measures used in the drug misuse intervention 
studies identified in the previous chapter.  
 
ICF identifies a range of different concepts across 4 components that provide a 
comprehensive framework for examining individuals’ well-being. However, EQ-5D only 
covers concepts in 2 of those components: b (body functions) and d (activities and 
participation). This indicates first that EQ-5D only partially maps onto the WHO’s 
framework. Second, and more importantly, it reveals one of the major limitations of using 
EQ-5D as the only outcome measure for drug misuse studies, as the other outcome 
measures considered also cover concepts in the third ICF component, e (environmental 
factors) and cover concepts that do not map onto those identified by the ICF. There are 53 
such concepts that EQ-5D does not cover that are covered by the other measures. 
 
The other measures also cover 51 different concepts in ICF component b and 92 in ICF 
component d, whereas EQ-5D only covers 2 concepts in component b and 12 in 
component d. All the concepts covered by EQ-5D were also covered by the other 
measures, but there were a great number of concepts that EQ-5D did not cover that were 
covered by the other measures. At first this might seem to suggest that it would be 
inadequate to use EQ-5D as a single outcome measure, however, closer examination 
revealed that this is not quite the case. Even though EQ-5D did not have a lot of 
overlapping concepts with the other outcome measures in components b and d, there was 
a high level of agreement at the first level of the ICF chapter. The first level of the ICF 
chapter denotes the general concern that is addressed in the questionnaire, such as self-
care (d5). It is only at the second level of the ICF chapter, which is much more detailed, 
that EQ-5D did not cover the same concepts. This means that although EQ-5D was not 
covering exactly same concepts as other measures it was frequently covering similar 
concepts and there was a great extent of general agreement in the content between the 
measurers. 
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Even though there was a general amount of content agreement between EQ-5D and the 
other measures within components b and d, this only indicates that EQ-5D might be an 
adequate single outcome measure for drug misuse studies if the interest is only with 
outcomes of drug misuse interventions related to body functions (b) and activities and 
participation (d). EQ-5D fails to take into account outcomes related to environmental 
factors (d) and other concepts not included in the ICF concepts, such as suicide, which 
other outcome measures consider. 
 
A further limitation of using EQ-5D as the only outcome measure is that even when it 
does cover the same concepts as other outcome measures, it is not clear that patients will 
necessarily respond to different questions covering the same concept in the same way. If 
patients did respond to different questions covering the same concept in the same way 
then strong correlation would be expected between questions in EQ-5D and other 
measures that cover the same concepts. However, the analysis of the RESULT study 
(Raistrick et al, 2008) has shown that there is often not strong correlation between the 
questions in overlapping concepts between EQ-5D and the other measures. These results 
themselves are limited, as there was only a small number of overlapping concepts 
between EQ-5D and the measures in the RESULT study. Nevertheless, they tentatively 
suggest that if EQ-5D is to be used as a single outcome measure, it is important to realise 
that it may not provide the same patient responses as other measures that cover the same 
concepts. To reveal whether or not these finding are more widely applicable it would be 
beneficial if future studies could examine the correlation between questions in EQ-5D and 
other outcome measures with which it has more overlapping concepts, such as SF-36 or 
WHODAS II.   
 
If EQ-5D covered the same concepts as other outcome measures and if patients could be 
expected to give the same responses to different questions within the same concept, then 
it may not be necessary to use as many questionnaires as are currently used in drug 
misuse intervention studies. In addition NICE (2008) recommends using the EQ-5D 
instrument with UK population values to measure health outcomes in the UK. There are 
advantages for policy makers if they can use a single generic outcome measure, however, 
this chapter and the previous one have questioned whether EQ-5D adequately reflects the 
other outcome measures used in drug misuse intervention studies by comparing the 
content of the measures and examining whether there are trends between their results. The 
2 chapters have highlighted the limitations with using EQ-5D, or indeed any single 
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outcome measure, to reflect the range of different outcome measures that should be taken 
into account to provide a comprehensive evaluation of the individual level outcomes for 
drug misuse policy. 
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Chapter 4 Systematic Review for drug misuse intervention on the 
individual patient level of the monetary outcome 
 
4.1 Background 
 
The previous two chapters have examined whether EQ-5D is an adequate outcome 
measure for drug misuse intervention studies by comparing it with other non-monetary 
outcomes. However, it is also important to consider the monetary (or the social cost) 
outcome in the economic evaluation of drug misuse interventions. One of the advantages 
of evaluating the monetary outcome is that a wide range of dimensions can all be 
presented in commensurate units of measurement. In addition the monetary outcome for 
health interventions may also be compared with interventions outside of the health sector 
where the results are all measured in monetary units. However, which monetary 
dimensions are measured depends on the perspectives and interests of those undertaking 
the research. Different regulatory authorities in different countries recommend different 
perspectives (Claxton et al, 2010). In the UK, the NHS recommends the inclusion of the 
difference of the resources used or the resources saved (Kelly et al, 2005). The resources 
used show what resources the individual patient has used, whereas the resources saved 
show the estimated savings to society from the patient receiving the intervention 
compared with patients not receiving the intervention. 
 
For drug misuse research it is especially important to estimate the societal cost. Drug 
misuse is regarded as being closely related to the social resource use, especially within the 
criminal justice system and with respect to the health burden of hepatitis and HIV 
(Cartwright, 1998; Cartwright, 2008; Garfein et al, 1996; Godfrey, 2006; Hser and Anglin, 
1991; Joseph, 1988; Mark et al, 2001; Masson et al, 2002; Neale et al, 2006; Sweeney et 
al, 2009; Wiessing et al, 2004). A wide range of outcome categories for economic 
evaluations in drug misuse interventions have been developed, which cover areas like 
resource use in health care, crime, social care, and productivity loss (Godfrey, 2006; 
Simoens et al, 2006; McCollister and French, 2003). However, there are only a few 
common methods for estimating the monetary benefit within these categories. For 
instance, the social costs related to crime can be based on the cost incurred by the victims, 
or the resource use within the criminal justice system. 
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This review is based on the dimensions of the monetary outcome categorised by Godfrey 
(2006). Although there are other ways of categorising dimensions (for example 
Cartwright, 1998), the advantage of using the dimensions categorised by Godfrey (2006) 
is that they are based on the economic evaluation theory suggested by M. F. Drummond 
and colleagues (2005), which is employed throughout this thesis. The study by Godfrey 
(2006) categorises monetary dimensions in 2 domains: resources saved and other value 
created. In the resources saved domain there are 3 dimensions: the health care cost, the 
criminal justice cost, and the social care cost. As interventions are primarily aimed at the 
drug misuse patients’ health it is very important to measure the health care cost. The 
social care services cost is also important, given that drug misuse patients are very likely 
to use services such as shelters in the case of homeless drug users or counselling in the 
case of unemployed drug users. Given that drug misuse patients are also likely to commit 
crime, the criminal justice cost is another important measure. 
 
In the other value created domain there are a further 5 dimensions: increased productivity; 
the value from reduced accidents and deaths to third parties; the value to communities 
from reduced drug related problems, the reduced risk to third parties of the spread of 
infectious diseases and the potential impact on future drug use and harms. Increased 
productivity is important given that healthy individuals will contribute to the productivity 
of society. The value from reduced accidents/ deaths to third parties is important to 
consider because drug misuse patients are likely to endanger the health of others, for 
example from accidents caused by driving under the influence of drugs. The value to the 
community from reduced drug related problems is particularly important given that drug 
users may commit crime and therefore the fear of crime and cost to the victims should be 
taken into account. The reduced risk to third parties of infectious diseases like HIV and 
hepatitis is especially considerable among injecting drug users. Although interventions 
might be effective in the short-term the patient might relapse later in life, therefore it is 
also important to measure the potential impact on future drug use and harms. For a 
comprehensive economic evaluation, then, the outcomes in both the resources saved and 
other value created domains should all be measured. 
 
4.2 Objectives 
 
The purpose of this review is to examine which dimensions of the monetary outcome 
have been chosen in the individual level patient data of the economic evaluation of drug 
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misuse interventions. The review examines the monetary dimensions that have been 
included in previous intervention research and how these are measured. 
 
The first objective of this review is to identify the studies that have estimated the 
monetary outcome for drug misuse interventions and examine which dimensions of the 
monetary outcome have been measured. This will provide an overview of the current 
development of economic evaluations of drug misuse interventions and the limitations 
with existing studies. The second objective is to investigate how the dimensions are 
determined within each outcome category. This will illustrate whether or not there is a 
common understanding within economic evaluations of how to estimate monetary 
dimensions. The results of the review will provide an overview of the monetary burden to 
the society arising from drug misuse, from which the implications for policy makers will 
be analysed. 
 
4.3 Methods 
 
The most common method for measuring the monetary outcome in economic evaluations 
is by conducting a cost-benefit analysis. A cost-benefit analysis compares all the costs 
and the benefits of different interventions in monetary terms, and therefore allows policy 
makers to assess directly whether or not an intervention is worthwhile, without recourse 
to any other standard in the analysis (Drummond, M.F. et al, 2005). However, this review 
focuses on all of the studies that have measured the individual level outcome in monetary 
terms and not just those that conducted a cost-benefit analysis. 
 
4.3.1 Inclusion Criteria for this review 
 
Type of studies: Studies measuring the monetary outcome at one point of time, at 
different points of time, or changes between points of time will be included. There will be 
no intervention comparison restriction in the searching criteria, because comparing 
different interventions is not the main interests of this review. Studies considering one or 
more interventions will be included. 
 
Type of intervention: Studies of interventions primarily aimed at reducing drug misuse 
problems will be included. All types of intervention delivered to the individual drug user 
or potential drug users will be considered. Studies of interventions delivered solely to the 
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drug users’ family/ partner will not be included as the focus here is only on the outcome 
of the individual drug users. 
 
Type of participants: People who misuse substances, including any type of illegal 
substance. Studies of people with only alcohol addiction or smoking problems will be 
excluded. Only studies collecting individual patient level data will be included. 
 
Outcome: Outcomes have to be measured in monetary terms and have to consider the 
impact of the intervention on others in society. Studies that consider some dimensions of 
the monetary outcome as well as other clinical or economic outcomes will also be 
included. Studies only measuring intervention costs or only measuring clinical 
effectiveness will not be included. 
 
Comparison: Studies considering at least one intervention will be included. Studies that 
measure outcomes either at one point of time, at different points of time, or the changes 
between points of time will be included. 
 
4.3.2 Data sources and search strategy 
 
Electronic and manual searches are undertaken to identify studies. 
Search strategy: 
The search was performed in June 2010. Studies which meet the inclusion criteria are 
identified from the following sources. There is no restriction for language or the year of 
publication. 
 
Econlit (1969 – to June 2010) 
EMBASE (1980–June 2010)  
MEDLINE (1950 –June 2010) 
PsycINFO (1806 –June 2010) 
CRD (Centre for Reviews and Dissemination) databases 
The Cochrane Library 
The Cochrane Central Register of Controlled Trials (CENTRAL) 
Current Controlled Trials Register 
 
Example of searching strategy: MEDLINE; 1950 –June 2010:  
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[(drug misuse or drug dependen* or substance misuse or substance abuse or substance 
dependen* or addict* or illegal drug* or illicit drug* or inject* drug* or methadone or 
heroin or opiat* or opium or cocaine or crack cocaine or ecstasy or LSD or magic 
mushroom* or amphetamine or cannabis or marijuana or ketamine) and (economic 
evaluation)] and [(cost* or resource use* or soci* cost)] 
 
4.4 Results 
 
4.4.1 Description of included studies and dimensions of monetary outcome included 
 
The purpose of this section is to identify the studies that measured the monetary outcome. 
Of 425 studies that were reviewed, 50 studies that are related to drug misuse treatment 
have been included. Most of the excluded studies only estimated the treatment costs or 
were modelling studies. 
 
The interventions used in the included studies were mainly treatment types of intervention 
like methadone maintenance treatment, outpatient treatment and residential treatment. 
There were also some prevention programmes such as drug testing, and crime-related 
interventions like drug courts.  
 
Only one of the included studies is a cross-sectional study (Neale et al, 2006), whereas the 
rest of the studies all followed the patients for a certain period of time, from 2 weeks up to 
10 years. The number of participants in the included studies also ranged widely. The 
smallest sample size was 25 patients (Mauser, VanStelle and Moberg, 1994), and the 
largest sample size was 3.9 million (Berger, 2003). Most of the studies estimated the 
outcome from the societal perspective, and 11 studies estimated the outcome from the 
health care service provider/ government’s perspective. 4 studies estimated the outcome 
from the perspective of the tax-payer (Daley et al, 2000; French, Fang and Fretz, 2010; 
Longshore et al, 2006; McCollister et al, 2009).  
 
Most of the included studies were conducted in the USA and 6 studies were conducted in 
the UK. There was also 1 Norwegian study, 1 Dutch study, 1 German study, 1 Taiwanese 
study and 2 Australian studies. Details of each included study are listed in Table 4.4.1 and 
Appendix 4.  
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46 of the included studies measure monetary dimensions in either the resources saved 
domain, the other value created domain or both domains. Of these 23 are cost-benefit 
analyses, which apply the human capital approach for estimating the monetary outcome. 
The human capital approach values life and health foregone in terms of lost productivity. 
The other 23 studies are either cost-utility analyses or cost-effectiveness analyses with 
additional estimations for the monetary outcome, or studies designed to measure the 
monetary outcome alone. There are a further 4 studies, however, that do not measure the 
monetary outcome in terms of the dimensions within the 2 domains (Bishai et al, 2008; 
Borisova and Goodman, 2003 and 2004; Tang et al, 2007; Zarkin, Cates and Bala, 2000). 
These are all cost-benefit analyses that adopt the willingness-to-pay approach, which uses 
hypothetical questions to estimate values of how much individuals are willing to pay to 
improve their life quality and quantity. The merits of this approach remain contested and 
there are reservations about adopting it (Drummond, M.F. et al, 2005). Given that most of 
the included studies measure monetary dimensions in at least one of either the resources 
saved or other value created domain, these alone will provide the focus for the remainder 
of the analysis in this chapter and the willingness-to-pay studies will be examined no 
further. 
 
Table 4.4.2 shows the different monetary dimensions measured, categorised by resources 
saved and other value created, which provides an overview of the dimensions of the 
monetary outcome that are covered in the included studies. All of the studies measured at 
least one dimension from the resources saved domain. However, of the 46 studies 
identified, 10 did not measure the health care cost, 26 did not measure the social care 
services cost, and 10 did not measure the criminal justice cost. Only 17 studies measured 
all 3 of the costs from the resources saved domain. In addition, only 32 of the 46 
identified studies measured any dimensions in the other value created domain. Of these 
23 measured productivity and 19 measured the value to communities from reduced drug 
related problems, but none of the other outcomes in this domain were measured at all. Of 
the 17 studies that measured all 3 costs in the resources saved domain, 8 measured either 
productivity or the value to communities from reduced drug related problems in the other 
value created domain, but only 4 measured both (Ettner et al, 2006; Koenig et al, 2005; 
Mark et al, 2001; Miller and Hendrie, 2009). 
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Table 4.4.1 Description of included studies 
Study, country Population Intervention Follow-up Study 
perspective 
Approach to estimate 
monetary outcome 
Abou-Saleh et al, 2003; 
Abou-Saleh et al, 2008 
(HEPC), UK 
33 injecting drug users 
(IDUs), recruited from 
drug treatment centres 
Trial enhanced HIV 
prevention 
counselling 
intervention 
-Stay Safe Therapy 
(SST; 4 sessions) 
-Simple Educational 
Counselling (SEC; 1 
session) 
12 months Societal 
perspective 
Monetary outcomes 
converted from Service Use 
Questionnaire (SUQ) 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
 
Ates et al, 2005, 
Germany 
57 drug misuse patients Three groups: 
-Specialised 
integration project 
(Mudra e.V.) 
-Standard work  
projects 
-Graduates of work 
projects 
1 year Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: 
increased productivity 
Avants et al, 1999, 
USA 
291 opioid dependent 
patients 
Two groups 
-Day treatment 
-Enhanced standard 
methadone 
maintenance 
programme 
6 months Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: 
increased productivity 
Barnett et al, 2006, 
USA 
126 IDUs Patients in methadone 
treatment 
6 months Health care 
system 
-Resource saved: health care 
costs 
Berg, 1997, Norway 61 patients who have 
used several substance 
(heroin, amphetamine, 
hashish, painkillers, 
benzodiazepines and/or 
alcohol) 
Residential 
detoxification and 
counselling for 3 
weeks 
-Completer 
-Non-completer 
2 weeks since 
the 
detoxification 
started 
Societal 
perspective  
Human capital approach 
-Resource saved: health care 
costs 
-Other value created: 
increased taxes from 
taxable income 
Berger, 2003, USA 3.9 million pregnant Universal drug 1 year estimate Societal -Resource saved: health care 
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women misuse screening based on data 
from existing 
literature 
perspective  costs 
Bishai et al, 2008, USA 241 heroin addicts Before entering a 
methadone 
maintenance 
treatment 
N/A Health care 
provider 
perspective 
Willingness-to-pay (WTP) 
approach 
-Heroin addicts’ 
willingness-to-pay for the 
methadone maintenance 
treatment 
Borisova and 
Goodman, 2003 and 
2004, USA 
303 drug misuse patients Methadone 
maintenance 
treatment 
N/A Health care 
provider 
perspective 
WTP approach 
-Drug misuse patients’ 
willingness-to-pay and 
willingness-to-accept of the 
travel time required to 
obtain methadone 
maintenance treatment 
Conover et al, 2006, 
USA 
1,138 patients with 
HIV/AIDS, chronic 
mental illness and 
substance misuse 
Two groups: 
-Employed 
-Unemployed 
30 days Societal 
perspective  
Human capital approach 
-Resource saved: social care 
costs 
-Other value created: income 
Daley et al, 2000, USA 439 pregnant drug 
misuse patients 
Public funded drug 
misuse treatment 
90, 180 and 270 
days 
Taxpayer 
perspective  
-Resource saved: criminal 
justice costs 
-Other value created: victim 
costs 
Davies et al, 2009 
(Drug treatment 
outcomes research 
study; DTORS), UK 
1,545 drug misuse 
patients 
Patients received 
structured drug 
misuse treatment: 
community-based 
drug treatment or 
residential drug 
treatment 
1 year Societal 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: victim 
costs 
Dijkgraaf et al, 2005, 
Netherlands 
430 Heroin addicts Two groups: 
-Methadone plus 
heroin 
-Methadone alone 
12 months Societal 
perspective 
Monetary outcomes 
converted from the 
European version of 
Addiction Severity Index 
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(EuropASI) 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: victim 
costs 
Dismuke et al, 2004 
(PETS; The Persistent 
Effects of Treatment 
Study), USA 
1,326 drug misuse 
patients from PETS 
Drug misuse 
programmes from 
Chicago Target Cities 
Project 
6, 24, 36 and 48 
months 
Societal 
perspective 
Monetary outcomes 
converted from Addiction 
Severity Index (ASI), human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
Drummond et al, 2004; 
Drummond, C. et al, 
2005 (UKCBTMM), 
UK 
60 opiate addicts, 
recruited from 10 
community based clinics 
Two groups: 
-Cognitive behaviour 
therapy (CBT) plus 
methadone 
maintenance 
treatment (MMT) 
-MMT alone 
6 and 12 months Societal 
perspective 
Monetary outcomes 
converted from SUQ 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
Ettner et al, 2006 
(CalTOP; California 
Treatment Outcome 
Project), USA 
2,567 drug misuse 
patients 
43 drug misuse 
treatment for CalTOP 
3 and 9 months Social 
planner/ 
government 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: income 
and victim costs 
Fals-Stewart, O'Farrell 
and Birchler, 1997, 
USA 
80 drug misuse male 
patients from married or 
cohabiting couple 
Two groups: 
-Behavioural couples 
therapy (BCT) 
-Individual-based 
drug misuse 
treatment (IBT) 
12 months Operation/ 
government 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
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Finigan, 1996, USA 1,267 drug misuse 
patients 
Two groups: 
-Drug misuse 
treatment 
(outpatient, 
residential and 
methadone) 
-No treatment 
3 years data 
from existing 
database 
Societal 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: victim 
costs 
Finigan, Carey and 
Cox, 2007, USA 
11,102 offenders Two groups: 
-Drug court 
-Traditional court 
10 years data 
from existing 
database 
Societal 
perspective 
-Resource saved: criminal 
justice costs 
-Other value created: victim 
costs 
Flynn et al, 1999 
(DATOS; Drug Abuse 
Treatment Outcome 
Studies), USA 
502 cocaine dependent 
patients 
Two groups: 
-Long-term  
residential treatment 
(LTR) 
-Outpatient drug-free  
treatment (ODF) 
12 months Societal 
perspective 
Human capital approach 
-Resource saved: criminal 
justice costs 
-Other value created: crime 
career/productivity loss and 
victim costs 
French et al, 2000, USA 263 addiction treatment 
patient 
Two groups: 
-Outpatient substance 
abuse treatment 
(PC) 
-Residential 
substance abuse 
treatment (FC) 
9 months Societal 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
French et al, 2002a 
(PAAM; Pregnant 
Addicts/Addicted 
Mothers), USA 
121 pregnant drug 
misuse patients 
Two groups: 
-Specialty residential 
treatment 
-Standard residential 
treatment 
6 months Societal 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
French et al, 2002b, 
USA 
186 patients from 
homeless shelters and 
psychiatric hospitals 
Two groups: 
-Treatment-as-usual 
(TAU) 
-Modified therapeutic 
12 months Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
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community 
treatment (TC) 
-Other value created: income 
and victim costs 
French et al, 2002c, 
USA 
178 drug misuse patients 3 outpatient drug-free 
programmes 
7 months Societal 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
French, Salome, and 
Carney, 2002, USA 
222 drug misuse patients 9 adult substance 
residential treatments 
6 months Societal 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
French et al, 2003, USA 600 adolescent cannabis 
users aged 12 to 18 
5 programmes of 
CYT study (Cannabis 
Youth Treatment) 
3, 6, 9, 12 
months 
Societal 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
French, Fang and Fretz, 
2010, USA 
571 criminal offenders Two groups: 
-Pre-release substance  
treatment 
-No treatment 
1 year after 
release 
Tax-payer 
perspective 
Human capital approach 
-Resource saved: criminal 
justice costs 
-Other value created: wage 
loss and victim costs 
Godfrey, Stewart and 
Gossop, 2004 (NTORS; 
National Treatment 
Outcome Research 
Study), UK 
549 drug misuse patients Patient from 54 
residential and 
community treatment 
programmes 
1 and 2 years Societal 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: victim 
costs 
Harris, 
Gospodarevskaya and 
Ritter, 2005, Australia 
139 heroin dependent 
patients 
Two groups: 
-Buprenorphine 
-Methadone 
3, 6, and 12 
months 
Societal 
perspective 
-Resource saved: health care 
costs and criminal justice 
costs 
Hartz et al, 1999, USA 102 opioid-addicted 
patients 
Two groups: 
-Methadone treatment  
with contingency  
6 months Government  
perspective 
-Resource saved: health care 
costs 
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contracting 
-Methadone treatment  
(control group) 
Harwood et al, 1988 
(TOPS; Treatment 
Outcome Prospective 
Study), USA 
11,000 drug users from 
TOPS 
41 drug misuse 
treatment of 
outpatient methadone, 
residential and 
outpatient drug-free 
programme 
12 months Societal 
perspective 
Human capital approach 
-Resource saved: criminal 
justice costs 
-Other value created: crime 
career/productivity loss, 
income and victim costs 
Healey et al, 1998, 
(NTORS), UK 
1,075 drug misuse 
patients 
Patient from 54 
residential and 
community treatment 
programmes 
12 months 
before treatment 
Societal 
perspective 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: victim 
costs 
Koenig et al, 2005 
(PETS), USA 
595 drug misuse patients Drug misuse 
programme 
(methadone, 
residential 
rehabilitation, 
intensive overnight, 
outpatient) 
6, 12, 24, 30 
months 
Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: income 
and victim costs 
Levine, Stoloff and 
Spruill, 1976, USA 
15,000 drug misuse 
patients 
45 public drug misuse 
treatment 
programmes 
4 years data 
from existing 
database 
Government 
perspective 
-Other value created: victim 
costs 
Logan et al, 2004, USA 745 offenders Three groups of drug 
court programme: 
-Graduated clients 
-Terminated clients 
-Assessed clients 
12 months Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: income 
Longshore et al, 2006 
(SACPA; The 
California Substance 
Abuse and Crime 
Prevention Act), USA 
130,152 offenders Two groups: 
-Probation with drug  
misuse treatment 
-Incarceration/ 
probation without 
treatment 
12 and 30 
months data 
from existing 
database 
Taxpayer 
perspective 
Human capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
and sale taxes 
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Mark et al, 2001, USA 600,000 heroin addicts Cost-of-illness of 
heroin dependence 
1 year data from 
existing 
literature 
Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: 
productivity due to 
premature mortality, 
income and victim costs 
Masson et al, 2002, 
USA 
3,147 opioid dependent 
patients 
Two groups: 
-Opioid dependent  
patients 
-General patient  
population 
2 years Health care 
provider 
perspective 
-Resource saved: health care 
costs 
Mauser, VanStelle and 
Moberg, 1994 (TAP; 
Treatment Alternative 
Program), USA 
25 patients Treatment alternative 
programmes 
6 months Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: 
increased productivity and 
victim costs 
McCollister et al, 2009, 
USA 
119 young       offenders 
aged 12 to 17 
Four different drug 
court interventions 
4 and 12 months Tax-payer 
perspective 
-Resource saved: criminal 
justice costs 
-Other value created: victim 
costs 
McGlothlin and Anglin, 
1981, USA 
187 drug misuse patients Two groups: 
-Patients from a  
closed down  
methadone treatment  
clinic (Bakersfield) 
-Patients from a  
continuing  
methadone treatment  
(Tulare) 
25-26 months 
after discharge 
Societal 
perspective 
-Resource saved: criminal 
justice costs and social care 
costs 
Miller and Hendrie, 
2009, USA 
0.4-1.1 million young 
drug users aged 12 to 14 
Drug misuse 
prevention 
1 year estimate 
based on data 
Societal 
perspective 
Human capital approach 
-Resource saved: health care 
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from existing 
literature 
costs, criminal justice costs 
and social care costs 
-Other value created: 
productivity loss (due to 
premature death, illness 
related to substance or 
incarceration and criminal 
careers) and victim costs 
Neale et al, 2006, UK 75 injecting drug users Patients recruited 
from existing needle 
exchange 
programmes in large 
city, small town, and 
medium town 
N/A Societal 
perspective 
Monetary outcomes 
converted from SUQ 
-Resource saved: health care 
costs, criminal justice costs 
and social care costs 
Robertson, Grimes and 
Rogers, 2001, USA 
293 young offenders 
aged 11 to 17 
Two groups: 
-Community-based  
intensive  
supervision and  
monitoring (ISM) 
-Cognitive 
behavioural 
intervention (CB) 
6, 12 and 18 
months 
Public policy 
perspective 
-Resource saved: criminal 
justice costs 
Salome et al, 2003, 
USA 
2,665 addiction patients Addiction treatment 
from 19 treatment 
facilities 
6 months Societal 
perspective 
Monetary outcomes 
converted from ASI, human 
capital approach 
-Resource saved: health care 
costs and criminal justice 
costs 
-Other value created: income 
and victim costs 
Scanlon, 1976, USA 37,184 drug misuse 
patients 
Drug misuse 
treatment from 6 
facilities 
5 years Societal 
perspective 
Human capital approach 
-Resource saved: health care 
costs and social care costs 
-Other value created: income 
Sirotnik and Bailey, 285 heroin addicts 5 community drug 9 months Societal Human capital approach 
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1975, USA misuse treatment 
programmes 
perspective -Resource saved: health care 
costs, criminal justice costs 
and social care costs 
-Other value created: 
productivity loss 
Sweeney et al, 2009, 
Australia 
393 IDUs Treatment for 
injecting-related 
injuries and diseases 
12 months Public health 
system 
perspective 
-Resource saved: health care 
costs 
Tang et al, 2007, 
Taiwan 
1,817 members of 
general public 
Drug misuse 
treatment 
N/A Societal 
perspective  
WTP approach 
-Willingness-to-pay of the 
general public for the drug 
misuse treatment 
Yu et al, 1991, USA 123 drug misuse patients Drug misuse 
treatment in 
workplaces 
2 years Health 
insurance 
perspective 
-Resource saved: health care 
costs 
Zarkin, Cates and Bala, 
2000, USA 
393 members of general 
public 
Drug misuse 
treatment 
N/A Societal 
perspective  
WTP approach 
-Willingness-to-pay of the 
general public for the drug 
misuse treatment 
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Table 4.4.2 List of dimensions of the monetary outcome in the included studies  
Study Resource saved Other value created 
 Health care 
costs 
Criminal 
justice costs 
Social care 
costs 
Increased 
productivity 
Value to communities from reduced 
drug related problems 
Abou-Saleh et al, 2003; Abou-Saleh et 
al, 2008 (HEPC) 
     
Ates et al, 2005      
Avants et al, 1999      
Barnett et al, 2006      
Berg, 1997      
Berger, 2003      
Conover et al, 2006      
Daley et al, 2000      
Davies et al, 2009 (DTORS)      
Dijkgraaf et al, 2005      
Dismuke et al, 2004 (PETS)      
Drummond et al, 2004; Drummond, C. 
et al, 2005 (UKCBTMM) 
     
Ettner et al, 2006 (CalTOP)      
Fals-Stewart, O'Farrell and Birchler, 
1997 
     
Finigan, 1996      
Finigan, Carey and Cox, 2007      
Flynn et al, 1999 (DATOS)      
French et al, 2000      
French et al, 2002a (PAAM)      
French et al, 2002b      
French et al, 2002c      
French, Salome, and Carney, 2002      
French et al, 2003      
French, Fang and Fretz, 2010      
Godfrey, Stewart and Gossop, 2004 
(NTORS) 
     
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Harris, Gospodarevskaya and Ritter, 
2005 
     
Hartz et al, 1999      
Harwood et al, 1988 (TOPS)      
Healey et al, 1998      
Koenig et al, 2005 (PETS)      
Levine, Stoloff and Spruill, 1976      
Logan et al, 2004      
Longshore et al, 2006 (SACPA)      
Mark et al, 2001      
Masson et al, 2002      
Mauser, VanStelle and Moberg, 1994 
(TAP) 
     
McCollister et al, 2009      
McGlothlin and Anglin, 1981      
Miller and Hendrie, 2009      
Neale et al, 2006      
Robertson, Grimes and Rogers, 2001      
Salome et al, 2003      
Scanlon, 1976      
Sirotnik and Bailey, 1975      
Sweeney et al, 2009      
Yu et al, 1991      
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4.4.2 Estimation methods for different dimensions of monetary outcome 
 
In the previous section, the different dimensions of the monetary outcome have been 
identified and categorised. This section examines how monetary dimensions are estimated 
and whether there are common methods between the studies. As shown in Table 4.4.3, 
there are 2 main methods for estimating monetary dimensions in the included studies. 
 
The first method estimates the outcome by multiplying the unit cost and the frequency of 
the social cost events. Of the 46 studies included, 39 estimated the monetary outcome by 
the first method. All of the studies acquire the unit cost either from the existing literature 
or from government reports or from both. The unit cost may be varied within the existing 
literature because drug misuse policies are varied between different countries and even 
different states in some countries. The economic burden caused by drug misuse patients 
will not be the same between different countries. 
 
Questionnaires are used to estimate the frequency of the social cost events, however the 
type of questionnaire used varies between studies. Some studies (11 of the 39) used a 
standardised questionnaire, like ASI or EuropASI (McLellan et al, 1980; Kokkevi and 
Hartgers, 1995, respectively), or the Service Use Questionnaire (SUQ) designed by 
Godfrey and colleagues originally for the UKATT trial (UKATT research team, 2001 and 
2005). The advantage of using a standardised questionnaire to estimate the frequency of 
the social cost events is that it provides a standard way between countries to measure the 
same dimensions. 
 
The design of ASI and EuropASI are very similar, as EuropASI is actually the revised 
version of ASI for European research. Both include questions about the patient’s use of 
various resources: medical services; employment/ support services; services related to 
alcohol problems; services related to drug problems; resources used for criminal justice; 
resources used relating to family and social relationships; and psychology services 
(McLellan et al, 1980; Kokkevi and Hartgers, 1995). The questionnaire estimates the 
improvement of the individual’s health state and social functioning state by calculating 
the health resources saved, the social care resources saved and the increased productivity. 
It also estimates the value of the prevented crime by calculating the criminal justice 
resources saved following the intervention. 
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SUQ is another type of standardised questionnaire which was used in 3 of the studies that 
estimate the monetary outcome: the hepatitis C intervention trial (Abou-Saleh et al, 2003; 
Abou-Saleh et al, 2008), the UKCBTMM trial (Drummond et al, 2004; Drummond, C. et 
al, 2005), and a cross-sectional study of injecting drug users in needle exchange 
programmes (Neale et al, 2006). SUQ includes questions about the patient’s use of health 
services; use of other social services (which includes individual’s employment status); use 
of drug related services; and use of criminal justice services. The purpose of SUQ is to 
evaluate the resources used by drug misuse patients. It estimates the value of the 
individual’s health state and social functioning state improvement by calculating the 
health resources saved and the social care resources saved. Like ASI and EuropASI, it 
also estimates the value of the prevented crime by calculating the criminal justice 
resources saved. 
 
The other 28 studies use non-standardised questionnaires, which differ from one another. 
Most of these also estimate the value of the individual’s health state and social 
functioning state improvement by calculating the health resources saved and the social 
care resources saved. However, they might also include the other types of value arising 
from prevented crime, such as the victim costs.  
 
The second method for estimating the monetary outcome does not use the frequency of 
the social cost events at all. Instead it uses the overall estimates for the sum of the 
resource use among the population and the percentage of the resource use that is 
attributed to a particular group in society, in this case drug misuse patients. These 
estimates are taken from either government reports or the literature. The main problem 
with this method is that it is difficult to accurately attribute social resource use to a 
specific group within society. 7 of the 46 studies used this method. 2 of these were 
focused on estimating the value created from prevented crime and considered criminal 
justice resources saved and the victim cost (Finigan, Carey and Cox, 2007; Levine, 
Stoloff and Spruill, 1976). 3 of the studies estimated the value of increased productivity 
and 5 estimated the value of the improvement of the individual’s health state, by 
considering the health care resources saved. 
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Even within the 2 methods different studies estimate the monetary outcome differently by 
considering different dimensions. This will depend on the perspective of those conducting 
the research. However, as the 2 different methods in many cases measure the same 
dimensions, it is important to recognise that when comparing the studies they may not be 
using the same method to estimate the value within the same dimensions.  
 
Table 4.4.3 Estimation of societal resource use in the included studies 
Source/methods Study 
Unit cost * frequency -Use EuropASI or ASI to estimate outcomes: Dijkgraaf et al, 
2005; Dismuke et al, 2004; Ettner et al, 2006; French et al, 
2000; French et al, 2002a; French et al, 2002c; French, Salome, 
and Carney, 2002; Salome et al, 2003 
 
-Use SUQ to estimate outcomes: Abou-Saleh et al, 2003; Abou-
Saleh et al, 2008; Drummond et al, 2004; Drummond, C. et al, 
2005; Neale et al, 2006 
 
-Others: Ates et al, 2005; Avants et al, 1999; Barnett et al, 2006; 
Berg, 1997; Conover et al, 2006; Daley et al, 2000; Davies et 
al, 2009; Fals-Stewart, O'Farrell and Birchler, 1997; Flynn et 
al, 1999; French et al, 2002b; French et al, 2003; French, Fang 
and Fretz, 2010; Godfrey, Stewart and Gossop, 2004; Harris, 
Gospodarevskaya and Ritter, 2005; Hartz et al, 1999; Harwood 
et al, 1988; Healey et al, 1998; Koenig et al, 2005; Logan et al, 
2004; Masson et al, 2002; Mauser, VanStelle and Moberg, 
1994; McCollister et al, 2009; McGlothlin and Anglin, 1981; 
Robertson, Grimes and Rogers, 2001; Scanlon, 1976; Sirotnik 
and Bailey, 1975; Sweeney et al, 2009; Yu et al, 1991 
Estimate of average 
resource use from the 
database or literature 
Berger, 2003; Finigan, 1996; Finigan, Carey and Cox, 2007; 
Levine, Stoloff and Spruill, 1976; Longshore et al, 2006; Mark 
et al, 2001; Miller and Hendrie, 2009 
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4.5 Conclusions and Discussion 
 
The aim of this chapter has been to identify the economic evaluations of drug misuse 
interventions and to examine whether or not they share a common method for evaluating 
the monetary benefits of the intervention. The results of the review have provided an 
overview of the different dimensions of the monetary outcome measured in existing 
studies. 
 
The results of this chapter, however, have shown that existing studies do not offer a 
comprehensive estimate of the monetary outcome. The dimensions of the monetary 
outcome may be classified in 2 domains. It is important to take into account all of the 
dimensions in the resources saved domain as they will all influence the monetary impact 
on the society. However, only 17 of the 46 studies considered all 3 dimensions. A further 
5 dimensions have been identified in the other value created domain. All of these 
dimensions are important and should be considered as they represent the potential impact 
on others in society. However, only 32 of the studies measured any of the dimensions in 
the value created domain at all, and these only covered 2 of the 5 dimensions. Only 4 of 
the studies considered all 3 of the dimensions in the resources saved domain and 2 of the 
dimensions in the value created domain. None of the studies provide a comprehensive 
estimate of the costs from the societal perspective and therefore policy makers might be 
misled when they make decisions if they assume that the studies do represent a 
comprehensive estimate. 
 
It is important that when policy makers use the existing research they are aware of the 
limitations within it. It is difficult for economic evaluations to take into account all of the 
dimensions in each domain, especially given the amount of information that is required to 
estimate the different dimensions. Few studies have the resources to conduct the analysis 
from a broad enough perspective to provide a comprehensive estimate of the societal 
monetary outcome and policy makers should be aware of these limitations and be able to 
justify which dimensions of the monetary outcome they think should be prioritised.  
 
If policy makers are only concerned with a certain problem, such as the health of the 
individual drug users, then it might be acceptable to adopt a narrow perspective, 
providing that the policy makers are both aware of the limitations of that perspective and 
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of the dimensions that they are neglecting, which would influence the monetary impact on 
society. If specific problems are targeted then it is also important that policy makers 
examine the costs of each dimension of the monetary outcome and not just the overall 
figure, as this may have important implications for who pays for the drug misuse 
intervention. For instance, if one intervention is directed at reducing the levels of crime 
committed, this may be paid for by the criminal justice department, whereas an 
intervention directed at reducing health care resources used may be paid for by the health 
department, such as the NHS in the UK. 
 
A more general consideration when measuring the monetary outcome is its relationship 
with specific individual patients’ characteristics and individual level outcomes, such as 
QALYs. Even though many of the studies included in the review used a standardised 
questionnaire for estimating the monetary outcome, none of them examined which type of 
drug user is more likely to use each type of resource, such as the health care services or 
criminal justice services. Given that the studies reviewed did not include all of the 
monetary dimensions it is all the more important to know whether or not there are specific 
relationships between different dimensions and patient characteristics as this might reveal 
potential bias within those studies if they exclude dimensions which relate more strongly 
to specific groups of drug misuse patient. In addition, if a profile of different types of 
drug user could be developed then this would provide useful information for policy 
makers as they would be able to direct specific types of intervention at specific types of 
drug misuse patient and allocate resources accordingly. The relationship between the 
monetary dimensions and the characteristics of individual drug users is examined in the 
next chapter. 
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Chapter 5 Problems of resource use estimation in drug misuse 
interventions 
 
5.1 Background  
 
In the previous chapter the methods that have been used to estimate the monetary 
outcome in economic evaluations of drug misuse interventions were examined. This 
chapter focuses on the resource use of drug misuse patients. The resource use is a 
category of the monetary outcome that estimates the cost of the services that drug misuse 
patients use within the public sector. The difference between the costs of the resources of 
a drug misuse patient as a result of drug misuse intervention from that of a patient who 
did not receive the intervention is called the resources saved, which was one of the 2 
domains of the monetary outcome categorised in the previous chapter. This chapter, 
therefore, is only concerned with the resources saved domain and not the other value 
created domain. 
 
One of the problems that emerged from the analysis in the previous chapter was that most 
drug misuse studies do not consider whether different types of patients use some 
resources more than others; indeed this is a problem with most drug misuse studies and 
not just those that measure the monetary outcome. The results from most existing studies 
only indicate the amount of resources used by either the total drug misuse patients or the 
average patient. However, this does not indicate whether or not some types of patient use 
more of one type of resource than another. For example, the results do not show which 
type of patients are most likely to commit crime or have a higher health care resource use. 
The results only show the overall or average figures, which does not account for variation 
within the sample of drug misuse patients surveyed. It might be that some types of patient 
have a high health care resource use and commit a low amount of crime, whereas over 
patients commit a lot of crime but have a low health care resource use. However, from the 
overall or average results it is impossible to conclude whether or not this is the case. 
 
Identifying the relationship between the types of drug users and the resource use may help 
policy makers decide about the allocation of resources, as they might be able to target 
specific interventions at specific types of drug users. It is important to understand which 
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factors are related to high societal costs and whether or not these vary between different 
types of drug misuse patients, especially when there is a financial incentive to minimise 
the burden to society.  
 
Some studies have attempted to capture the characteristics of different types of drug 
misuse patients by considering their gender, age and location (Daley et al, 2000; Neale et 
al, 2006). However, these might not be the only significant characteristics, and it is also 
important to consider whether or not other characteristics affect drug misuse, such as 
patients’ employment status, physical health status and whether they use other substances 
like cigarettes.  
 
5.2 Objectives 
 
The aim of this chapter is to use an existing date sample to examine whether or not a 
profile can be developed of the resource use in the public domain, by distinguishing 
between drug misuse patient characteristics.  
 
The first objective is to cluster the patients together according to the distribution of their 
costs within their various social cost categories and to identify the statistically significant 
characteristics of the patients in each cluster. The statistically significant social costs for 
the clusters will also be identified. 
 
The second objective is to examine whether or not there are any patterns between the 
significant characteristics and the significant social costs across the clusters. For example, 
if the patients have high health care costs whether or not they are also more likely to have 
high addiction and crime costs, or whether there is any relationship between employment 
status and social costs. If relationships can be identified across the clusters then a profile 
of different types of drug misuse patients may be identified. 
 
5.3 Methods 
 
5.3.1 Problems of using the mean average in highly skewed data 
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This chapter uses data from RESULT (Raistrick et al, 2008), which uses the Service Use 
Questionnaire (SUQ) originally designed by Godfrey and colleagues for the UKATT trial 
(UKATT research team, 2001 and 2005). This is used to determine patients’ resource use 
in 4 main categories: health care services, addiction related services, social care services, 
and criminal justice services.  
 
In each category a wide range of events are listed and the patients are asked in the 
interview whether or not they have experienced these events, such as a visit to the GP in 
the last 6 months. Based on the data of the frequency and unit cost of each event, the 
resource use of the 4 main categories and the overall resource use are estimated. As 
shown in Table 5.3.1 and Table 5.3.2, at the baseline the mean of resource use in health 
care services, addiction services and social care services are all lower than £1,000, and 
both the resource use in criminal justice and the overall resource use are higher than 
£4,500. In Table 5.3.2 there are similar findings at the 6 month follow-up period showing 
that both the crime costs and the overall societal costs are over £2,000, whereas the costs 
in the other 3 categories are much lower. 
 
Table 5.3.1 and Table 5.3.2 reveal that the data of all 4 social cost categories and the 
overall societal costs are highly positively skewed at both baseline and the 6 month 
follow-up period. For instance, Figure 5.3.1 and Figure 5.3.2 show that in the RESULT 
sample patients’ overall resource use is within the lowest clusters of the social costs at 
both baseline and 6 month follow-up. In addition, Table 5.3.1 and Table 5.3.2 show that 
over 55% of patients at baseline do not use any resources relating to addiction services, 
social care services and criminal justice services. Similarly, over 65% of patients do not 
have any costs relating to social care services and criminal justice services. The results of 
kurtosis show that the sample has a highly leptokurtic distribution at both baseline and the 
6 month follow-up period. This shows that the majority of patients’ social costs are 
clustered in a small cost range. The results of skewness and kurtosis show that the societal 
costs of patients in the RESULT sample are mainly clustered at the lowest end of the 
societal cost ranges. 
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Table 5.3.1 Description of the sample at baseline 
Baseline N % of Patients 
with £0 
Mean; £ S.D. of 
mean 
Skewness Kurtosis 
health care costs 402 24.1% 940.54 3838.68 10.15 122.85 
addiction service 
costs 
402 70.5% 422.79 1932.80 7.64 65.09 
social care costs 402 68.0% 85.12 294.09 5.93 43.25 
crime costs 402 55.1% 4580.51 10545.21 7.61 94.54 
total societal 
cost 
402 8.7% 6028.96 11803.32 5.94 59.94 
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Figure 5.3.1 Distribution of total societal costs at baseline 
 
Table 5.3.2 Description of the sample at 6 month follow-up 
6 month N % of Patients 
with £0 
Mean; £ S.D. of 
mean 
Skewness Kurtosis 
health care costs 268 9.0% 1,197.74 5210.52 13.77 205.63 
addiction service 
costs 
268 4.1% 757.48 2000.75 8.67 85.15 
social care costs 268 66.0% 93.51 302.08 5.44 36.12 
crime costs 268 73.9% 2084.51 4788.98 2.71 7.40 
total societal cost 268 2.2% 4133.24 7242.09 5.36 47.11 
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Follow-up total societal cost
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Figure 5.3.2 Distribution of total societal costs at follow-up 
 
In order to examine how different factors are related to the social cost, a range of different 
values is needed. When the data is highly positively skewed, it reveals a lack of variance 
in the sample. For instance, when the majority of the patients in the sample have £0 in the 
health care services category, their age, gender and other characteristics make no 
difference. It would, therefore, be impossible to use general statistical techniques to 
determine whether age, gender and any other characteristics are relevant factors for 
predicting the health care services cost. When the data is more normally distributed across 
a wider range of different health care service costs, it is possible to examine whether there 
are any factors related to the different range of health care costs, for example, whether or 
not the older patients have higher health care costs. Due to the highly skewed data, this 
chapter will pursue a different approach by using clustering techniques and examining the 
relationship between social costs and patients’ characteristics within the subgroup in the 
RESULT sample. 
 
5.3.2 Cluster analysis 
 
Cluster analysis allows researchers to establish subgroups within the sample and then 
analyse the group membership (Garson, 2009). The di
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sample is examined and the cases with the lowest distance are grouped into homogenous 
groups and distinct clusters (Garson, 2009; Tryfos, 1998). Once the subgroups have been 
identified, the relationship between social costs and patients’ characteristics may be 
examined within each cluster later in the chapter.  
 
The two-step cluster analysis is chosen to identify the subgroups in the RESULT sample. 
The two-step cluster analysis is a type of clustering technique and is considered to be a 
better technique than hierarchical clustering and k-mean clustering for a large sample 
because it scales more efficiently (Garson, 2009). The two-step cluster analysis allows 
researchers to handle mixed type attributes and automatically determine the number of 
clusters (Bacher, Wenzig and Vogler, 2004). The cases have minimised distances 
between each other in one cluster, and each cluster has the maximum variance (Garson, 
2009). 
 
The two-step cluster analysis aims to analyse the relationship between patients’ 
characteristics and the social costs in the RESULT study. RESULT has a relatively large 
sample (n=401) and the patients’ characteristics cover a range of both continuous and 
categorical variables, hence it is appropriate to use the two-step cluster analysis. K-mean 
cluster analysis is also good for handling a large number of cases, but it is necessary to 
define the number of clusters (k) in advance (Garson, 2009). The cases in the RESULT 
study are highly skewed and it is difficult to decide the ideal number of clusters. It is 
therefore a better option to use the two-step cluster analysis as the number of clusters is 
automatically determined. 
 
All 4 categories of social costs as well as the total societal cost are included in the two-
step cluster analysis. This allows the homogeneous subgroups to be clustered together and 
makes it easy to compare the differences between the cost categories. In a hypothetical 
cluster, for example, the mean of the health care cost may be the lowest among all the 
clusters, but the cluster may have the highest mean of the crime cost. Combining these 
results with patients’ characteristics would provide a profile for this particular group of 
patients. The results of the clustering analysis will provide an overview of the distribution 
of the higher and lower cost clusters within each social cost category, which will provide 
a brief mapping of the societal cost clusters and a basis for later sections.  
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5.3.3 Factors related to the social costs within the subgroups 
 
In section 5.3.2 all patients were divided into different clusters, based on the results of the 
two-step clustering analysis. Within each cluster, the patients’ characteristics are 
examined, such as gender, age, smoking habit, employment status, having children or not, 
the types of drug that they have taken, and their recent social resource use such as hospital 
visits, drug treatment and prescriptions for medication. Patients’ individual level 
outcomes, such as QALYs, dependence, physical and psychological health status and 
social satisfaction are also considered as variables. Whether or not they complete the 
follow-up interview after 6 months will also be examined. The exploratory analysis of the 
missing patients will provide a brief overview of how drop-outs in drug misuse research 
are related to the different social costs. The descriptive results at baseline and the 6 month 
follow-up period are presented as a percentage of the patients within each cluster. Taking 
a hypothetical cluster for example, 200 patients are grouped into cluster 1 and 60% of 
these patients have children and the other 40% do not. The results would thus illustrate 
the characteristics of the patients in each societal cost cluster and provide an exploratory 
description of the different cost clusters. 
 
Using the chi-square test for the categorical variables and the t-test for the continuous 
variables as a simple statistical technique, the statistical significance of each factor will 
also be tested within the cluster. The test will show whether or not the patients’ 
characteristics are statistically significant factors for forming the clusters. 
 
5.3.4 Factors related to the social costs changes 
 
The previous sections show how the social cost clusters will be determined at both 
baseline and the follow-up period, and compare the significance of different factors for 
the formation of each social cost cluster. Using a similar approach, the aim of this section 
is to obtain a profile of the changes of social costs between baseline and the follow-up 
period. In section 5.3.2, all categories of social costs are included in the clustering process. 
Similarly, the changes within all categories of social costs are included in the two-step 
cluster analysis in this section. Patients with the least variance are clustered in the same 
social cost cluster. The results provide a descriptive profile of patients’ social cost 
changes between baseline and the 6 month follow-up period. Within each cluster, the 
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results indicate whether or not each category of social cost has increased or decreased 
between the 2 time points. 
 
The RESULT study (Raistrick et al, 2008) is not a clinical trial. It is an observational 
study between 2 time points that are 6 months apart, during which the patients receive 
drug misuse interventions. The treatment episodes of each individual patient are not clear, 
thus it is not possible to examine the differences before and after the treatment. The large 
number of participants in the RESULT study, however, provides a broader overview of 
the drug misuse patients in treatment than is provided by most clinical trials. The results 
of this section therefore provide a description of the characteristics of patients who have 
higher and lower costs at the baseline while receiving drug misuse treatment, which could 
be used as a profile of drug misuse patients for future studies.  
 
5.4 Results 
 
There are 2 types of patient characteristics that are examined in the cluster analysis. The 
categorical variables include age, gender, employment status, whether or not the patients 
have a child, whether or not they smoke, whether or not they take heroin, methadone or 
crack, whether or not they have received treatment for drug problems, visited hospital, or 
had a prescription in the last 6 months. The continuous variables are age, and results for 
EQ-5D, LDQ, CORE, SSQ, and SCL. EQ-5D is the health related utility measure, LDQ 
measures the drug dependence outcome, CORE measures the psychological health of the 
patient, SSQ measures the patients’ satisfaction regarding social relationships, and SCL 
measures the physical health outcome. 
 
5.4.1 Results at baseline 
 
As described in section 5.2.1, the two-step clustering is performed to analyse the 
distribution of the societal cost among the patients in the RESULT study. The total 
societal cost and the social costs of all 4 categories are included in the analysis: health 
care services, addiction services, social care services and crime costs.  
 
As shown in Table 5.4.1 and Table 5.4.2, at baseline 401 patients are included in the two-
step cluster analysis and 13 patients are excluded, due to missing data in one or more of 
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the variables. 3 clusters are determined: 50.1% of patients are grouped in cluster 1 and 
40.7% of patients are in cluster 2, with the remainder of the patients (6%) in cluster 3. 
 
Table 5.4.1 shows the characteristics of patients within each cluster at baseline. Within 
cluster 1 none of the patients have taken methadone and this is the most statistically 
significant categorical variable, although other variables such as follow-up completion 
(43.1%), whether they take heroin (59.4%), whether they have recently received drug 
treatment (17.8%), and whether they are unemployed (71.8%) are also statistically 
significant. None of the continuous variables are statistically significant. Table 5.4.2 
shows the mean social cost categories at baseline. The statistically significant costs are 
health (£335.22), addiction (£105.15) and total social cost (£4,302.60). 
 
Within cluster 2 the only statistically significant categorical variables are whether patients 
have completed the follow-up evaluation (100%), taken methadone (92.7%), or taken 
heroin (93.3%). There are no statistically significant continuous variables. The 
statistically significant mean costs are addiction (£248.25), crime (£3,289.18) and total 
social cost (£4,316.50). The addiction cost is over twice that of cluster 1, whereas the total 
cost is only marginally higher (£13.90) than cluster 1. 
 
Within cluster 3 only 2 categorical variables are statistically significant: whether the 
patient has received treatment for drug problems (75%) and whether they have visited the 
hospital in the last 6 months (75%). There are no statistically significant continuous 
variables. The only statistically significant mean cost is the total societal cost 
(£33,587.09), which is the highest among the clusters.  
 
With the results for all 3 clusters at baseline set out some conclusions may be drawn. To 
draw strong conclusions about the character profile of patients that are likely to have 
higher or lower costs the same characteristics must be statistically significant variables in 
more than one cluster and there must be comparable statistically significant mean costs. If 
there are no such comparable statistically significant results across the clusters then no 
conclusions can be drawn about the relationship between individual characteristics, both 
with one another and with the different types of social costs. 
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None of the characteristics were significant variables in all 3 clusters, however, in clusters 
1 and 2 the percentage of patients that take both methadone and heroin were statistically 
significant. In cluster 1 the results were 0% and 59.4% respectively compared with 92.7% 
and 93.3% respectively in cluster 2. The total societal cost between the 2 clusters was not 
particularly different: £4,302.60 in cluster 1 compared with £4,316.50 in cluster 2. 
However, the addiction cost in cluster 1 was £105.15, whereas in cluster 2 it was £248.25, 
over twice as much. This indicates, as might be expected, that patients who take 
methadone or heroin are likely to use more addiction resources, even if their societal cost 
is not that different from other drug misuse patients. 
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Table 5.4.1 Patient characteristics within each cluster at baseline 
Baseline 
 
Total 
(n=390) 
Cluster 
1 
(n=202) 
Cluster 
2 
(n=164) 
Cluster 
3 
(n=24) 
complete follow-up Yes (n=263) 67.4% 43.1%* 100.0%* 50.0% 
Mean 30.70 31.15 30.00 31.75 Age 
S.D. 6.89 7.12 6.63 6.63 
Sex 
 
Male (n=283) 72. 6% 80.2% 65.2% 58.3% 
Employment Have job 
(n=312) 
20.0% 28.2%* 12.8% 0.0% 
Have child Yes (n=208) 53.3% 57.4% 48.8% 50.0% 
Smoker Yes (n=369) 94.6% 91.6% 98.2% 95.8% 
Taking methadone Yes (n=232) 40.5% 0.0%* 92.7%* 25.0% 
Taking heroin Yes (n=291) 74.6% 59.4%* 93.3%* 75.0% 
Taking crack Yes (n=382) 2.1% 4.0% 0.0% 0.0% 
Treatment for drug problem in 
last 6 months 
Yes (n=271) 30.5% 17.8%* 39.6% 75.0%* 
Visited hospital in last 6 
months 
Yes (n=270) 30.8% 23.3% 33.5% 75.0%* 
Prescriptions in last 6 months Yes (n=258) 33.8% 30.2% 36.0% 50.0% 
Mean 0.74 0.76 0.73 0.62 EQ-5D a baseline overall score 
S.D. 0.27 0.23 0.30 0.37 
Mean 16.24 15.65 16.95 16.33 LDQ a baseline overall score 
S.D. 8.09 7.89 8.34 7.87 
Mean 56.47 56.26 57.02 54.42 CORE a baseline overall score 
S.D. 23.76 24.00 23.54 24.19 
Mean 13.68 13.92 13.94 10.00 SSQ a baseline overall score 
S.D. 5.72 5.63 5.63 6.03 
Mean 15.63 15.25 15.99 16.29 SCL a baseline overall score 
S.D. 7.88 8.22 7.44 8.12 
*: p<0.05 
a: The higher scores of EQ-5D and SSQ represent the better outcomes. The higher scores 
of LDQ, CORE and SCL represent the worse outcomes. 
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Table 5.4.2 Mean costs within each cluster at baseline 
health care costs addiction service costs social care costs crime costs total societal cost Baseline 
 
N 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Cluster 1 202 335.22* 867.44 105.15* 499.83 56.67 177.01 3805.55 6657.02 4302.60* 6756.81 
Cluster 2 164 710.02 1702.87 248.25* 597.10 69.06 217.92 3289.18* 5986.69 4316.50* 6229.95 
Cluster 3 24 7851.78 13269.82 4428.05 6516.04 459.49 859.19 20847.78 31143.81 33587.09* 29649.09 
Total 402 955.39 3895.47 431.35 1960.56 86.67 298.18 4637.16 10611.45 6110.57 11893.78 
*:  p<0.05 
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5.4.2 Results at the 6 month follow-up period 
 
Table 5.4.3 and Table 5.4.4 show that at the 6 month follow-up period 268 patients are 
included in the cluster analysis. 25% of patients are excluded because of missing patient 
information. 4 clusters are formed: 31.3% of patients are in cluster 1, 14.2% in cluster 2, 
19.0% in cluster 3 and 10.04% in cluster 4.  
 
The characteristics of patients within each cluster are shown in Table 5.4.3. Within cluster 
1 all of the patients have a child and this is the most statistically significant categorical 
variable, although whether the patients have taken heroin (92.9%) or methadone (79.8%) 
are also statistically significant variables. The only statistically significant continuous 
variable is the average age of the patients (33.02 years old). Table 5.4.4 shows the mean 
cost of each cluster at the 6 month follow-up period. In cluster 1, however, there are no 
statistically significant mean costs. 
 
Within cluster 2, whether the patients take methadone (0%), heroin (15.8%), or crack 
(13.2%), as well as how many are unemployed (47.4%) are all significantly statistic 
categorical variables. There are no statistically significant continuous variables. The 
statistically significant mean costs are addiction (£85.57) and social care (£36.61). 
 
Within cluster 3, whether the patients have visited hospital (3.9%) or received 
prescriptions in the last 6 months (19.6%), as well as whether they have a child (2%) are 
the statistically significant categorical variables. There are 2 statistically significant 
continuous variables: the average age of the patients (25.49 years old) and the average 
EQ-5D score (0.91). The statistically significant mean costs are health (£468.58), 
addiction (£445.05) and the total societal cost (£2,294.56). 
 
Within cluster 4, whether the patients have a child (3.6%), gender (100% male), and 
whether they have visited hospital (75%) or received prescriptions in the last 6 months 
(71.4%) are the statistically significant categorical variables. Average CORE and SSQ 
scores (61.36 and 12.36 respectively) are both significantly statistically continuous 
variables However, the only statistically significant cost is social care (£27.38) 
 
  102 
It is very difficult to draw any conclusions from the results at the 6 month follow-up 
period as there are only a few statistically significant results in the same characteristics 
and cost categories across the clusters. There is only one statistically significant 
characteristic across 3 of the 4 clusters (whether the patient has a child), however there 
are no comparable statistically significant mean costs for those 3 clusters. 
 
Table 5.4.3 Patient characteristics within each cluster at follow-up 
6 month Total 
(n=201) 
Cluster 
1 
(n=84) 
Cluster 
2 
(n=38) 
Cluster 
3 
(n=51) 
Cluster 
4 
(n=28) 
Mean 30.79 33.02* 31.12 25.49* 33.31 Age 
S.D. 7.25 6.60 7.94 3.56 8.40 
Sex 
 
Male 
(n=140) 
69.7% 56.0% 78.9% 68.6% 100.0%* 
Employment Have job 
(n=163) 
18.9% 15.5% 52.6%* 9.8% 0.0% 
Have child Yes (n=108) 53.7% 100.0%* 57.9% 2.0%* 3.6%* 
Smoker Yes (n=195) 97.0% 98.8% 89.5% 98.0% 100.0% 
Taking methadone Yes (n=121) 60.2% 79.8%* 0.0%* 58.8% 85.7% 
Taking heroin Yes (n=148) 73.6% 92.9%* 15.8%* 78.4% 85.7% 
Taking crack Yes(n=195) 2.5% 0.0% 13.2%* 0.0% 0.0% 
Treatment for drug 
problem in last 6 
months 
Yes (n=197) 98.0% 100.0% 92.1% 100.0% 96.4% 
Visited hospital in last 
6 months 
Yes (n=124) 38.3% 40.5% 52.6% 3.9%* 75.0%* 
Prescriptions in last 6 
months 
Yes (n=115) 42.8% 45.2% 47.4% 19.6%* 71.4%* 
Mean 0.79 0.77 0.79 0.91* 0.61 EQ-5D a 6 month 
overall score S.D. 0.30 0.30 0.30 0.14 0.42 
Mean 8.63 9.13 5.89 7.63 12.64 LDQ a 6 month 
overall score S.D. 7.94 8.29 6.01 7.97 7.70 
Mean 44.43 47.57 34.74 37.20 61.36* CORE a 6 month 
overall score S.D. 24.01 23.61 20.27 22.64 22.07 
Mean 15.44 15.02 17.37 16.37 12.36* SSQ a 6 month overall 
score S.D. 5.24 5.20 5.60 4.66 4.44 
Mean 11.98 13.07 8.21* 10.14 17.18 SCL a 6 month overall 
score S.D. 8.17 7.94 6.75 7.40 8.90 
*: p<0.05 
a: The higher scores of EQ-5D and SSQ represent the better outcomes. The higher scores 
of LDQ, CORE and SCL represent the worse outcomes. 
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Table 5.4.4 Mean costs within each cluster at follow-up 
health care costs addiction service costs social care costs crime costs total societal cost 6 month 
 
N 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Cluster 1 84 1116.44 1346.74 760.17 819.73 144.41 410.34 1832.45 3726.56 3853.46 4444.80 
Cluster 2 38 2630.83 13018.13 85.57* 183.02 36.61* 87.19 1334.58 4271.32 4087.59 13432.79 
Cluster 3 51 468.58* 593.95 445.05* 402.53 60.24 238.79 1320.69 3543.97 2294.56* 3656.76 
Cluster 4 28 1035.11 742.27 2493.58 5634.09 27.38* 76.36* 4372.41 7691.43 7928.49 8752.61 
Total 268 1227.03 5727.03 794.15 2267.63 86.37 298.12 1962.30 4611.38 4069.85 7627.13 
*: p<0.05 
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5.4.3 Results of the clustering for the changes 
 
The previous section has covered the results of clustering analysis of social costs at both 
baseline and the 6 month follow-up period. In this section a similar clustering analysis is 
performed to determine the profile of the social cost change clusters and the factors 
relating to the changes. 
 
Table 5.4.6 shows that 268 patients are included in the two-step cluster analysis, whereas 
68 cases are excluded due to missing data. 4 clusters are identified: 20.9% of patients are 
within cluster 1, 29.5% of patients are in cluster 2, 3.4% are in cluster 3 and 20.9% of 
patients are grouped in cluster 4. 
 
Patients’ characteristics within each social cost cluster are shown in Table 5.4.5. In cluster 
1 the only statistically significant categorical variables are the unemployment level 
(62.5%), and whether they take methadone (10.7%) or heroin (14.3%). There are no 
statistically significant continuous variables. Table 5.4.6 shows the mean cost changes 
within each cluster. The only statistically significant cost change is addiction, where the 
cost increased by £46.86. 
 
Within cluster 2 there is a wide range of statistically significant categorical variables: 
whether the patients take methadone (87.3%) or heroin (98.7%), the unemployment rate 
(94.9%), gender (53.2% male), and whether they have visited hospital (62%) or received 
a prescription in the last 6 months (67.1%). There are no statistically significant 
continuous variables or cost changes. 
 
Within cluster 3 the only statistically significant categorical variables are the amount of 
smokers (77.8%) and the amount that do not take crack (77.8%). Again, there are no 
statistically significant continuous variables or cost changes. 
 
Within cluster 4 the statistically significant categorical variables are whether the patients 
have taken heroin (100%), and whether they have visited hospital (0%) or received a 
prescription in the last 6 months (0%). Average age is the only statistically significant 
continuous variable (28.61 years old), and there are no statistically significant cost 
changes. 
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As there is only one statistically significant cost change across all the clusters it is 
difficult to compare the different characteristics with the different social costs. The only 
comparisons that are statistically significant are those between different characteristics. 
For example, there is a close relation between the percentage of patients that take 
methadone and heroin. The results in cluster 1 are 10.7% and 14.3% respectively, and 
87.3% and 98.7% in cluster 2 respectively. Similarly, the percentage of patients visiting 
hospital and receiving prescriptions is very close. The results in cluster 1 are 62% and 
67.1% respectively, and 0% for both in cluster 4. 
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Table 5.4.5 Patient characteristics within each cluster at 6 month change 
6 month change Total 
(n=200) 
Cluster 
1 
(n=56) 
Cluster 
2 
(n=79) 
Cluster 
3 
(n=9) 
Cluster 
4 
(n=56) 
Mean 30.81 32.30 31.81 26.51 28.61* Age 
S.D. 7.26 8.27 7.37 6.61 5.22 
Sex 
 
Male 
(n=140) 
70.0% 80.4% 53.2%* 66.7% 83.9% 
Employment Have job 
(n=162) 
19.0% 37.5%* 5.1%* 0.0% 23.2% 
Have child Yes 
(n=107) 
53.5% 48.2% 68.4% 11.1% 44.6% 
Smoker Yes 
(n=194) 
97.0% 94.6% 98.7% 77.8%* 100.0% 
Taking methadone Yes 
(n=120) 
60.0% 10.7%* 87.3%* 66.7% 69.6% 
Taking heroin Yes 
(n=147) 
73.5% 14.3%* 98.7%* 55.6% 100.0%* 
Taking crack Yes 
(n=195) 
2.5% 5.4% 0.0% 22.2%* 0.0% 
Treatment for drug 
problem in last 6 months 
Yes 
(n=196) 
98.0% 94.6% 100.0% 88.9% 100.0% 
Visited hospital in last 6 
months 
Yes 
(n=123) 
38.5% 39.3% 62.0%* 66.7% 0.0%* 
Prescriptions in last 6 
months 
Yes 
(n=115) 
42.5% 51.8% 67.1%* 33.3% 0.0%* 
Mean 0.03 0.00 0.03 0.03 0.05 EQ-5D a overall score 
change S.D. 0.15 0.15 0.16 0.12 0.14 
Mean -7.34 -7.00 -8.71 -8.00 -5.64 LDQ a overall score 
change S.D. 8.94 7.51 10.47 5.02 8.24 
Mean -10.77 -11.21 -8.96 -24.00 -10.75 CORE a overall score 
change S.D. 23.68 23.07 26.57 27.07 18.84 
Mean 1.21 0.54 1.34 5.22 1.04 SSQ a overall score 
change S.D. 5.45 4.84 6.17 4.12 4.94 
Mean -3.72 -3.18 -2.96 -9.67 -4.36 SCL a overall score 
change S.D. 7.97 9.65 7.43 10.76 5.84 
*: p<0.05 
a: Patients’ outcome score changes for EQ-5D, LDQ, CORE, SSQ, SCL = (follow-up 
score) – (baseline score), If change >0, patients’ scores at follow-up is higher than scores 
at baseline. The higher scores of EQ-5D and SSQ represent the better outcomes. The 
higher scores of LDQ, CORE and SCL represent the worse outcomes. 
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Table 5.4.6 Mean costs within each cluster at 6 month change 
health care costs 
difference a 
addiction service costs 
difference a 
social care costs 
difference a 
crime costs difference 
a 
total societal cost 
difference a 
6 month 
change 
 
N 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Cluster 1 56 65.60 1225.22 46.86* 377.93 4.59 132.82 -644.64 3800.04 -527.60 4109.35 
Cluster 2 79 260.47 2503.12 511.51 1007.14 -5.91 573.91 -1523.98 6123.86 -757.90 6778.44 
Cluster 3 9 4311.70 31649.15 3778.34 12672.26 -31.50 68.55 -17130.33 45557.38 -9071.79 57946.28 
Cluster 4 56 172.97 724.21 224.59 1667.17 32.03 177.23 -592.54 6046.00 -162.96 6510.37 
Total 268 363.71 6635.38 448.08 2867.67 6.50 378.36 -1719.25 11120.61 -900.96 13137.61 
*: p<0.05 
a: Cost difference = (cost of follow-up) - (cost of baseline). If change > 0, patients’ social costs increase at follow-up. 
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5.5 Conclusions and Discussion 
 
One of the problems in most existing drug misuse research is that it is unclear whether or not 
different types of drug misuse patients are more likely to use different social resources. Very 
few studies have examined the relationship between dimensions of the monetary outcome 
and patient characteristics or the relationship between the different dimensions of the 
monetary outcome. This information may prove important for policy makers because if 
different characteristics of patients can be identified that relate to specific dimensions of the 
monetary outcome then different patients can be targeted with specific interventions. 
 
The aim of this chapter has been to use an existing data sample to cluster patients by the 
resources they use and to attempt to build a profile of drug misuse patients within these 
clusters. Although the statistically significant characteristics of the patients in each cluster 
have been identified and described, it has proved difficult to compare these characteristics 
with the different social cost categories across the clusters. One exception was identified in 
clusters 1 and 2 at baseline, where patients who take methadone or heroin have a much 
higher mean addiction service cost than those who do not, even though there is little 
difference between the mean total societal costs. 
 
The reason that it has not proved possible to identify more relationships is that only very few 
statistically significant characteristics and costs were identified in the different clusters. 
Where characteristics were identified, they were often not the same across the clusters, 
therefore they could not be compared to see whether or not they consistently lead to different 
social costs. This is because the results do not identify any significant characteristic that can 
be used to describe the patients across all the clusters. In addition, in many cases there were 
also no statistically significant costs. 
 
The main limitation with the RESULT sample used in this chapter is that it is not an 
intervention study, therefore the patients within the sample did not all start the treatment at 
the same time. This might affect how much of the resources they use, and this may partly 
explain why it was difficult to identify common characteristics between the patients. Future 
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studies that aim to identify a patient profile may benefit from having all the patients start the 
treatment at the same time. 
 
There is also a limitation with using clustering techniques as the clusters are only 
hypothetical groups based on a given set of characteristics. However, if other characteristics 
were used then the cluster groups would be different and it is possible that more statistically 
significant characteristics would be identified. In this chapter 16 single characteristics were 
used to determine the clusters without finding any significant results. This indicates that 
clustering analysis may be inadequate for determining the profile of drug misuse patients. 
 
These limitations aside, the fact that there were few statistically significant characteristics 
suggests that the profile of drug misuse patients might be more complex than expected. The 
data used in this chapter sampled over 400 patients and still failed to identify many 
statistically significant characteristics. In addition, a national UK study, NTORS (Godfrey, 
Stewart and Gossop, 2004), has also found that no specific characteristics can be used to 
explain the monetary outcome in their sample, while using a regression technique that 
examines multi-variable characteristics. This indicates that the difficulties with identifying 
statistically significant characteristics might not be primarily due to the limitations of the 
sample in the RESULT study or the clustering technique used in this chapter, but rather 
simply due to the complexity of the different characteristics of drug misuse patients. 
Although it is important for policy makers to know whether they can target interventions at 
specific groups of drug misuse patients, this chapter has revealed the main limitations with 
identifying the relevant characteristics. 
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Chapter 6 Systematic Review for decision analytic models in the economic 
evaluation of drug misuse interventions 
 
6.1 Background 
 
The previous chapters have shown that outcomes in the economic evaluation of drug misuse 
interventions involve a complex of dimensions and cannot be predicted by patient 
characteristics alone. Furthermore, despite drug misuse being considered as a chronic 
condition (Zarkin et al, 1994), there are very few studies which follow the patients for longer 
than 24 months, even though it is important that policy makers consider long-term outcomes 
(NICE, 2008). 
 
One way of potentially taking into account the complexity of drug misuse patients and 
estimating their long-term outcomes is by developing modelling studies. A decision analytic 
modelling study is an analytical approach that is developed to synthesize the costs and the 
outcomes of interventions (Buxton et al, 1997). It provides a structural framework for 
decision making under conditions of uncertainty. It provides the full structure of the possible 
prognoses of the individuals, brings together the relevant evidence from different resources, 
and translates the relative evidence into estimates of cost and effectiveness to predict 
outcomes in the long-term (Drummond, M.F. et al, 2005).  
 
There are different types of structuring techniques for decision analytic models. The decision 
tree model and the Markov model are the 2 most frequently used types of structuring 
technique. The decision tree model is probably the most common structure for decision 
analytic models in economic evaluations (Drummond, M.F. et al, 2005). The decision tree 
provides a visual illustration of the prognoses of the individuals after the interventions. By 
following the pathway of the individuals throughout the intervention the decision tree model 
illustrates the possible outcomes and costs at each chance point (the point at which the 
patient’s outcome can go down one of many pathways), as well as predicting the costs and 
outcomes at the end point of the model. The structure of the Markov model represents a 
series of ‘states’ that a patient can occupy at any given point of time (Drummond, M.F. et al, 
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2005). The Markov model estimates the probability that a patient could be in any given 
‘state’ over a period of time.  
 
Using decision analytic models in economic evaluations helps decision makers to understand 
the costs and outcomes of the interventions involved. The decision tree model in drug misuse 
interventions can provide comprehensive estimates of the possible prognoses in both the 
interventions of interest and alternative intervention strategies. The Markov model can 
provide the probability of the patients being in any given health state after receiving the drug 
misuse interventions. However, there are only a limited number of studies that have applied 
decision analytic models in the economic evaluation of drug misuse interventions, and very 
few studies have reviewed the applications of doing so. This chapter will therefore examine 
the current development of decision analytic models in economic evaluation studies of drug 
misuse interventions. 
 
6.2 Objectives 
 
The purpose of this review is to explore the different methods of estimating costs and 
outcomes that have been applied in decision analytic modelling studies of drug misuse 
interventions. The previous chapters have examined the short-term outcomes derived from 
the patient-level data in the economic evaluation for drug misuse interventions. This review, 
by contrast, will focus on the long-term outcomes and provide information about what 
outcomes have been chosen in the modelling studies in the previous treatment or prevention 
research, how the outcomes are translated into monetary terms and the theoretical constructs 
of the models. This chapter focuses on the extent to which modelling studies are able to 
overcome the problems and limitations identified in the previous chapters with other types of 
drug misuse intervention studies. In particular, it is therefore concerned to examine whether 
or not existing modelling studies provide comprehensive evaluations of drug misuse 
interventions from the societal perspective that consider the patients outcomes over a long 
period of time.  
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The first objective of this review is to identify the studies in which decision analytic models 
have been conducted, particularly those that have applied the decision tree model and 
Markov model techniques to estimate the costs and outcomes for drug misuse interventions. 
This will reveal the current applications of the decision analytic modelling techniques in the 
drug misuse research. The second objective is to assess the quality of these models by 
adopting a quality assessment checklist developed by Philips and colleagues (2004) to 
examine the theoretical structures and data synthesis techniques in the identified models. The 
checklist is a comprehensive guideline of good practice for all types of health related 
economic evaluation models, thus this chapter focuses on the aspects of the guideline that are 
especially relevant for drug misuse models in order to evaluate the benefits and limitations of 
modelling studies for drug misuse interventions. 
 
The results of this review will provide an overview of how long-term costs and outcomes are 
estimated through the decision analytic modelling techniques in the current drug misuse 
modelling research. This will complete the methodological examination of existing drug 
misuse interventions that has been carried out throughout the thesis. With the methodological 
critique complete, the following chapter will then propose a model that attempts to take into 
account both the long-term outcomes and the other outcomes of drug misuse interventions 
discussed previously. 
 
6.3 Methods 
 
6.3.1 Inclusion Criteria for this review 
 
The first objective of this chapter is to identify the economic evaluation studies that have 
applied the decision analytic model in drug misuse research, which is achieved by using the 
searching strategies detailed in this section and section 6.3.2 to identify these studies.  
 
Type of studies: The main inclusion criterion is that only studies which conducted decision 
analytic modelling methods to estimate the costs and outcomes in the economic evaluation 
will be included. The studies should give a full description of their model, including details 
  113 
of which predictive variables have been chosen, which outcomes have been measured, how 
the outcomes are translated into the surrogate and monetary outcomes in the long-term and 
the theoretical constructs of the decision analytic models. 
 
Type of intervention: All types of intervention delivered to the individual drug user or 
potential drug users and primarily aimed at reducing problems related to drug misuse will be 
considered. Studies on intervention delivered to the drug users’ family/ partner will not be 
included. 
 
Type of participants: Only studies modelling individual drug users or potential user data of 
drug misuse intervention are included. 
 
Outcome: Only studies with outcomes from the economic evaluation will be included. 
Outcome data must be from the data synthesis within the modelling studies, instead of the 
data from the actual individual drug users in a trial or research. 
 
Comparison: To provide scope for comparison only studies considering at least 2 alternatives 
will be included, for instance, intervention versus no intervention or 2 different types of 
intervention in the model. 
 
6.3.2 Data sources and search strategy 
 
Electronic and manual searches are undertaken to identify studies. 
Search strategy: 
The search was performed in July 2010. Studies which meet the inclusion criteria are 
identified from the following sources. There is no restriction for language or the year of 
publication. 
 
Econlit (1969 – to July 2010) 
EMBASE (1980–July 2010) 
MEDLINE (1950 –July 2010) 
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PsycINFO (1806 –July 2010) 
CRD (Centre for Reviews and Dissemination) databases 
The Cochrane Library 
 
Example of searching strategy: MEDLINE; 1950 –July 2010:  
[(drug misuse or drug dependen* or substance misuse or substance abuse or substance 
dependen* or addict* or illegal drug* or illicit drug* or inject* drug* or methadone or or 
buprenorphine or heroin or opiat* or opium or cocaine or crack cocaine or ecstasy or LSD or 
magic mushroom* or amphetamine or cannabis or marijuana or ketamine or tranquiliser* or 
tranquilizer* or club drug*) and (economic evaluation or cost-benefit analysis or cost-
effectiveness analysis or cost-utility analysis)] and [(decision analytic model* or decision tree 
or Markov or Monte Carlo)] 
 
6.3.3 Quality assessment of the included models 
 
The second objective of this chapter is to examine the quality and structures of the decision 
analytic models in economic evaluations of drug misuse interventions. The quality 
assessment checklist for decision analytic models has been developed by Philips and 
colleagues (2004), which was published by the Health Technology Assessment (HTA) 
programme of the NHS in the UK. This HTA report establishes the guideline for good 
practice of decision analytic models (Philips et al, 2004). Therefore, in order to examine the 
quality of the included models, this chapter will adopt the checklist as the guideline for the 
review. The checklist identifies 3 general components of a model (Philips et al, 2004):  
 
1. Structure of a model: quality assessment related to the structure of the model has 9 
dimensions, including objectives, scope and perspective of the model, rationales and 
assumptions for the structure, the strategies for comparison in the model, model types, time 
horizon, disease pathway, and the cycle length of the model. 
 
2. Data of the model: quality assessment for the data used in the model covers 4 dimensions: 
the identification of data in the model, modelling the data (treatment effects, costs, and 
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utilities), data incorporation, and the assessment of the uncertainty for methodology, structure, 
heterogeneity, and parameters. 
 
3. Consistency of the model: assessment of the internal and external consistency of the model. 
 
Details of the dimensions will be discussed while the included models are examined in the 
later sections of this chapter. The third dimension, the consistency of the model, will not be 
examined among the included models. This is because none of the included models have 
examined the internal and external consistency/ validity. The review will focus on the 
dimensions of the guideline that are particularly important for drug misuse modelling studies, 
rather than those that are only of more general relevance for health related models. The 
results of this section will provide an overview of the current development and problems with 
decision analytic models in the economic evaluation of drug misuse interventions. This will 
provide the basis to make recommendations about the application of decision analytic models 
in drug misuse research for policy makers and for future research. 
 
6.4 Results 
 
The first objective of this review is to identify the decision analytic models in the economic 
evaluation studies of drug misuse interventions. Using the searching strategies described in 
section 6.3.1 and 6.3.2, 42 studies were identified and 19 studies using decision-analytic 
modelling were included. Most excluded studies are related to opiate treatment for the pain 
symptoms of cancer patients. 3 of the included studies are sub-studies of 2 models; hence, 16 
models were identified in this review. Among the 16 models, there are 6 decision tree models 
and 7 Markov models. The other 3 models combine the decision tree model and Markov 
models in their studies. Details of each included model are listed in the Table 6.4.1.  
 
6 of the included models are conducted with the population in the UK and 4 models are 
conducted with the population in the United States. There are also 2 models that consider the 
population in Italy, 1 in Canada, 1 in France, 1 in Spain, and 1 in New Zealand. There are 2 
main types of interventions which are examined in the included modelling studies. 8 of the 
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16 models examined the first type of intervention, which examines the costs and outcomes of 
the screening of injecting drug users, such as screening for hepatitis C, HIV and tuberculosis. 
The other 8 models examined the second type of intervention, which examines the costs and 
outcomes of the drug misuse treatment, such as maintenance treatment and needle exchange 
programmes. 
 
Among the 16 models, 6 were cost-utility analysis models, which measure QALYs; 4 were 
cost-benefit analysis models, which calculate the ratio between the costs and benefits; and 6 
were cost-effectiveness analysis models, of which 5 measure the life years saved and 1 
measures the number of HCV (hepatitis C infection) cases identified. 11 of the models used a 
hypothetical cohort and 5 used a real cohort. 
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Table 6.4.1 Description of the included studies 
Study, country Type of model and 
population 
Intervention/ scenarios Period of 
prediction 
Study 
perspective 
Costs and outcome of economic 
evaluation in the model 
Adi et al, 2007, 
UK 
Decision tree 
model with Monte 
Carlo simulation 
for a hypothetical 
cohort of 10,000 
opioid dependent 
drug users 
Two scenarios: 
-Oral naltrexone for relapse 
prevention 
-Placebo 
12 months -NHS and 
Personal 
Social 
Service 
(PSS) 
-Societal 
perspective 
(for costs) 
Simulation with 2004 value (not 
discounted) 
 
Costs (NHS perspective) 
-Treatment cost: naltrexone, 
counselling, and urine tests 
-Health care costs: GP, A&E, 
hospital stays, mental health 
service visits 
Costs (societal perspective) 
-Criminal justice system cost: 
drug arrests, acquisitive crime 
arrests, held in custody, court 
appearance, imprisonment 
-Victim cost of crime 
 
Outcome of the model: 
-From NHS perspective, ICER= 
£42,500 per QALY 
-From the societal perspective, 
Naltrexone dominates placebo 
in ICER (placebo is more 
costly and less effective) 
Barnett, 1999, 
USA 
Markov model of 
a hypothetical 
cohort of 1,000 
25-year-old heroin 
addicts 
(when entering 
methadone 
treatment) 
Two scenarios: 
-Methadone treatment 
-Drug-free treatment 
Lifetime Societal 
perspective 
Simulation with 1996 value (3% 
discount rate) 
 
Costs: cost of treatment 
 
Outcome of the model: cost-
effectiveness ratio= $5,915/life-
year gained 
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Connock et al, 
2007, UK 
Decision tree 
model with Monte 
Carlo simulation 
for a hypothetical 
cohort of 10,000 
opioid dependence 
patients 
 
Three scenarios: 
-Methadone maintenance therapy 
(MMT) 
-Buprenorphine maintenance 
therapy (BMT) 
-No treatment 
12 months -NHS and 
PSS 
-Societal 
perspective 
(for costs) 
Simulation with 2004 value (not 
discounted) 
 
Costs (NHS perspective) 
-Treatment cost: 
pharmacological treatment, 
counselling, and urine tests 
-Health care costs: GP, A&E, 
hospital stays, mental health 
service visits 
Costs (societal perspective) 
-Criminal justice system cost: 
drug arrests, acquisitive crime 
arrests, held in custody, court 
appearance, imprisonment 
-Victim cost of crime 
 
Outcome of the model 
-From NHS perspective, MMT 
vs. no treatment ICER= 
£13,697 per QALY; BMT vs. 
no treatment ICER=£26,429 
per QALY 
-From the societal perspective, 
MMT dominates BMT and ‘no 
treatment’ group in ICER, and 
BMT dominates ‘no treatment’ 
group 
Gold et al, 1997, 
Canada 
Decision tree type 
model of incidence 
outcome for a 
cohort of 275 
IDUs 
Two scenarios: 
-Needle exchange programme 
along with related harm-reduction 
services (counselling and  referral, 
HIV testing, hepatitis B 
vaccination, provision of condoms 
5 years Societal 
perspective 
Simulation with 1995 value (5% 
discount rate) 
 
Cost: 
-Cost of interventions: operating 
cost of the programme, costs 
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and dental dams) 
-No programme 
for the time contributed by the 
community volunteers and the 
pharmacists 
-Health care costs related to 
HIV: inpatient and outpatient 
hospital costs, physician 
services and medication costs 
 
Outcome of the model: Needle 
exchange programme prevents 24 
HIV infection over 5 years, and 
$1.3 million cost-saving. The 
ratio of cost savings to costs is 
4:1. 
Leal, Stein and 
Rosenberg,1999, 
UK 
Markov model for 
5,600 IDUs in 
South and West 
health region 
Screening for hepatitis C 30 years NHS Simulation with 1995 value (6% 
discount rate) 
 
Costs: 
-Intervention costs: cost of hep 
C screening, counselling, liver 
biopsy 
-Treatment cost: cost of 12 or 
40 weeks interferon α (IFNα) 
treatment, cost of post-
treatment testing 
-Cost of adverse events 
-Cost of monitoring 
 
Outcome of the model: cost-
utility ratio=£9,300 per QALY 
Loubiere, Rotily 
and Moatti, 2003, 
France 
Decision tree 
model with 
Markov model for 
a hypothetical 
Four scenarios of screening: 
-No screening and no treatment for 
HCV 
-‘Wait and treat cirrhosis’: HCV 
Lifetime Health care 
system 
Simulation with 1998 value (3% 
discount rate) 
 
Costs 
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cohort of 1,000 
patients with 
hepatitis C 
infection (HCV) 
treatment after the diagnosis of 
cirrhosis 
-‘Two EIA’ screening test (enzyme 
immunoblot assay): a EIA test 
followed a positive EIA test 
-‘EIA+PCR(polymerase chain 
reaction)’: PCR test followed a 
positive EIA test 
-Cost of screening tests: cost of 
PCR, cost of EIA 
-Cost of HCV treatment: cost of 
pre-treatment testing, 
Interferon costs, Ribavirin 
costs 
-Cost of HCV management: cost 
of remission, cost of chronic 
hepatitis, cirrhosis, 
hepatocellular carcinoma, 
transplantation 
 
Outcome of the model 
For IDUs (prevalence=80%): 
-Intervention of ‘wait and treat’ 
dominates 
-‘Two EIA’, ICER=$4,513 per 
life-years saved 
-‘EIA+PCR’, ICER=$4,897 per 
life-years saved 
For general population 
(prevalence=1.2%): 
-‘Wait and treat’, ICER=$4,102 
per life-years saved 
-Intervention of ‘two EIA’ 
dominates 
-‘EIA+PCR’, ICER=$5,821 per 
life-years saved 
For transfusion recipients 
(prevalence=7%): 
-‘Wait and treat’, 
ICER=$18,054 per life-years 
saved 
-Intervention of ‘two EIA’ 
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dominates 
-‘EIA+PCR’, ICER=$283,495 
per life-years saved 
Martinez-Raga et 
al, 2010, Spain 
Decision tree 
model of 
budgetary impact 
analysis with for 
86,017 opioid 
addicted patients 
Two scenarios: 
-Suboxone 
(Buprenorphine/Naloxone) 
-Methadone as an agonist opioid 
treatment 
3 years NHS in 
Spain 
Simulation with 2007 value 
(discount rate is not presented) 
 
Costs: cost of medication, 
logistics, dispensing, medical and 
pharmacy personnel, and 
counselling 
 
Outcome of the model: 
incremental cost (Suboxone - 
methadone)=EUR 791,418 in 
year 1, EUR480,226 in year 2, 
EUR492,671 in year 3 
Masson et al, 
2004, USA 
Markov model for 
179 opioid 
addicted patients 
Two scenarios: 
-Enriched 180-day methadone 
detoxification (with psychosocial 
services and drug-free substance 
misuse treatment) 
-Standard methadone maintenance 
treatment 
Lifetime Health care 
system 
Simulation (3% discount rate) 
 
Costs 
-Cost of the treatment provided 
by study 
-Health care utilisation: costs of 
hospitalisation, A&E, 
substance misuse and mental 
health treatment 
 
Outcome of the model: 
-ICER= $16,967 per life-year 
gained 
-ICER= $19,997 per QALY (if 
heroin has very large effect on 
quality of life; deduct 0.03 
utilities) 
Perlman et al, Decision tree type Three scenarios: 5 years Societal Simulation (not discounted) 
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2001, USA model for a 
hypothetical 
cohort of 10,000 
IDUs at a syringe-
exchange 
programme 
-Tuberculosis (TB) screening and 
directly observed preventive 
therapy 
-TB screening only 
-No intervention 
perspective  
Costs: screening costs, treatment 
costs(directly observed 
preventive therapy), monitoring 
costs, and hepatoxicity costs 
 
Outcome: costs prevented of TB 
 
Outcome of the model: 
-If isoniazid preventive therapy 
(INH) efficacy rate is 0.65 
Net savings of ‘no 
intervention’= $53,094 
Net savings of ‘TB screening 
only’= $49,336 
Net savings of ‘TB screening 
plus treatment’= $46,226 
-If isoniazid preventive therapy 
(INH) efficacy rate is 0.90 
Net savings of ‘no 
intervention’= $129,950 
Net savings of ‘TB screening 
only’= $126,192 
Net savings of ‘TB screening 
plus treatment’= $123,081 
Sheerin, Green and 
Sellman, 2004, 
New Zealand 
 
Markov model for 
a cohort of 1,000 
IDUs in 
methadone 
maintenance 
treatment (MMT) 
Methadone maintenance treatment 
(MMT) and antiviral therapy for 
Hepatitis C 
 
Six scenarios: 
-MMT only 
-MMT31: 5% Receive 
conventional combination therapy 
(COT) after stabilising on MMT 
Lifetime Perspective 
of tax payers 
Simulation with 2000 value (3% 
discount rate) 
 
Costs 
-Treatment cost of MMT: 
operating cost of methadone 
treatment, prescription cost of 
methadone, cost of assessment 
and basic counselling 
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at age 31 
-MMT31+COT: all patients receive 
COT after stabilising on MMT at 
age 31 
-MMT26+COT: same as 
‘MMT31+COT’, but stabilising 
on MMT at age 26 
-MMT31+PEG: all patients receive 
PEG (pegylated interferon 
combined with ribavirin) after 
stabilising on MMT at age 31 
-MMT26+PEG: same as 
‘MMT31+PEG’, but stabilising 
on MMT at age 26 
-Treatment cost of COT: 
screening cost, follow-up 
appointment costs, cost of liver 
biopsy and laboratory tests, 
cost of pharmaceuticals 
-Treatment cost of PEG: cost of 
pharmaceuticals 
 
Outcome of the model with lower 
rate of disease progression, ICER 
for ‘MMT31+COT’, 
‘MMT26+COT’, 
‘MMT31+PEG’, 
‘MMT26+PEG’: 
If the presented value is in ( ), 
value<0 
-For non-Maori men, ICER are 
$New Zealand 22,305, 
$NZ(10,774), $NZ26,201, 
$NZ(2,723) per LYS 
respectively 
-For Maori men, ICER are $NZ 
34,825, $NZ(8,551), 
$NZ37,904, $NZ(1,621) per 
LYS respectively 
-For non-Maori women, ICER 
are $NZ 19,044, $NZ(11,157), 
$NZ22,929, $NZ(3,048) per 
LYS respectively 
-For Maori women, ICER are 
$NZ 23,268, $NZ(20,757), 
$NZ27,260, $NZ(10,500) per 
LYS respectively 
Stein et al, 2002, Markov model Screening for hepatitis C among 50 years NHS Simulation with 2001 value 
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Stein et al, 2003 
and Stein et al, 
2004, UK 
with a hypothetical 
cohort of IDUs 
IDUs 
Two scenarios: 
-Screening in drug services 
-Screening in genitourinary 
medicine clinics (GUM) clinic 
(costs and QALYs at 6% and 
1.5% discount rate, respectively) 
 
Costs 
-Cost of interventions: staff cost 
(cost of assessing and 
counselling eligibility), cost for 
ELISA(enzyme-linked 
immunosorban assay) and 
PCR(polymerase chain 
reaction) tests, cost of liver 
biopsy 
-Health care resource use: cost 
of hospitalisation, GP, 
outpatient visit, , cost of liver 
transplant and follow-up care, 
cost of cost of HCV related 
therapy 
 
Outcome of the model 
-Cost-utility ratio of screening in 
drug services=£28,120 per 
QALY 
-Cost-utility ratio of screening in 
GUM clinics=£84,570 
adherence to medication 
Sutton, Edmunds 
and Gill, 2006, UK 
Decision tree 
model with 
Markov model for 
a hypothetical 
cohort of 1,000 
IDUs in prison 
Detecting cases of chronic hepatitis 
C infection on reception into prison 
 
Five scenarios: 
-Scenario 1: verbally screen for 
‘ever had a positive HCV test’ 
and ‘ever injected illicit drugs’ 
-Scenario 2: verbally screen for 
15 years 
(until 
2017) 
Health care 
provider 
Simulation with 2004 value 
(3.5% discount rate) 
 
Costs: 
-Intervention costs cost of 
screening, cost of doctor and 
nurse, staff cost 
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‘ever had a positive HCV test’ 
only 
-Scenario 3: verbally screen for 
‘ever injected illicit drugs’ only 
-Scenario 4: no verbal screening 
-Scenario 5: no verbal screening 
and no testing 
Outcome of the model 
Comparing to scenario 5 (no 
interventions): 
-Scenario 1, ICER=£2,102 per 
HCV case identified 
-Scenario 5 dominates scenario 
2, scenario 2 is the least cost-
effective 
-Scenario 3, ICER=£16,625 per 
HCV case identified 
-Sscenario 4, ICER=£6,388 per 
HCV case identified 
Thompson Coon et 
al, 2006, UK 
Decision tree 
model with 
Markov model for 
a hypothetical 
cohort of 10,000 
former IDUs 
Two scenarios: 
-Systematic case finding strategy 
(‘population’ or ‘targeted’ 
approach) for hepatitis C in 
primary care 
-Non-case-finding strategy 
Lifetime NHS Simulation with 2004 value 
(costs and QALYs at 6% and 
1.5% discount rate, respectively) 
 
Costs 
-Intervention costs: cost of 
hepatitis C testing, liver 
biopsy, counselling, referral; 
-Health care costs: health care 
cost of patients with Hep C and 
Hep C related conditions, 
waiting list for liver transplant, 
health care costs of liver 
transplant and post-transplant 
 
Outcome of the model: 
-For population approach, 
ICER=£15,493 per QALY 
-For targeted approach, 
ICER=£16,493 per QALY 
Tramarin et al, 
2008, Italy 
Markov model for 
two cohorts: 9,460 
Two scenarios: 
-HCV screening to enable early 
Lifetime societal 
perspective 
Simulation with 2007 value (3% 
discount rate ) 
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IDUs, and 
4,738,313 IWSs 
(individuals with 
surgery related to 
risk of HCV 
infection.) 
treatment of hepatitis C 
-No screening 
 
Costs 
-Cost of screening 
-Health care cost: costs of 
cirrhosis, cost of 
transplantation in HCC 
(hepatocellular carcinoma), 
cost of acute and chronic 
therapy 
 
Outcome of the model: 
-For IDUs cohort, ICER= EUR -
3,132, per QALY (HCV 
screening dominates that it is 
less costly and more effective) 
-For IWSs cohort, ICER=EUR 
918,147 per QALY 
Villari et al, 1996, 
Italy 
Markov model for 
a hypothetical 
cohort of 
IDUs 
Four scenarios: 
-No HIV screening 
-HIV screening 
-Delayed early treatment (DEA) 
which starts 5 years after 
infection) 
-Early treatment (EA) started 
immediately after seroconversion 
Lifetime NHS in Italy Simulation with 1991 value (5% 
discount rate) 
 
Costs 
-Cost of HIV screening: costs of 
laboratory tests, counselling, 
basic medical follow-up for 
asymptomatic HIV-positive 
patients 
-Cost of early antiviral therapy: 
costs of ZDV (zidovudine) 
-Health care costs: costs of 
HIV-positive symptomatic 
patients, costs of AIDS 
patients treated with ZDV, and 
costs of untreated AIDS 
patients 
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Outcome of the model: 
-Low HIV prevalence scenario 
(5%): ICER of HIV-testing 
shows that it is less costly and 
more effectively than the 
scenario without HIV-testing. 
ICER of DEA and EA are Lire 
(L) 41,079,810 per life-years 
saved (LYS) and L 54,923,198 
per LYS, respectively. 
-Medium HIV prevalence 
scenario (30%): ICER of HIV-
testing, DEA and EA are L 
13,995,242 per LYS , L 38, 
502,063 per LYS and L 
44,335,492 per LYS, 
respectively 
-High HIV prevalence scenario 
(60%): ICER of HIV-testing, 
DEA and EA are L 55,800,000 
per LYS , L 39,222,657 per 
LYS and L 42,505,898 per 
LYS, respectively 
Zarkin et al, 1994, 
Zarkin et al, 2005, 
USA 
Decision tree 
model with Monte 
Carlo simulation 
for a hypothetical 
cohort of 1 million 
heroin users and 
non-users 
Four scenarios: 
-Scenario 1(baseline): current drug 
misuse and treatment environment 
-Scenario 2: 100% increase that 
heroin users going to methadone 
treatment 
-Scenario 3: 25% increase of length 
of stay in methadone treatment for 
heroin users 
-Scenario 4: Heroin users do not 
Lifetime Societal 
perspective 
Simulation with 2001 value (3% 
discount rate) 
 
Costs 
-Costs of intervention: 
methadone treatment costs 
 
Economic benefits: 
-Crime costs: costs per crime, 
costs per arrest, costs per 
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receive methadone treatment incarceration which occurred 
at the beginning, monthly costs 
of incarceration 
-Earning from employment 
-Health care costs: costs of 
inpatient service use for non-
users and heroin users, costs of 
outpatient service use and 
A&E 
 
Outcome of the model 
-For scenario 2, incremental 
benefit-cost ratio=76.02 
-For scenario 3, no significant 
benefit or cost changes 
-For scenario 4, incremental 
benefit-cost ratio=37.72 
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6.4.1 Quality assessment of the included models: dimensions related to the model 
structure 
 
The second objective of this chapter is to examine the quality and structure of the decision 
analytic models included in this review using the quality assessment checklist (Philips et 
al, 2004). As the checklist is of general application for health related economic evaluation 
models, some of the dimensions of the guideline are more relevant and instructive for 
drug misuse models than others. Rather than comprehensively evaluating each model 
against each dimensions of the checklist, this review instead focuses on the specific 
dimensions and models that reveal the problems and limitations with modelling drug 
misuse interventions. The results thus provide an overview of the models paying 
particular attention to the problems of modelling a range of outcomes that have been 
discussed previously in the thesis and the limitations of modelling long-term outcomes. 
 
Dimensions of structure 
 
S1: Statement of decision problem/ objective 
 
The first dimension is the structure of the model. The guideline recommends that for a 
good decision analytic model there should be a clear statement of the decision problems 
and that the objective of both the evaluation and the model should be defined (Philips et 
al, 2004). As shown in Table 6.4.1, all of the treatment and screening intervention models 
have stated the decision problems and the objectives for their models.  
 
Most of the included treatment models are designed to examine the costs and 
effectiveness of methadone maintenance treatment (MMT) or to compare methadone 
treatment to alternative treatments like buprenorphine maintenance therapy or Suboxone 
for opioid-dependent patients (Barnett, 1999; Connock et al, 2007; Martinez-Raga et al, 
2010; Masson et al 2004; Zarkin et al, 2005) Other models aim to compare the costs and 
effectiveness of other interventions such as adding the anti-viral therapy for hepatitis C to 
current MMT (Sheerin, Green and Sellman, 2004), relapse prevention intervention with 
oral naltrexone (Adi et al, 2007) and the needle exchange programme to prevent HIV 
transmission among injecting drug users (Gold et al, 1997). 
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Most of the included screening models aim to examine the costs and effectiveness of the 
screening for hepatitis C infection among injecting drug users. 2 of the models are 
designed to examine the costs and effectiveness of the screening for tuberculosis 
(Perlman et al, 2001) and the screening of HIV (Villari et al, 1996) among injecting drug 
users.  
 
S2: Statement of scope/perspective 
 
The second dimension of the quality assessment of the decision analytic model is that the 
statement of scope and perspective should be stated clearly in the model and the data 
input of the model should be consistent with the stated perspective and objectives (Philips 
et al, 2004). This is especially important given the emphasis that previous chapters have 
placed on considering a wide range of both non-monetary (chapter 2) and monetary 
outcomes (chapter 4) to provide a comprehensive evaluation of drug misuse interventions. 
Table 6.4.1 shows that all included models have clearly stated the perspective of the study 
and the scope of the model.  
 
3 of the drug misuse treatment models stated that their intention is to examine the costs 
and outcomes from the societal perspective, of which 2 examined the costs of 
interventions as well as the societal costs of the drug users in the model. The model by 
Gold and colleagues (1997) examined the health care costs of HIV-related illness as the 
cost-saved for society from providing needle exchange programmes. Although the study 
claims to be from a societal perspective, it only considers one dimension of the monetary 
benefit, and therefore may be incomprehensive. The other model (Zarkin et al, 1994; 
Zarkin et al, 2005) provides a more comprehensive societal perspective as it examined the 
costs of crime, health care, and individuals’ earning from the increased employment of 
the drug users to calculate the economic benefit of the methadone treatment. However, it 
also omitted important dimensions of the monetary outcome, such as those related to the 
cost of social care resources that the drug misuse patients may use, which would greatly 
influence the monetary impact on society. The model developed by Barnett (1999) states 
that it is based on the societal perspective, however, only the costs of methadone 
maintenance treatment therapy are defined. No other types of costs from the societal 
perspective are measured in this study, such as crime related costs. 
 
  131 
Only 2 of the preventative intervention models state that that they are based on the 
societal perspective. The model by Perlman and colleagues (2001) has taken into account 
the cost of the screening as well as the costs of the prevented tuberculosis (TB) cases for 
the TB screening. Similarly, the other model (Tramarin et al, 2008) has considered the 
cost of the screening of hepatitis C infection, and the health care costs of hepatitis C 
related diseases. Both models only consider the health care costs and omit other costs 
such as criminal justice costs, which are important considerations from the societal 
perspective, the omission of which might lead to an incomprehensive estimation of the 
interventions. 
 
11 of the included models stated that their aim is to examine the outcomes and costs from 
the perspective of the health care system. All of these models examined the intervention 
costs, as well as the health care costs of related health conditions. However some of the 
models only considered a narrow perspective of heath care costs. For example, the model 
by Martinez-Raga and colleagues (2010) examined treatment costs, as well as the health 
care resource consumption related to the treatment, such as the costs of psychiatric 
supervision and social worker supervision, but did not consider other types of health care 
costs, such as GP visits or A&E visits. In addition, 2 of the models from the health care 
system perspective also stated that their aim is to evaluate the costs from the societal 
perspective and have accordingly estimated the broader monetary effect of the 
interventions, including the criminal justice system costs and the victim costs of crimes 
(Adi et al, 2007; Connock et al, 2007). However, these may not be comprehensive as 
neither of the studies have taken into account any social care costs.  
 
There is only one model that is based on the perspective of the tax payers. Sheerin and 
colleagues (2004) have developed the model from the perspective of the tax payers in 
New Zealand and only the costs of the interventions are considered as the financial 
burden for the tax payers. Previous chapters of this thesis, however, have stressed the 
complexity of drug misuse, which is related to a range of other health or psychological 
problems that would lead to high health care costs, which would be funded by the 
taxpayer. By neglecting these costs the economic impact of the interventions for the 
taxpayer may be misjudged. Of the 16 models in total, only 7 aimed to provide a societal 
perspective. Although most of the models consider some dimensions of the monetary 
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outcome, none of them take into account all of the important dimensions identified in 
chapter 4. 
 
This section also includes the scope of the study. As shown in Table 6.4.1, 10 of the 
included models examine the costs and effectiveness for a hypothetical cohort and the 
number of the cohort varies from 1,000 to 1 million patients. However, how these scopes 
are chosen for these models is not clearly described. The other 6 models examine the 
actual cohort, based on the prevalence of the targeted population, such as injecting drug 
users. The smallest sample size of these models is 179 opioid addicted patients in the 
study by Masson and colleagues (2004). The largest sample size is over 4.7 million 
patients who are at risk of hepatitis C infection in a population simulation modelling 
study in Italy (Tramarin et al, 2008). All of the included models have stated the scope of 
the sample, with the exception of 2 models that do not describe the sample (Stein et al, 
2002; Villari et al, 1996). 
 
S3 Rationale for structure  
 
The guideline recommends that the model structure should be consistent with a coherent 
theory and that the treatment pathway of the model should reflect the health condition 
under consideration (Philips et al, 2004). All of the 16 included models have developed 
the structures of treatment pathway based on the progression of the drug misuse problems.  
 
Of the 16 models, 5 use decision tree models alone. The 2 UK studies (Adi et al, 2007; 
Connock et al, 2007) have constructed a decision tree based on whether the patients 
stayed in or dropped out of the treatment for opioid dependents. The structure of the 
decision tree model by Gold and colleagues (1997) is based on whether or not the patients 
are infected with HIV after having received a needle exchange programme. The structure 
of the Spanish decision tree model (Martinez-Raga et al, 2010) is based on the 
transmission of adherence-related groups within the maintenance treatment, and the 
decision tree model by Perlman and colleagues (2001) has followed patients’ pathways 
regarding whether or not they have received the primary tuberculosis testing and then the 
further screening. 
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7 of the included models have used the Markov model alone. These models are all based 
on more complicated dynamics of patients’ states and how the patients move between the 
different states. 2 of these models (Barnett, 1999; Masson et al, 2004) are based on the 
survival rate of the patients in the treatments from the time point when they enter the 
treatment. The model by Sheerin and colleagues (2004) is based on the patients’ transition 
of different possible states of HCV-related liver disease after receiving the additional 
hepatitis C treatment along with methadone maintenance treatment. 2 studies (Leal, Stein 
and Rosenberg,1999; Stein et al, 2002) developed the Markov model based on whether 
patients have received the primary HCV screening and confirmatory screening and biopsy, 
as well as whether the patients have received the treatments. Tramarin and colleagues 
(2008) developed a Markov model of the patients’ transition between different states 
based on the probability of their acceptance of HCV screening and the treatment, as well 
as whether they have developed HCV-related diseases. The Markov model by Villari and 
colleagues (1996) is based on the probability of patients in different states related to their 
HIV infection states, such as HIV positive or HIV-positive asymptomatic.  
 
The final 4 models combined decision tree and Markov models. The decision tree of the 
model by Zarkin and colleagues (1994 and 2005) is based on the probability of whether or 
not the patients continue using drugs after receiving treatment. The Markov model then 
examines the patients’ transition between 5 different states, with each state based on 
whether or not they continue using drugs and whether or not they are in jail. The study by 
Thompson Coon and colleagues (2006) has developed a decision tree model based on 
whether or not the patients have received the HCV screening and treatment and whether 
they have positive results of the screening. The Markov model in this study is based on 
the patients’ transitions between different states of HCV-related diseases. The decision 
tree model by Loubiere and colleagues (2003) is not presented; however, the authors have 
stated that the decision tree structure is based on the patients’ life expectancy and lifetime 
expenditure for each of the alternative strategies. As with the model by Thompson Coon 
and colleagues, the Markov model in this study is based on the probability of patients 
being in different states of HCV-related diseases. Sutton and colleagues (2006) have 
developed the decision tree model based on whether or not the patients have ever injected 
drugs and whether the patients have positive HCV screening results to identify the 
possible intervention scenarios. The Markov model of this study is then based on the 
probability of which different scenarios the patients are in. 
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S4 Structural assumptions 
 
The guideline recommends that it is good practice for a decision analytic model to justify 
the assumptions for the structure and that these should be transparent and reasonable 
according to the objective, perspective, and scope of the study (Philips et al, 2004). All of 
the 16 included models have justified the structural assumptions based on either the 
current practice of the interventions or based on the evidence from related literature, and 
have related their justification to their objectives. For example, the UK treatment model 
for oral naltrexone (Adi et al, 2007) has assumed that the compliance rates are not 
enhanced by contingent management rewards based on the current practice. The USA 
treatment model for methadone maintenance treatment (Barnett, 1999), by contrast, made 
assumptions based on the evidence from the literature for risks of death in methadone 
treatment and drug-free treatment.  
 
S5 Strategies/ comparators 
 
The guideline recommends that there should be a clear definition of the strategies in the 
model and that the model should evaluate all feasible and practical strategies (Philips et al, 
2004). Most of the 8 included treatment models only consider a few alternatives in their 
models because their objective is to examine the effectiveness of the specific intervention. 
The model by Adi and colleagues (2007) aims to evaluate the costs and effectiveness of 
the oral naltrexone as an intervention to prevent relapse, hence, it is only compared with 
the alternative routine care. Similarly, the model by Gold and colleagues (1997) aims to 
examine the effectiveness of a needle exchange programme and is only compared with 
the scenario without the needle exchange programme. All of the other 6 models aimed to 
examine the effectiveness of the alternative maintenance treatment; hence, these 
interventions are compared with standard methadone treatment. 
 
Among the 8 preventive models, 6 were designed to examine the effectiveness of the 
screening of hepatitis C infection, hence they are mainly compared with the alternative 
scenario of no screening. The study by Leal and colleagues (1999) only examined the 
outcomes of the hepatitis C screening and is not compared with any other options. The 
French study (Loubiere, Rotily and Moatti, 2003), however, also examined the scenarios 
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when patients receive treatment after being diagnosed for hepatitis C. Similarly, the 
model by Perlman and colleagues (2001) examined the costs and effectiveness of 
tuberculosis (TB) screening, as well as the options when patients receive the screening 
and treatment. Villari and colleagues (1996) developed a model to compare the costs and 
effectiveness of HIV screening, as well as the options of early HIV treatment and delayed 
treatment. Overall, most of the preventive models considered possible alternatives.  
 
S6 Model type 
 
The guideline recommends that the chosen type of model should be related to the stated 
decision problem and the choice should be based on the causal relationship within the 
model (Philips et al, 2004). As detailed previously (S1 and S3), among the 16 models 
there are 5 decision tree models, 7 Markov models, and 4 models combining decision tree 
and Markov models. All of the studies have chosen the appropriate type of model based 
on their decision problems. For instance, Villari and colleagues (1996) have chosen the 
Markov model to evaluate the costs and effectiveness of the HIV screening, because the 
transition of HIV patients between different states of the disease is very complicated and 
is difficult to examine in a decision tree model.  
 
S7 Time horizon 
 
The guideline recommends that the time horizon should be sufficient to reflect all of the 
important differences between the included strategies in the model (Philips et al, 2004). 
This is an especially important consideration given that one of the reasons for conducting 
this review was that the drug misuse intervention studies examined in previous chapters 
only measure outcomes in the short-term. However, 2 of the models only estimated the 
costs and outcomes of the cohort over 12 months. Adi and colleagues (2007) justified this 
as there is no information for the model’s long-term outcome parameters and the 
treatment (oral naltrexone) is only available for a short period of time. Connock and 
colleagues (2007) developed the model of maintenance treatment based on the meta-
analysis from the short-term outcomes of the trials literature as the study failed to identify 
any long-term trial literature. These justifications reflect a major problem with drug 
misuse modelling studies, which is that there is often insufficient information to set 
parameters for estimating longer-term outcomes. However, it is unlikely that the time 
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horizons used would be sufficient to reflect all of the important effects arising from the 
intervention, especially given the dimensions of the monetary outcomes that the models 
consider. It may be longer than 12 months before many of the costs that are considered in 
the model occur. For example some of the criminal justice costs, such as the costs 
associated with trials, will not be realised until many months after a crime is committed. 
These models therefore fail to meet the time horizon requirement as both of the 
interventions modelled will have long-term effects, which the models cannot take into 
account. 
 
The model by Gold and colleagues (1997) only followed the patients receiving the needle 
exchange programme for 5 years because it is difficult to predict the status of HIV 
prevention and treatment beyond this period. Perlman and colleagues (2001) also 
followed the patients in TB screening for 5 years, because the data in the model is from a 
5-year follow-up study. Another model followed the study cohort for 3 years (Martinez-
Raga et al, 2010) because it only aimed to evaluate the budgetary impact of the three-year 
treatment programme of Suboxone, and the study by Sutton and colleagues (2006) 
predicted the outcomes in 2017 of HCV screening for injecting drug users in prison. 
These models are all less likely to be affected by the problems that the first 2 models 
faced, providing that the changes arising from the intervention do not take longer than the 
trial period to come into effect. However, the models provide little indication of whether 
or not this would be the case, for example the study by Sutton and colleagues (2006) 
gives no reason for its time horizon and therefore it is unclear whether it would meet this 
requirement. 
 
8 of the remaining models followed the patients up over their lifetime, as these studies 
consider that drug misuse is a chronic condition and that the interventions will have a 
long-term impact. Similarly, 2 of the models also followed the patients in HCV screening 
for 30 and 50 years (Leal, Stein and Rosenberg, 1999; Stein et al, 2002, respectively) for 
the same reasons. Even though most of the prevention models followed the patients up 
over a long period of time, which appears to meet the time horizon requirement, it is 
important to stress that these models used parameters based on short-term studies. 
However, the longer the time horizon the more uncertain the model becomes because the 
parameters are less precise, a problem that is discussed in more detail below in D4, 
Assessment of uncertainty. 
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S8 Health/ disease states/ pathways 
 
The guideline recommends that the health states or pathways should reflect all of the 
appropriate states related to the health condition with which the model is concerned 
(Philips et al, 2004). The disease states or pathways of all of the 16 included models are 
developed according to the prognoses of the drug misuse related health problems, and 
were discussed previously in section S3 Rationale for structure. 
 
S9 Cycle length  
 
The guideline recommends that the cycle length should be the minimum interval over 
which the pathology or symptoms are expected to alter (Philips et al, 2004). 2 of the 
models examined the costs and outcomes over an irregular cycle at weeks 2, 6, 13, 25 and 
then after 12 months, which they justified as the patient’s drop-out rate is higher during 
these periods of time as more patients drop-out towards the beginning of the intervention 
(Adi et al, 2007; Connock et al, 2007). The costs and outcomes were only estimated at the 
end of the model as there is insufficient information at the earlier time points.  
 
One model examined the costs and outcomes of patients in methadone maintenance 
treatment over a monthly cycle (Zarkin et al, 2005), even though the maintenance 
programme is long-term. The rationale for doing so was that the model aimed to consider 
employment status, which could possibly change over a monthly cycle. Another model 
applied a 3-month cycle length (Thompson Coon et al, 2006), based on the stated 
assumption of the progression states of HCV-related diseases. 
 
6 models examined chronic health care problems such as opioid addiction (Martinez-Raga 
et al, 2010; Masson et al, 2004), drug-related HIV infection (Gold et al, 1997; Villari et al, 
1996), or drug-related hepatitis C (Stein et al, 2002; Tramarin et al, 2008). As these 
models were interested in long-term outcomes they adopted an annual cycle length. 6 of 
the models did not describe the cycle length and therefore do not meet this requirement. 
 
Dimensions of data 
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D1 Data identification 
 
The guideline recommends that the methods of data identification should meet the 
objectives of the model, and there should be justification for the reasons for the choices of 
the data sources, as well as the quality assessment of the data (Philips et al, 2004). All of 
the included studies have clearly identified the sources of the data which are used in the 
model, which are all from the relevant literature. As there are considerable differences 
between the drug misuse policies of different countries, most of the models considered 
evidence from studies conducted in the same country. For instance, the UK model 
developed by Adi and colleagues (2007) mainly adopted data from the UK literature. 
 
D2 Data modelling 
 
The guideline recommends that the data modelling methodology should be based on 
justifiable statistical and epidemiological techniques (Philips et al, 2004). These include 
application of the half-cycle correction to both costs and outcomes and justification of 
how the short-term results are extrapolated to simulate the final outcomes in the model. 
The costs of the model should follow the appropriate guideline of economic evaluation 
and if the quality of life weights have been applied, they should be justified and applied 
appropriately in the model. 
 
All of the included models justified the statistical methods that they used to derive the 
data from the literature in order to estimate the costs and effectiveness of the interventions. 
The data from the literature are synthesised through a simple mathematical model. Only 3 
of the included models applied the half-cycle corrections for adjustment of costs (Adi et 
al, 2007; Connock et al, 2007; Masson et al, 2004). 
 
The data in the model are mainly from clinical trials. As there are time constrains 
regarding time and resources when conducting clinical trials, they can only examine 
short-term outcomes. Only one model was able to identify evidence from a 5-year follow-
up HIV study (Perlman et al, 2001). As there is not enough evidence from longitudinal 
studies, the data adopted in the model have to be extrapolated, which leads to problems of 
uncertainty considered below in D4, Assessment of uncertainty. All of the included 
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models applied simulation methods to extrapolate the costs and outcomes of the 
interventions. 
 
The types of costs and outcomes of the included model are based on the type of economic 
evaluation adopted in the model. All of the models justified the costs and outcomes. 7 of 
the models carried out a cost-utility analysis where QALYs (quality-adjusted life years) 
are considered as the main outcome in the economic evaluation. 6 of the included models 
were cost-effectiveness analysis models, of which 5 considered life-years saved and 1 
considered the number of identified HCV cases (Sutton, Edmunds and Gill, 2006). None 
of the models considered non-health related non-monetary outcomes such as outcomes 
related to social integration, the importance of which was discussed in chapter 2. The 
other 4 included models carried out cost-benefit analyses of dimensions of the monetary 
outcome, such as the costs saved by the interventions. The limitations of the dimensions 
of the monetary outcome measured based on the perspective of the study were discussed 
in S2, Statement of scope/ perspective.  
 
D3 Data incorporation 
 
The guideline recommends that all of the data used in the model should be described and 
referenced and the inconsistent data should be justified (Philips et al, 2004). All of the 16 
included models referenced and provided a description of the data they used. The data 
were then modified into the unit costs, unit effectiveness, or the parameters for the model. 
When a number of different data sources were available for use in the model, most 
models adopted the most conservative estimates so as not to overestimate the effect of the 
intervention. For example, in the model by Gold and colleagues (1997), 5 different HIV 
prevalence rates for injecting drug users before commencing the intervention were 
available, ranging from 3% to 11.1%. The model adopted the lowest rate of 3%, which 
would mean that there was not a high prevalence rate before the intervention, thus it 
would be harder to prove that the intervention decreased the prevalence rate. 
 
D4 Assessment of uncertainty: methodological, structural, heterogeneity, parameter 
 
The guideline identifies 4 main types of uncertainty that models should assess through 
sensitivity analysis: methodological, structural, heterogeneity, and parameter (Philips et al, 
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2004). Of these types of uncertainty, the included models are mainly concerned with the 
uncertainty regarding parameters and all of the models conducted sensitivity analyses to 
address this problem. However, only 3 of the models conducted a probabilistic sensitivity 
analysis (Adi et al, 2007; Connock et al, 2007; Thompson Coon et al, 2006). The 
probabilistic sensitivity analysis applies all the different possible parameters at each stage 
of the model to generate all the possible outcomes and costs, and then calculates the 
probability for each outcome and cost. This is the most comprehensive way to account for 
the uncertainty of the parameters. All sensitivity analyses are based on the assumptions of 
the study, as well as the availability of the parameter data from the literature, and the 
limitations of the parameters thus encompass some of the problems that have been 
highlighted already. 
 
The main problem regarding parameters occurs for models that attempt to estimate long-
term outcomes, which usually have to use parameters based on short-term studies as few 
longitudinal studies have been conducted for drug misuse interventions. Problems will 
arise if the data regarding the costs and outcomes of the intervention over a short-term 
period are likely to be different from the data for subsequent years. If this is the case then 
parameters based on data extracted from short-term studies may be inappropriate for 
long-term models, as biases may arise when the short-term costs and outcomes are 
extended into longer-term models.  
 
This problem is illustrated in the model developed by Masson and colleagues (2004), 
which conducted a 12 month trial comparing the costs and effectiveness of 2 types of 
methadone treatment. The differences between the 2 treatments over the final 6 months of 
the trial were used to set the parameters for the model, which they applied over 10 years. 
At this point they assumed that the effects would diminish and used the findings to project 
lifetime costs and outcomes. However, the parameters would only be appropriate if the 
differences observed in the final 6 months of the trial could be expected to apply for the 
remainder of the first 10 years. It is not clear that this would be the case with all the costs 
estimated, such as the cost of mental health visits. If the treatment is effective then it may 
take longer than a year before the mental health benefits are realised and the model may 
therefore overestimate the mental health care costs over the 10 years.  
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Another problem with setting parameters is that the data on which they are based often 
has to be extracted from a number of different studies. Although models attempt to extract 
data from similar studies, such as studies all from the same country, there may still be 
differences between the studies that affect the parameters, and it is therefore important to 
test different parameters from different studies. For example, the study by Gold and 
colleagues (1997) used HIV prevalence rates at baseline taken from Canadian studies. 
However, as there were no satisfactory Canadian studies for the HIV prevalence rate 
among injecting drug-users without the needle exchange programme, this data was 
extracted from studies conducted in the USA. One limitation of this model, therefore, is 
that bias may occur if the drug misuse patients from Canada and the USA have different 
HIV prevalence rates, which is likely given that different countries have different drug 
taking cultures. 
 
A final problem regarding parameters with respect to treatment models is worth 
mentioning. In many cases researchers want to know the effects of giving drug misuse 
patients a certain treatment compared with not giving them that treatment. For example, 
Barnett (1999) aims to compare methadone treatment to drug-free treatment, and Gold 
and colleagues (1997) aim to compare the effectiveness of a needle exchange programme 
to no programme. However, real-world estimates are unavailable to set the parameters for 
both models as it would be unethical to give one group of drug misuse patients a 
treatment, yet deny access to treatment to the control group. Parameters concerning the 
effect of a given treatment compared to a control group usually have to be estimated 
without support from real-world data. 
 
6.5 Conclusions and Discussion 
 
Although decision analytic models are widely applied for other health care interventions, 
only a limited number have been developed for drug misuse interventions. This chapter 
has identified 16 models, of which 8 were designed to estimate the costs and effectiveness 
of the drug misuse treatment and 8 were designed to examine screening interventions. 
The quality of these models has been reviewed using a guideline developed by Philips 
and colleagues (2004). Although most of the identified models met most of the criteria for 
a good model, a number of limitations and problems have been identified. The main 
problem for modelling studies is choosing appropriate parameters for the model under 
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conditions of uncertainty. A number of limitations with choosing parameters have been 
identified throughout the chapter but the most important relate to the time horizons that 
the model aims to cover and the perspective adopted by the study range and thus the 
outcomes with which it is concerned.  
 
One of the potential advantages of modelling studies is that a range of outcomes can be 
modelled to provide a comprehensive evaluation of drug misuse interventions. Of the 16 
models, 7 aimed to provide a societal perspective. However, many of the models omitted 
dimensions of the monetary outcome that would prove important for estimating the 
monetary impact on society, and therefore face the same limitations as the drug misuse 
intervention studies that were discussed in chapter 4. It is important to measure a wider 
range of dimensions, such as criminal justice costs, social care services costs, and 
addiction services costs, however, none of the models conducted from a societal 
perspective take into account the social care services cost.  
 
One reason that models often omit certain dimensions is that the more dimensions that are 
modelled the more complex the model becomes. If lots of dimensions are taken into 
account there will be a greater amount of parameters required. However, decision tree 
models frequently have to be simplified so that they are not too complicated to handle. 
This proves to be especially problematic for drug misuse models given that the prognoses 
of drug misuse patients are particularly complicated. As previous chapters have detailed, 
there are a range of both monetary and non-monetary outcomes that need to be taken into 
account to consider the societal impact of drug misuse interventions. The results of this 
chapter show that most of the included decision analytic models are simplified, thus the 
models may misjudge the costs and outcomes. 
 
Another of the potential benefits of modelling studies is that they can estimate outcomes 
over a longer time period. As drug misuse is often considered as a chronic condition (van 
het Loo, van Beusekom and Kahan, 2002), it is necessary to consider the long-term 
outcomes of the interventions in order to provide all the relevant information for policy 
makers. Of the 16 models reviewed, 2 only adopted a time horizon of 12 months, and 3 
others only considered time horizons of up to 5 years. The 2 short-term models extracted 
their data from clinical trials, and these are rarely longer than 24 months. Indeed there are 
very few longitudinal drug misuse studies available from which models can extract data 
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to set their parameters. Given this, any longer-term models have to make assumptions 
about how the patients’ pathways will develop over time, even though there is little real-
world evidence to support these assumptions. One of the major limitations of long-term 
models, therefore, is that there may not be enough information to justify the parameters 
that they use. If the parameters are based on data extracted from short-term studies then 
the model must assume that these parameters will continue to apply over a longer period 
of time. However, given that many of the effects and costs of drug misuse interventions 
may not have taken effect in the short-term period upon which the parameters were based, 
these parameters may not prove to be appropriate in the long-term. 
 
As parameters are uncertain over the long-term, models tend to use sensitivity analyses to 
address these problems. One way of doing this is to apply a different set of parameters to 
the model to examine the effect of the results, or to use a probabilistic sensitivity analysis 
to calculate the probability of different outcomes and costs if a range of estimates are 
available. As only 3 of the models reviewed used a probabilistic sensitivity analysis, this 
would be a way that other models could attempt to address the uncertainty of their 
parameters. However, the problem with all long-term models is that they are more 
complex and so have to make more simplifications as not all pathways can be modelled, 
which might still lead to the results being biased. The uncertainty regarding how 
parameters might change over the long-term cannot be fully addressed unless there are 
more longitudinal drug misuse studies, which would provide real life experience to check 
the estimates used in the model against. 
 
The limitations with drug misuse modelling studies identified in this chapter indicate that 
policy makers should be aware of the uncertainty regarding the outcomes and costs 
predicted by the models and the lack of realism that they might reflect. The more 
comprehensive the model attempts to be, the more assumptions and simplifications it has 
to make, which could distort the results. Long-term models need to be supported by data 
from longitudinal studies, however, few of these are available for drug misuse models. 
Nevertheless, given that drug misuse is usually considered to be a chronic condition and 
that there are rarely the resources to conduct long-term clinical trials, modelling may still 
prove to be the best way to estimate long-term costs and outcomes, despite its limitations. 
If long-term models are to provide a comprehensive evaluation of drug misuse 
interventions they must take into account a greater range of outcomes and costs than those 
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considered by the models reviewed in this chapter. To examine the limitations and 
problems with developing a model that estimates a wide range of long-term outcomes it is 
therefore necessary to build more drug misuse models, an example of which is developed 
in the next chapter.  
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Chapter 7 Drug testing in schools: illustration of outcomes in modelling 
studies 
 
7.1 Background and objectives 
 
The preceding chapters of this thesis have provided a methodological critique of current 
drug misuse intervention studies. A number of different problems have been highlighted, 
but for present purposes two may be stressed. The first is that many drug misuse studies 
that use individual patient level data fail to consider the long-term outcomes of the 
intervention. The second is that many existing studies do not measure a wide enough 
range of dimensions of the monetary outcome to provide a comprehensive evaluation of 
the societal impact of drug misuse interventions. In the previous chapter existing 
modelling studies for drug misuse were reviewed, and although many of these state that 
they consider the long-term societal perspective, they all omit important dimensions of 
the monetary outcome. The criteria for good modelling studies have been examined and 
the limitations for applying these to drug misuse models revealed. This provides the 
background for the model that is developed in this chapter, which attempts to redress 
many of the problems that have been identified with existing drug misuse studies 
throughout the thesis. 
 
This chapter aims to build a drug testing in schools model in order to examine the benefits 
and limitations of developing a long-term drug misuse model that takes into account a 
wide range of outcomes to provide a comprehensive evaluation of the intervention from 
the societal perspective. The drug testing in schools model is an innovative approach as 
there is a need to capture multiple outcomes over a long time period. It is also an area 
where there has been debate and conclusions drawn about this policy without a full 
economic evaluation. 
 
The development of the drug testing in schools model illustrates the structure of the 
possible scenarios when introducing random drug testing in schools and the rationales for 
including certain outcomes, which has only been discussed at a theoretical level 
previously. The estimated outcomes for drug testing in schools provides an example of 
how different outcome domains from the societal perspective are determined, and 
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secondly how individual level outcomes, such as drug misuse, transform into monetary 
outcomes for society in the long-term. 
 
Adolescent drug misuse is regarded as a social problem with many studies showing that 
such use is related to delinquency, poorer health status and lower educational outcomes in 
schools (Godfrey et al, 2002b; Godfrey et al, 2004; McCrystal, Higgins and Percy, 2006).  
Current policy directed at reducing the misuse of illegal drugs among young people 
across the UK involves a range of general information and more targeted initiatives. The 
question considered in this chapter is whether random drug testing in schools would be a 
useful part of the overall drug intervention strategy. Most prevention programmes are 
directed at providing information and advice to young people. Drug testing, by contrast, 
can be seen to be part of a more regulatory approach, particularly if positive tests are 
associated with some sort of punishment. The hypothesis is that drug testing programmes 
will deter drug misuse.   
 
Random drug testing in schools has been applied in many middle schools and high 
schools in the U.S.A. The nature of the policies and incentives or disincentives for pupils 
and their parents vary. Some schools require students to take drug tests before issuing 
them with a parking permit etc. (DuPont, Campbell, and Mazza, 2002), whereas others 
have restricted testing to a specific group, such as adolescent athletes (Goldberg et al, 
2003; Goldberg et al, 2007). 
 
In 2004 the UK government also declared support for random drug testing in schools, 
which was then applied in 2005 by a school in Kent and Hucknall (BBC News, 2006; 
Gerada and Gilvarry, 2005), but there has not been widespread adoption of such policies. 
A previous Joseph Rowntree Foundation supported review suggested that there was very 
limited evidence to support the wide scale introduction of drug testing in schools 
(McKegnaney, 2005). However, drug prevention policies with even limited levels of 
effectiveness can be shown to be cost-effective (Caulkins et al, 1999). The social costs 
associated with problematic drug misuse are very high and therefore expensive 
programmes that prevent some young people from becoming problematic drug users 
could prove to be good value for money. In the absence of primary data collection, an 
alternative research design is to construct a simulation model of the potential beneficial 
and adverse effects of drug testing in schools. 
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In order to evaluate the impact on the student cohort after introducing drug testing, a 
simulation model is developed to compare two groups of pupils: one cohort in a school 
with random drug testing and one cohort in a school without random drug testing. These 
two groups are assumed to have similar characteristics, in order to avoid other factors 
which might be related to drug misuse among pupils, such as alcohol use and smoking. 
The model was designed to simulate the cost-effectiveness of introducing random drug 
testing in a secondary school compared to the alternative of no such random testing. 
 
2 outcome domains are considered at the end point of this model: drug misuse and 
educational outcomes. In the drug testing in schools model the number of pupils using 
drugs may differ from those in the model of no testing, based on the assumption that 
random drug testing in schools has some deterrent effect. This is related to the probability 
of pupils who become recreational drug users or problematic users in the end point of the 
model and their lifetime cost of being drug users. The other main focus in this model is 
the educational outcome. Random drug testing in schools may increase exclusions and 
influence pupils’ truancy behaviour which in turn could lower pupils’ educational 
outcomes. Poor educational outcomes are also associated with considerable lifetime social 
costs. 
 
The first stage in estimating the cost-effectiveness of introducing random drug testing in 
schools is to construct the conceptual model indicating the different pathways individual 
pupils may experience as a result of different outcomes associated with the drug testing 
regime. This model will of course be dependent on the type of policy within which the 
random drug testing is embedded. The next stage is to find the best estimates for the 
different parameters of the conceptual model from the evidence base and UK data sources. 
Once the best sources for all data requirements are found, results can be generated. By 
changing key parameters the sensitivity of the model and the results for the cost 
effectiveness of drug testing can be presented. 
 
7.2 Structure of the model  
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The model was constructed as a decision analytic model, with the primary question being 
whether the introduction of random drug testing in schools was cost-effective against the 
alternative where there was no random drug testing. 
 
Building the conceptual model is made of up of the following stages: 
• Determining the nature of the random testing regime 
• Determining the nature of policies in the school arm with no drug testing 
• Determining the time period, scope and implementation of the testing within the 
simulated model and time horizon of the outcomes  
• Determining the different outcomes states  
• Determining the different pupil pathways in both arms of the model 
 
The full model and different pathways for both the school with drug testing and without 
drug testing are reproduced in Appendix 5. 
 
7.2.1 Simulated random drug testing regime 
  
It is assumed that the initial test will use non-invasive methods such as saliva or sweat 
tests. Parents and pupils will be informed about random drug testing and the non-invasive 
testing methods, and will be asked for their consent for being tested and providing 
samples. However, they will not be informed about the specific date of testing in order to 
prevent possible absence on the testing day. Testing is assumed to take place each year 
from Year 7 through to Year 11. 
 
If pupils’ initial test results are positive, the school will inform pupils’ parents or 
guardians and advise pupils to take confirmatory tests in hospitals. The confirmatory tests 
will use invasive methods such as blood or urine tests. If pupils have negative results in 
the confirmatory test, they will return to the same school and will not receive any 
penalties or punishment. If pupils’ confirmatory test results are positive, they may be 
excluded from the school for a fixed period of time (suspension). The school may also 
provide a consultation programme for pupils who have been caught using drugs.  
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If pupils refuse to participate in random drug testing or in the later confirmatory test, they 
may receive fixed period exclusion or even permanent exclusion from school, depending 
on the school policy. Within this model, it is assumed that if pupils refuse to participate in 
random drug testing or in the later confirmatory test, they may receive fixed period 
exclusion (suspension). Pupils that are suspended and then return to the same school will 
still enter the next random drug testing cycle. 
 
If pupils have positive results in the confirmatory test, they may be excluded from school 
permanently or suspended for a period of time, depending on the school policy. The DfES 
(Department for Education and Skills) drug guidance for schools (2004) recommends that 
schools inform pupils’ parents or guardians when they find out that pupils have used 
drugs. If these are illegal drugs, the guideline suggests that the school may inform the 
local police. However, it is questionable whether or not the school will actually inform 
the local police about the pupils’ illegal drug usage, due to their concern with their 
reputation. The next step is that the school will need to identify the needs for the 
appropriate disciplinary action or referral to other services, such as consultation 
programmes for the pupils. 
 
Within this model, once the pupils are confirmed as having used drugs they are suspended. 
If the school decides to only suspend the pupil, the school will need to provide or refer the 
pupil to an appropriate consultation programme. The pupils will still enter the next cycle 
for random drug testing. In reality, if the school’s policy recommends permanent 
exclusion, the pupils may enter another school, or a special programme provided by 
different educational authorities, or they may start working.  
 
Pupils refusing to participate in random drug testing or the confirmatory test could receive 
different penalties, depending on the school’s policy. The school may assume that pupils 
who refuse to participate in the test may have been taking drugs. Therefore, pupils may be 
suspended for a fixed period of time. 
 
If pupils exclude themselves from school at any point of the drug testing process, the 
school and local educational authorities may need to take certain action regarding pupils’ 
truancy. Depending on the school’s truancy policy, a pupil’s teacher will try to contact the 
parents or guardians about the truancy and ask the self-excluded pupil to return to the 
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school. The head teacher of the school and truancy officer from the local education 
authorities may be involved in the pupils’ truancy problem. If pupils decide to come back 
to the same school, they will then enter the next random drug test cycle. 
 
If the self-excluded pupils decide not to return to the same school, they may choose to go 
to another school without random drug testing, or join special educational programmes, or 
they may decide to leave the education system and start working. If the pupils decide not 
to return to the original school where random drug testing in schools is introduced, it 
would be very difficult to trace the cost and consequences of their long-term educational 
and drug outcome within this model. In this model, if the pupils decide to leave the school 
their final outcome at age 16 is estimated based on simple assumptions. 
 
It is believed that all types of exclusion may affect pupils’ educational outcomes. 
(Brookes, Goodall and Heady, 2007). Some research even shows that exclusion may be 
related to pupils’ drug misuse and delinquency (McCrystal, Higgins and Percy, 2006) and 
missed time at school may affect their educational outcomes. Therefore, it is assumed that 
pupils who self-exclude or are suspended from school may have a higher probability of 
having lower educational outcomes and may also have a higher probability of becoming a 
problematic drug user within this model. 
 
7.2.2 Control group model: no drug testing in schools 
 
In the control group model the school relies on the existing school detection and 
disciplinary system for drug misuse prevention. It is assumed that the majority of pupils 
in the school never use drugs (as in both simulated schools based on UK population 
figures) but that some of them have been using drugs for recreational purposes. If pupils 
are recreational drug users, it is assumed that none of them have been caught. This is a 
simplifying assumption as the model could be extended to allow for some drug misuse 
discoveries and potential exclusions in the control model. At the age of 16 these pupils 
will either stop using drugs, continue using drugs recreationally, or become problematic 
drug users. Although these pupils will remain in the same school and the normal 
education system, any drug misuse may affect their educational outcomes. They may also 
have a higher probability of becoming problematic drug users.   
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7.2.3 Outcome domains and end states 
 
To undertake an economic evaluation, outcomes have to be expressed either in monetary 
terms or by focussing on a single primary outcome. For example, the model could be 
constructed in terms of the net cost per reduction in drug misuse or by the number of 
problem drug users. An alternative approach is to seek monetary values for all outcomes 
and express the model in terms of net benefits or net costs, which is the additional cost or 
gain from introducing a policy compared with the alternative.   
 
In constructing potential pathways and outcomes at the end of the model cycles, 2 main 
outcome domains were identified: drug misuse and educational outcome at age 16. 
Previous economic studies based on English and Welsh data had also yielded monetary 
values of the costs of being either a problematic drug user (Godfrey et al, 2004) or having 
poor educational outcomes (Godfrey et al, 2002b). The study estimates the annual cost of 
being a problematic drug user or recreational user. With parameter values of the length of 
a drug using career these estimates can be used to determine the lifetime costs of a 
problem drug user at age 16. The second study estimated the lifetime costs of not being in 
education, employment or training (NEET) at age 16-18 compared with the non NEET 
population at the same age.    
 
Depending on the availability of these data pupils will be categorised into six different 
outcome groups, based on their educational status and their drug usage status. These six 
states are: 
  Drug free and normal educational attainment 
  Recreational drug user and normal educational attainment 
  Problem drug user and normal educational attainment 
  Drug free and NEET 
  Recreational drug user and NEET 
  Problem drug user and NEET 
 
7.2.4 Time period and scope 
 
In the model presented below it is assumed that pupils participate in random drug testing 
throughout their secondary school career. The model takes a cohort through their school 
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career from 11 to 16, such that those in the school with random drug testing will be likely 
to have a test every year if they continue at the school. It is assumed that there will be 500 
pupils in the whole school cohort for both arms – drug testing school and the control 
group. 
 
7.3 Building the random drug testing in schools model 
 
The simulation model starts from the decision node, where 1000 pupils are divided into 2 
different scenarios: the random drug testing in schools model and the no testing model. 
The decision node is usually shown as a square (□) and the chance node as a circle (○). 
Different probabilities are needed for each branch of the chance node and the sum of 
these probabilities must equal 1. In the first stage of the model, it is assumed that 50% of 
pupils are allocated to the no drug testing model and 50% of pupils are allocated to the 
random drug testing in schools model. 
 
Figure 7.3.1 Decision node 
 
The rest of this section sets out the different pathways through decision and chance nodes 
for these two different branches with the full model being reproduced in the following 
section. 
 
7.3.1 No drug testing model 
 
Looking at the no drug testing branch first, pupils enter the model at age 11 and it is 
assumed that they could either be recreational drug users or drug free. It is assumed that 
in the no drug testing model, the recreational users will never be caught for using drugs 
and both recreational users and pupils who are drug free will stay in the same school. 
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Figure 7.3.2 Scenario of no drug testing 
 
If pupils are never caught for using drugs, they might stop using drugs or continue using 
drug recreationally or become a problematic user at age 16. 
 
 
Figure 7.3.3 Recreational user pathway 
 
Depending on pupils’ status, the terminal or end stage node at age 16 will be presented 
according to their drug status (drug free, recreational user or problematic user) and their 
education status (NEET or normal education). 
 
Figure 7.3.4 Recreational user end node 
 
Those pupils who are originally drug free and remain in the same school might still 
change their drug usage status and become a recreational user or a problematic user by the 
end. 
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Figure 7.3.5 Non-user pathway 
 
7.3.2 Random drug testing in schools model 
 
The pathways for the random testing in schools model are more complex and individual 
pupils cycle through the drug testing programme each year they remain in the school. 
Pupils may have different reactions towards random drug testing. They may participate in 
the testing regime, self-exclude themselves and decide not to go back to school, or they 
may refuse to participate in the testing. 
 
Figure 7.3.6 Random drug testing scenario 
 
Self exclusion arm 
 
If pupils self-exclude themselves the school may have policies in place, such as 
contacting with parents or guardians. After a period of self-exclusion, pupils may come 
back to the same school afterwards, or they may decide to leave the school. 
 
Figure 7.3.7 Self-exclusion pathway 
 
When pupils go back to the same school, they might still enter the next cycle of random 
drug testing. When they get to age 16, they may have a different drug status but they 
would all have completed normal education. 
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Figure 7.3.8 Self-exclusion end node 
 
If pupils decide not to go back to the same school, they might end up going to another 
school or special educational programme and stay in education, or they might decide to 
leave the education system. If pupils leave the original school they would also leave the 
random drug testing model and their final outcomes will only be estimated when they are 
16. 
 
Figure 7.3.9 Permanent exclusion pathway 
 
If pupils decide to leave the original school but still stay in the education system their 
final outcomes at age 16 will be estimated based on their educational status (normal 
education) and their drug status. If pupils decide to leave the education system completely, 
they might start working without any qualification and they might become NEET.  
 
 
Figure 7.3.10 Permanent exclusion end node 
 
Refusal of initial test arm 
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If pupils decide to refuse the initial test, it is assumed that they will receive some 
punishment, such as suspension. It is assumed that they will return to the same school 
afterwards and enter the next random drug testing cycle. Their outcome will be based on 
the drug and education status at age 16.  
 
Figure 7.3.11 Initial test refusal pathway 
 
Participation in test arm 
 
If pupils decide to participate in the initial test, they may have positive or negative test 
results. The probability of having positive or negative test results depends on the 
sensitivity and specificity of the test. 
 
Figure 7.3.12 Initial test participation pathway 
 
If pupils have negative initial test results they will remain in the same school and enter the 
next cycle of random drug testing. However, there is still a chance that they might either 
remain drug free, become a recreational user or a problematic user at age 16. 
 
Figure 7.3.13 Initial test negative results 
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If pupils have positive initial test results, their parents or guardians will be informed and 
the pupil will be advised to take the confirmatory test (blood test) at the local hospital 
with their parents or guardians. When they are advised to take the confirmatory test, there 
may still be some chance that they refuse to take it.  
 
Figure 7.3.14 Initial test positive results 
 
As with the situation for refusal of the initial tests, if pupils decide to refuse to take the 
confirmatory test it is assumed that they will be suspended for a fixed period of time. 
They will return to the same school after suspension and enter the next cycle of random 
drug testing. The final outcome will be based on their drug and education status (normal 
education) when they are 16.  
 
Figure 7.3.15 Initial test positive results pathway 
 
The confirmatory test should be more effective at detecting drug usage among pupils. 
Pupils may have positive or negative result in the confirmatory test.  
 
Figure 7.3.16 Confirmatory test pathway 
 
If pupils have a positive confirmatory test result, they may receive some punishment from 
school, such as suspension. When they come back to the same school, they may need a 
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related counselling programme. They may still enter the next cycle of random drug 
testing in schools. Their outcomes will be based on their drug and educational status. 
 
 
Figure 7.3.17 Confirmatory test positive results pathway 
 
If pupils have a negative confirmatory test result, they may not have used drugs. However, 
like all the drug tests, there might be some false negative cases in the confirmatory tests. 
This may happen if the test sample is too dilute to be examined properly.  
 
Figure 7.3.18 Confirmatory test negative results pathway 
 
Pupils who have a negative result and have not used drugs will stay in the same school 
and enter the next cycle of testing. Their final outcomes will be estimated, based on their 
drug and educational status.  
 
Figure 7.3.19 Confirmatory test negative results end node 
 
If pupils have used drugs but are not caught in the confirmatory test, they will still remain 
at the same school and enter the next cycle. The invasive confirmatory test, such as the 
blood test, is usually more effective in detecting drug usage. Pupils’ final outcomes at age 
16 will be calculated, depending on their drug and educational status.                                         
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Figure 7.3.20 Confirmatory test false negative results pathway 
 
The pathways of the full model can be seen in Appendix 5. 
 
7.4 Parameters of the model 
 
This section explains the development of the parameters and how the individual level 
outcomes relate to the social costs, which has been discussed in previous chapters. The 
parameters for the model are in two main forms: monetary amounts and probability 
estimates. For monetary parameters there are the costs of the drug testing interventions 
and the estimated costs for each of the 6 final outcome domains. The probability estimates 
are required to determine the proportion of the overall cohort split into the various 
pathways as set out in Appendix 5. In this section the sources of data and parameters used 
in the model are set out. The model takes a societal perspective, including all costs 
wherever they are borne and all costs are in 2005/6 UK prices. 
 
7.4.1 Estimating the costs of drug testing 
 
This section lists all the costs which may have occurred while introducing random drug 
testing in schools. These include the unit cost of random drug testing in schools (the 
initial test) and the unit cost for the confirmatory test. The cost of the reaction to pupil’s 
truancy from their schools or local authorities will also be considered. If pupils are 
advised to participate in the confirmatory test in hospital, the costs for travel and the time 
of the pupils’ parents or guardians will also be included.  
 
No direct information about the cost of random drug testing in schools in the UK is 
available. Existing literature was searched for potential UK examples. One study 
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identified was a review of drug testing within a workplace setting. It shows the costs of 
drug testing in the workplace based on the market price and level of usage (Joseph 
Rowntree Foundation, 2004). A potential model related Home Office study used a 
bottom-up approach to costing within a public sector type intervention (Matrix Research 
and Consultancy and Institute for Criminal Policy Research, 2007). In this study, the unit 
cost of a test varied between different sites because of different levels of usage and the 
setting up costs. Assuming within a school setting, there is likely to be a greater number 
of tests, the unit cost could be predicted more accurately and would be lower than the 
Home Office reported price. 
 
In a Joseph Rowntree Foundation study of drug testing in the workplace (Joseph 
Rowntree Foundation, 2004), it is reported that one of the drug testing companies, Altrix, 
charges between £30 and £35 for an initial test and £52 for the confirmation test. In the 
Home Office Report about Drug Interventions Programme pilots for children and young 
people, costs for drug tests in 5 different sites between November 2003 and September 
2005 are reported (Matrix Research and Consultancy and Institute for Criminal Policy 
Research, 2007). The set-up cost includes personnel, training, overheads and equipment 
costs. The cost of drug testing cartridge kits is included in the overheads costs within this 
Home Office study. The running costs breakdown into personnel, training, premises and 
overheads costs. The unit cost of this particular study varies between £57 to £62 per test, 
or £100 to £121 per test from the 5 different sites, depending on the number of tests taken 
in each site. These tests took place at police stations or other similar settings rather than 
schools.  
 
In the simulation model presented below, the price from the Home Office 2007 report 
(Matrix Research and Consultancy and Institute for Criminal Policy Research, 2007) is 
used, instead of the market price of drug testing. It is assumed that the setting within the 
Home Office 2007 report is closer to the model than commercial testing in workplaces. It 
is also assumed that the school will use the school nurse, or hire external staff from 
hospitals or a nurse from the local health centre to take samples and to run random drug 
testing within the school. The average unit cost from the lowest 2 costs from the Home 
Office 2007 study have been taken and converted to 2005/06 prices with GDP deflators 
(HM Treasury, 2007, accessed on 29 June 2007) to get £61.89 per test as the unit cost of 
the initial test for the random drug testing in schools model, as shown in Table 7.4.1. 
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The confirmatory test would be a one-off test conducted in a health care setting. A recent 
study of UK offender populations has compared the cost of saliva and urine tests among 
UK offenders (Bird, Pearson and Strang, 2002). The average unit cost for a urine test 
from this study is converted into 2005/06 prices to get the unit cost of a confirmatory test 
within the model between £122.34 and £133.46 per test. 
 
Table 7.4.1 Unit cost of drug test 
Type of drug test 2005/06 price * Source 
Initial test £61.89 £57-£62 per test (Matrix 
Research and 
Consultancy and 
Institute for Criminal 
Policy Research, 2007) 
Confirmatory test £122.34-£133.46 £110-£120 per urine test 
(Bird, Pearson and 
Strang, 2002) 
*: All prices are converted into 2005/06 prices with GDP deflators (HM Treasury, 2007). 
 
7.4.2 Parents’ time and travel cost 
 
Within this model it is assumed that the school will inform pupils’ parents or guardians if 
pupils have positive results for their initial drug testing. The school will then advise the 
parents or guardians to take their children to the hospital for the confirmatory test. The 
confirmatory test will use invasive methods such as blood or urine tests and it may require 
consent from the pupils’ parents or guardians. The confirmatory test may take place 
during the normal office hours on weekdays. If the parents or guardians have a full-time 
job, it is likely that they will need to take at least a few hours off for the confirmatory test 
of their children. 
 
The model calculates the approximate time for taking a confirmatory test and calculates 
the cost of the parents’ or guardians’ time. This cost is supposed to be equal to parents’ 
hourly wage rate multiplied by the duration of the confirmatory test and travel time. It is 
assumed that the parents or guardians of pupils who have positive initial test results all 
have a full-time job, and the average wage rate in the UK, 2005/06 is used to calculate the 
cost of time for pupils’ parents or guardians.  
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According to the Annual survey of hours and earning of labour market trend (National 
Statistics, 2005), the median hourly earnings of all full-time employees in 2004 were 
between £10.00 to £10.60 across all industries and services in the UK. The midpoint of 
these is taken as the hourly earning in 2004 of £10.30 and converted into 2005/06 prices 
with GDP deflators (HM Treasury, 2007) to get £10.80 as the average hourly earning for 
the cost of parents’ or guardians’ time within the model. 
 
It is assumed that the total length of time of the parents’ or guardians’ involvement during 
the confirmatory test is approximately 1 to 1.5 hours, including the time of travelling 
from the pupil’s house to the hospital where the test takes place. The total length of time 
for parents’ involvement may be underestimated, depending on different situations, for 
instance, the traffic and the distance between the pupil’s house and the hospital. It is 
assumed that the result will be sent to the school and to the pupil’s house through the post. 
It is estimated that the cost of the parents or guardians’ involvement for the confirmatory 
test is between £10.80 and £16.20 per person. 
 
It is assumed that the pupils and their parents or guardians travel to hospital either by car, 
bus or by foot. The single bus fare is £1.60 per person per journey in 2007 according to 
the information provided by a nationwide bus company (First Group, 2007) and the 
average distance between a pupil’s house and the hospital is 3 miles. The car running cost 
information from AA.com (2007) is used for the travel cost by car.  It is estimated that the 
running cost per mile is between £0.16 and £0.29. Therefore, it is assumed that the travel 
cost by car is £0.48 to £0.87 per test. If the pupil and parent walk to the hospital, there 
would be no travel cost. 
 
Table 7.4.2 Cost of parents’ involvement 
 Unit Source 
Total length of Parents’ 
involvement (hours) 
1-1.5 Based on study assumption 
Average hourly earning 
(2005/06 price)* 
£10.80 Average earning: £10.30 per hour in 2004 
(National Statistics, 2005) 
Cost of parents’ involvement 
(per person) 
£10.80-
£16.20 
Calculated 
*: Price is converted into 2005/06 prices with GDP deflators (HM Treasury, 2007). 
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Table 7.4.3 Travel cost 
Mode of 
travel 
Per person per 
journey 
Source 
By car £0.48-£0.87 Average distance between the hospital and the pupil’s 
house(assume 3 miles)*running cost per mile (AA.com, 2007) 
By bus £1.60 Price listed on First Group (2007) 
Walk £0 N/A 
 
7.4.3 Cost of truancy and exclusion 
 
If pupils self-exclude themselves from school in order to avoid the drug test during the 
whole drug testing in school process, the school and perhaps the local educational 
authorities will need to react to pupils’ truancy. Pupils’ teachers may need to work 
overtime or visit pupils at home or visit pupils’ parents or guardians to understand the 
reasons for truancy and try to convince pupils to come back to school. If pupils’ teachers 
are not able to convince pupils to return to the same school, the school may report to the 
local educational authorities and let the education welfare services become involved. The 
cost of tackling the truancy problems will be included within the random drug testing in 
schools model.  
 
It is quite difficult to determine how much money the school, local educational authorities 
and education welfare services spend on tackling the truancy problems. In a recent report 
of the costs of truancy and exclusion by Brookes and colleagues (2007) it is estimated, 
based on the costs of educational welfare services, that the cost per truant is about £706 
per person per annum in 2005 prices. They also estimated £676 per person for the cost of 
managing the process of exclusion and £19,434 per person or £7,181 per person per 
annum in 2005 prices for the alternative education costs, including pupil referral unit, 
college, special school, mainstream school, home/ alternative education etc. They 
estimated that the total exclusion cost is £20,110 per person. 
 
Due to the limited information and difficulties of determining the cost of truancy, 
estimates are taken from Brookes and colleagues (2007) on the truancy cost within the 
random drug testing in schools model and only the cost of truancy per annum is 
calculated due to the difficulties of predicting the length of truancy. 
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Table 7.4.4 Cost of truancy and exclusion 
Type of cost 2005/06 
price 
Source 
Truancy (per 
person per 
annum) 
£706 £706 per truant per annum in 2005 price(Brookes, Goodall 
and Heady, 2007) 
Exclusion (per 
person) 
£20,110 £676 managing the process of exclusion + £19434 (per 
person in 2005 price) alternative education cost (Brookes, 
Goodall and Heady, 2007) 
 
Table 7.4.5 Cost of random drug testing in schools 
Type of cost 2005/06 price 
Initial test (per test) £61.89 
Confirmatory test (per test) £122.34-£133.46 
Cost of parents’ involvement (per person) £10.8-£16.2 
Cost of travel by foot (per person per journey) £0 
By car (per journey) £0.48-£0.87 
By bus (per person per journey) £1.60 
Truancy (per person per annum) £706 
Exclusion (per person) £20110 
 
7.5 Costs of different outcomes 
 
7.5.1 Drug domain outcome: cost and transition of different groups 
 
The drug domain outcome in this study is categorised into 3 different groups: drug free, 
recreational user and problematic user. The lifetime cost of crime and health care at age 
16 of being in these 3 different groups is estimated. The data for the cost of crime and 
cost of health care is extracted from a study by Godfrey and colleagues (2004). The 
average social cost per drug user includes the costs of health care, crime (including 
criminal justice resources used and victim costs), driving, work, deaths and child care. It 
shows that the average social cost per young recreational user is £65 per annum, including 
£2 of health care costs, £54 of cost of deaths and £8 of crime costs. 
 
The cost of crime and the cost of health care and deaths of the young drug users are 
included and converted into 2005/06 prices with GDP deflators (HM Treasury, 2007) to 
get the lifetime cost of being a recreational drug user at age 16. The mean cost of crime of 
a recreational user is estimated as £8.38 and the cost of health care and deaths as £60.11 
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per user per annum. Therefore, the total cost of recreational user is £68.49 per user per 
annum. 
 
In this model, it is assumed that there is no difference in the social costs of being a young 
problematic drug user and being a problematic adult drug user. It is estimated that the 
annual social cost per problematic drug user is £44,232, where £1,413 is from the cost of 
health care, £2,663 from the cost of deaths and £39,956 from the cost of crime in the 
updated study by Godfrey and colleagues (2004). 
 
Within the random drug testing in schools model, the cost of crime, the cost of health care 
and deaths to estimate the cost of being a problematic drug user at age 16 are included 
and converted into 2005/06 prices using a GDP deflator (HM Treasury, 2007). It is 
estimated that the cost of crime of a problematic user is £41,875 and the cost of health 
care and death is £4,375 per user per annum. Therefore, the total costs for a problematic 
user would be £46,250 per user per annum.   
 
It is assumed that drug free pupils will not have any cost of crime or drug-related health 
care and deaths, although in reality there might be transition between the drug free pupils, 
the recreational users and the problematic users. Due to the limited information about this 
transition, it is assumed that there will not be any transition between these three different 
groups within the model after the end of the simulation period. 
 
Table 7.5.1 Drug domain outcome 
Type of cost* Drug free Recreational user Problematic user 
Cost of crime* £0 £8.38 £41,875.70 
Cost of health care an deaths* £0 £60.11 £4,375.17 
Total (per person per annum) £0 £68.49 £46,250.87 
*: All prices are converted into 2005/06 prices with GDP deflators (HM Treasury, 2007). 
Source: study by Godfrey and colleagues (2004); the updated social costs of Class A drug 
use in England and Wales from a Home Office research study (Godfrey et al, 2002a). 
 
7.5.2 Education domain outcome 
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The educational outcome domain in this model includes normal education and NEET. 
Pupils who remain in their original school or change to another secondary school will 
have no education cost within this model. 
 
In the drug testing model, if pupils decided to leave the education system and start 
working without any qualification or training, they may suffer from being unemployed 
and become NEET. The 2002 DfES research report (Godfrey et al, 2002b) estimates that 
the lifetime cost of being NEET is approximately £45,000 per capita for resource costs 
and £52,000 per capita for public finance costs in 2002. 
 
In the DfES 2002 NEET study (Godfrey et al, 2002b) the lifetime costs of being NEET at 
age 16 to 18 included current costs, medium-term costs and long-term costs. The current 
costs include educational underachievement, unemployment, inactivity, teenage mothers, 
crime, poor health and substance misuse. The medium-term costs include educational 
underachievement (over 40 years), unemployment (over 40 years), early motherhood, 
(over 10 years) crime (over age 19-30), poor health (total for 40 years) and substance 
misuse (over 10 years). The long-term costs include pension differences. In the model, 
most of the costs within the DfES 2002 NEET study except the direct and indirect tax 
forgone are considered and the 2002 NEET costs are converted into 2005/06 prices with 
GDP deflators (HM Treasury, 2007). The resource cost of being NEET is £450,999 and 
£523,616 for public finance cost per person per annum. Therefore, the total cost of being 
NEET is £97,460. 
 
Table 7.5.2 Education domain outcome 
Type of cost* Normal education NEET 
Resource cost £0 £45,099 
Public finance cost £0 £52,361 
Total £0 £97,460 
*: All prices are converted into 2005/06 prices with GDP deflators (HM Treasury, 2007). 
Source: 2002 DfES research report (Godfrey et al, 2002b) 
 
7.5.3 The 6 final outcomes 
 
In the final cycle of the drug testing model, all pupils will be categorised into 6 different 
outcome groups, based on their educational status and their drug usage status. Pupils may 
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receive normal education until age 16 and remain drug free. Alternatively they may 
continue in normal education as a recreational drug user or a problematic user. It is also 
assumed that the different drug status may affect the pupils’ educational performances in 
the school. 
 
If pupils are self-excluded or excluded at different stages of random drug testing in 
schools and leave the normal education system and become NEET, their drug status may 
vary from drug free to problematic drug user. It is also assumed that if pupils become 
NEET, they may have a higher probability of becoming a problematic drug user. The cost 
of each group is estimated in Table 8. 
 
Table 7.5.3 Final outcomes  
Description (per person per annum) Drug 
outcome 
Education 
outcome 
Total  (2005/06 
price) 
Drug free and normal education £0 £0 £0 
Drug free and NEET £0 £97,500 £97,500 
Recreational drug user and normal 
education 
£68 £0 £68 
Recreational drug user and NEET £68 £97,500 £97,568 
Problematic drug user and normal 
education 
£46,300 £0 £46,300 
Problematic drug user and NEET £46,300 £97,500 £143,800 
 
7.6 Probability Parameters 
 
7.6.1 Parameters: description 
 
Due to the limited information regarding random drug testing in UK schools, probabilities 
from similar studies and government reports in the UK and the USA are used in the 
model (Barnes et al, 2003; Levy et al, 2007; Matrix Research and Consultancy and 
Institute for Criminal Policy Research, 2007). 
 
It is assumed that 1,000 pupils enter the model at age 11, and 500 pupils are tested, while 
the other half will stay in the scenario without testing. Within the scenario of no testing, it 
is assumed that pupils might have already been recreational drug users or are drug free. 
According to the report of Smoking, drinking and drug usage among young people in 
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England (National Centre for Social Research, 2007), about 24% of pupils have ever 
taken drugs and 2% of pupils have taken Class A drugs in the last month. It is assumed 
that 24% of pupils are recreational users when they enter the non drug testing model. 
Among these pupils, 2% of them become problematic users, 24% of them remain as 
recreational users and the rest become drug free at age 16. It is assumed that if pupils are 
drug free when they enter the non drug testing model they will have the same outcome 
probabilities as recreational users. 
 
In the drug testing model, it is assumed that pupils may participate in the test, refuse the 
test or self-exclude themselves in order to avoid testing. Due to the limited information 
about random drug testing in schools, the probabilities of testing among young offenders 
are used (Matrix Research and Consultancy and Institute for Criminal Policy Research, 
2007). The report shows that 97% of tests are completed from 5 different sites among 
young people for the initial test, and less than 0.5% of young people refused to participate 
in the initial test. 
 
It is assumed that within the testing model, 97% of pupils will participate in the initial test 
and the participation rate will remain the same through the whole period of random drug 
testing in schools. It is assumed that 0.5% of pupils may refuse to participate in the test 
and may then receive punishment, such as suspension or permanent exclusion. The rest of 
the pupils may self-exclude themselves from school. If pupils are only suspended for 
refusing the initial test, they will return to the same school and enter the next initial test. 
 
If pupils self-exclude themselves, their teachers and the local educational authorities may 
react to the unauthorised absence. According to the DfES statistics (DfES, 2006), about 
0.12% of pupils were permanently excluded from schools. The study by Brookes and 
colleagues (2007) shows that 6% of excluded children do not receive any education after 
exclusion. It is assumed that in the drug testing model 0.12% of the self-excluded pupils 
will not decide to come back to the same school, and these pupils will then not be 
included in the random drug testing in schools model thereafter. Among these pupils, it is 
assumed that 6% of them will not stay in the education system, and the rest of them may 
go to another school or receive alternative education. 
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The report of Smoking, drinking and drug usage among young people in England 
(National Centre for Social Research, 2007) shows that the proportion of pupils who have 
taken drugs in the previous month differs by age. For instance, 3% of pupils at age 11 
have taken drugs in the last month and 17% of pupils at age 15 have taken drugs in the 
last month. Overall, 10% of pupils between the ages if 11 to 15 have taken drugs in the 
last month. These percentages are used to calculate the positive rate for the initial test 
results. 
 
In the model, the pupils who have positive results are advised to take the confirmatory 
test in hospitals accompanied by their parents or guardians. The pupils who have negative 
results remain in the same school and may enter the next test. It is assumed that the 
refusal rate of confirmatory tests is the same as the refusal rate of the initial test and about 
0.005% of pupils refuse to participate in the confirmatory test (Matrix Research and 
Consultancy and Institute for Criminal Policy Research, 2007). If pupils refuse to take the 
confirmatory test they would be suspended. 
 
According to the study by Barnes and colleagues (2003) the sensitivity of the detection in 
oral fluid test is 82.9%. It is assumed that the positive rate for the initial test and the 
confirmatory test will be the sensitivity of the saliva test multiplied by the overall 
percentage of pupils who have taken drugs in the last month (confirmatory test positive 
rate: 82.9% * 10%= 8.29%).  
 
In the random drug testing study by Levy and colleagues (2007) results showed that 6% 
of negative urine samples were too dilute to interpret and they may be false-negative 
cases. It is assumed that 6% of the pupils who have got negative results for the 
confirmatory test may have had a false negative result.  
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Table 7.6.1 Parameters  
Variable: proportion Value Value deterrent 
effect (-0.24) 
Source 
Random drug testing 0.50 0.50 - 
Recreational user 0.24 0.18 proportions of pupils who have ever taken drugs, 2006 (National Centre for Social Research, 2007) 
Recreational then 
problematic user 
0.02 0.01 proportions of pupils who have taken any Class A drugs in the last month, 2006 (National Centre 
for Social Research, 2007) 
Participate initial test 0.97 0.97 Total test completed from 5 sites among young people(Matrix Research and Consultancy and 
Institute for Criminal Policy Research, 2007) 
Refuse initial test (non self-
exclude) 
0.005 0.005 Total test refused from 5 sites among young people=<1, less than 0.5% (Matrix Research and 
Consultancy and Institute for Criminal Policy Research, 2007) 
Initial test positive 0.10 0.08 proportions of pupils who have taken drugs last month, 2006 (National Centre for Social Research, 
2007) 
11 years old 0.03 0.02 
12 years old 0.03 0.02 
13 years old 0.06 0.05 
14 years old 0.13 0.10 
15 years old 0.17 0.13 
proportions of pupils who have took drugs in the last month, by age, 2006 (National Centre for 
Social Research, 2007) 
Refuse confirmatory test 0.005 0.005 Total test refused from 5 sites among young people=<1, less than 0.5% (Matrix Research and 
Consultancy and Institute for Criminal Policy Research, 2007) 
Confirmatory test positive 0.08 0.06 sensitivity (82.9%), specificity(98.7%) and efficiency(95.6%) of the Cozart Microplate EIA Opiate 
Oral Fluid Kit for Detection of Codeine and Metabolites in Oral Fluid at different 
immunoassay/GC-MS Cutoffs (Cutoff (ug/L=20/20)(Barnes et al, 2003) 
False negative 0.06 0.06 Found substantial proportion (6%) of urine samples were negative, but too dilute to interpret and it 
could have led to false-negative (Levy et al, 2007) 
Truant not return to the same 
school 
0.0012 0.0012 0.12% of pupils in schools were permanently excluded from primary, secondary and all special 
schools in 2004/05 (DfES, 2006) 
Do not receive any education 
after leaving the original 
school 
0.06 0.06 6% of excluded children have no education (including any alternative education). (Brookes, 
Goodall and Heady, 2007) 
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7.6.2 Parameters: deterrent effect 
 
Reduction of drug users in schools 
 
Some research suggests that random drug testing in schools will reduce the drug usage 
among pupils (Goldberg et al, 2003; Goldberg et al, 2007). Although it is difficult to 
determine what makes pupils take drugs, it is normally suggested that peer influence may 
be one of the reasons. It may affect pupils’ behaviour by excluding or punishing the 
pupils who have used drugs. 
 
There is very limited information on the deterrent effect in the previous studies of random 
drug testing in schools. Goldberg and colleagues (2003) studied the deterrent effect on the 
past 30 days illicit drug use. The study was conducted in 2 high schools with similar 
characteristics in Oregon, USA in autumn 1999, using the self-report survey. In order to 
find the impact of random drug testing among athletes, such as students in football or 
swimming teams, the study participants are divided into athletes and non-athletes, and 
each contains the control group (no drug testing) and the treatment group (random drug 
testing). 
 
The Goldberg study (2003) used the self-report drug misuse index. It shows that the pre-
test score of past 30-day illicit drug use is 0.074 and the post-test score is 0.053 among 
the athlete group. Among the non-athlete group, the pre-test score is 0.327 and the post-
test score is 0.266. In this report no clear explanation of the score of the drug index was 
provided. However, in their later study published in 2007 (Goldberg et al, 2007), the drug 
index range is between 0 and 3, where 0 means no drug misuse and 3 means heavy use. 
The study by Goldberg and colleagues (2007) found the deterrent effect only in the past 
year of drug misuse. 
 
The outcome data from the study by Goldberg and colleagues (2003) for the deterrent 
effect is used for the model. The drug misuse index score for illicit drugs decreased by 
28% among the athlete group and by 19% among the non-athlete group. The average, 
24%, is taken as the deterrent effect in the model. 
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Table 7.6.2 Parameters: deterrent effect 
Variable: 
deterrent effect 
Value Source 
Deterrent 
effect from 
literature 
(athlete) 
-0.28 
Deterrent 
effect from 
literature (non-
athlete) 
-0.19 
Difference of pre-test mean and post-test mean for past 30-day 
illicit drug use index(Goldberg et al, 2003) For Treatment Group 
among athletes students: pre-test mean is 0.074; post-test mean is 
0.053.(significant p<.05) For Treatment Group among non-athletes 
students: pre-test mean is 0.327; post-test mean is 0.266. 
(significant p<.10) 
 
7.7 Results 
 
7.7.1 Comparing cost and outcomes of the two scenarios 
 
The model was run for both random drug testing in schools and non drug testing in 
schools for 5 years and the final outcome when pupils are at age 16 was calculated. The 
total cost and outcomes of both models is shown in Table 7.7.1.  
 
The costs include the cost of truancy and the cost of exclusion if pupils self-exclude 
themselves. The truancy and exclusion costs both include the administration costs. The 
exclusion cost also includes the alternative education costs.  
 
Costs of drug testing include the unit cost of both the initial test and the confirmatory test, 
the cost of parents’ time and the travel costs for both the pupil and his or her parent.  
These costs are varied, depending on how the pupils and their parents travel to the 
hospital from their house and how long it takes if pupils are advised to take the 
confirmatory test. Hence, the highest cost and the lowest cost of testing are calculated. 
The cost of testing occurs every year, and it is assumed that there will only be one random 
drug testing in school every year. 
 
The outcomes within this model are presented in monetary terms. The outcome has 2 
different domains according to pupils’ drug usage status and educational status at age 16. 
Pupils might become drug free, recreational users or problematic users at age 16, while 
they may receive normal education or may not receive any qualification and become 
NEET. The outcomes within the drug status domain include the cost of crime and the cost 
of health care of being drug free, recreational users or problematic users. The educational 
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outcomes are presented as the cost of being NEET and the cost of receiving normal 
education. For instance, in the model of random drug testing in schools, if a pupil is a 
recreational user and has stayed in normal education until age 16, his or her outcome will 
be -£68. The outcome is presented as a negative value, since it is the cost to society.  
 
The number of pupils in the 6 different final outcome groups is then multiplied by the 
cost to society. For instance, in the baseline model, the final outcome of each pupil who is 
a recreational user and stays in normal education is -£68 and the total number of pupils in 
this outcome group is 120 within the random drug testing in schools model. Within the 
non drug testing in schools model, the total number of pupils who are recreational users 
and stay in normal education is 120. The outcome for pupils who are in this particular 
group can then be compared between the random drug testing in schools model and the 
non drug testing in schools model. The total outcome for recreational users who stay in 
normal education is -£8,200 in the testing model, and -£8,200 in the non-testing model. 
There is no difference between the 2 models. Outcomes of -£8,200 represents the cost to 
society when introducing random drug testing in schools.  
 
The total outcome sum (A) of the 6 outcome groups in both models is then calculated. In 
the testing model the total outcome is -£471,200, and in the non-testing model the total 
outcome is -£471,600. The difference between the 2 models is -£400 for the whole cohort 
of pupils. If it is assumed that there is a deterrent effect of 24%, the total outcome is -
£360,900 in random drug testing in schools model, and in the non-drug testing model the 
total outcome remains the same, -£471,200. The difference between the 2 models is 
£110,300 for the whole cohort of pupils, when there is a 24% deterrent effect. 
 
Costs of random drug testing are varied due to the difference in travel costs and unit costs 
of testing. The sum of the highest total costs (B) and the lowest total costs (B’) among the 
whole cohort of pupils in both models are calculated. In the non-drug testing model, the 
total cost of testing is 0, while in the random drug testing in schools model the highest 
total cost of testing is £226,700 or £222,800 for the lowest total cost of testing. The 
highest total cost of testing is £219,400 or £216,400 for the lowest total cost of testing 
when there is a 24% deterrent effect.  
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The net benefit is total outcome minus total benefit (A-B or A-B’). It shows that within 
the random drug testing in schools model, the net benefit is between -£694,400 and -
£698,300 in the baseline model or between -£577,300 and -£580,300 when there is a 
deterrent effect. In the non-drug testing in schools model, the net benefit is -£471,200 and 
it does not change according to the deterrent effect. The difference of net benefit between 
the 2 models is between £223,200 and £227,100 at baseline, or between -£106,100 and -
£109,100 when there is a deterrent effect. 
 
The cost of testing and net benefit for each individual pupil is then calculated. This shows 
that the highest total cost of testing per pupil is £453 and the lowest total cost of testing 
per pupil is £446 at baseline. The total cost per pupil is between £439 and £433 when 
there is a 24% deterrent effect in the testing model and there is no cost per pupil in the 
non-testing model. The costs include truancy costs and exclusion costs. The net benefit 
per pupil is between -£1,397 and -£1,389 at baseline or between -£1,161 and -£1155 with 
a deterrent effect in the testing model and -£942 per pupil in the non-drug testing model. 
The difference per pupil between the 2 models is between -£454 and -£446 at baseline or 
between -£218 and -£212 with a 24% deterrent effect. 
 
It is often suggested that random drug testing in schools may affect pupils’ behaviour and 
may reduce the drug usage among young people (Goldberg et al, 2003; Goldberg et al, 
2007). However, this random drug testing simulation model indicates that any deterrent 
effect of random drug testing in schools is not cost-effective. In fact it is about 16 times 
more costly than the non-testing in schools scenario.   
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Table 7.7.1 Total cost and outcomes of baseline model (number rounded)  
Outcome(£) Number of 
pupils(no test) 
Number of pupils(drug 
testing in schools) 
No drug test 
(outcome) (£) 
Drug testing in schools 
(outcome) (£) 
Difference(£) 
drug free and normal education (a) 370.0 370.0 0 0 0 
recreational user and normal education (b) 120.0 120.0 -8200 -8200 0 
problematic user and normal education (c) 10.0 10.0 -463000 -463000 0 
drug free and NEET (d) 0.0 0.0 - -325 -325 
recreational user and NEET (e) 0.0 0.0 - -105 -105 
problematic user and NEET (f) 0.0 0.0 - -13 -13 
Total outcome (A=a+b+c+d+e+f) - - -471200 -471600 -400 
Total cost of testing, highest (B) - - 0 226700 226700 
Total cost of testing, lowest (B') - - - 222800 222800 
Net benefit (A-B) - - -471200 -698300 -227100 
Net benefit (A-B') - - - -694400 -223200 
Cost per pupil, highest (=B/500) - - 0 453 453 
Cost per pupil, lowest (=B'/500) - - - 446 446 
Net benefit per pupil (=(A-B)/500) - - -942 -1397 -454 
Net benefit per pupil (=(A-B')/500) - - - -1389 -446 
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Table 7.7.2 Total cost and outcomes of model with a deterrent effect of 24% (number rounded) 
Outcome Number of 
pupils(no test) 
Number of pupils(drug 
testing in schools) 
No drug test 
(outcome) (£) 
Drug testing in schools 
(outcome) (£) 
Difference(£) 
drug free and normal education (a) 370.0 400.5 0 0 0 
recreational user and normal education (b) 120.0 91.8 -8200 -6200 2000 
problematic user and normal education (c) 10.0 7.7 -463000 -354200 108800 
drug free and NEET (d) 0.0 0.0 - -325 -325 
recreational user and NEET (e) 0.0 0.0 - -105 -105 
problematic user and NEET (f) 0.0 0.0 - -13 -13 
Total outcome (A=a+b+c+d+e+f) - - -471200 -360900 110300 
Total cost of testing, highest (B) - - 0 219400 219400 
Total cost of testing, lowest (B') - - - 216400 216400 
Net benefit (A-B) - - -471200 -580300 -109100 
Net benefit (A-B') - - - -577300 -106100 
Cost per pupil, highest (=B/500) - - 0 439 439 
Cost per pupil, lowest (=B'/500) - - - 433 433 
Net benefit per pupil (=(A-B)/500) - - -942 -1161 -218 
Net benefit per pupil (=(A-B')/500) - - - -1155 -212 
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7.7.2 Sensitivity analysis 
 
This model was constructed using a variety of data. In particular there was limited 
evidence regarding the deterrent effect. A sensitivity analysis was therefore conducted to 
investigate different deterrent effects and compare the difference between the outcomes, 
such as the net benefit and total costs (Table 7.7.3 and Table 7.7.4). The sensitivity 
analysis shows that the difference of net benefit between the no-testing model and the 
testing model gradually decreases when there is a higher deterrent effect.  
 
The deterrent effect was also calculated to determine the breakeven point of random drug 
testing, where the difference between no drug testing and random drug testing will be 
close to 0. The breakeven point will need to have around 45.3% deterrent effect. However, 
in reality, as the finding in the study by Goldberg and colleagues (2003) shows, the 
deterrent effect is between 19% and 28%. 
 
Different prevalence rates are used to estimate the net benefit in both the random drug 
testing model and the no drug testing model. The proportion of pupils who have taken 
class A drugs in the last month (2%) is used as the probability of problematic users in the 
model (National Centre for Social Research, 2007). Different proportions are used, 
including pupils who have taken class A drugs in the last month (2%), in the last year 
(4.3%) and ever taken them (5.4%) as the probability of problematic users in the 
sensitivity analysis. The difference between no deterrent effect and deterrent effect of 
24% is also compared. This shows that the higher the proportion of problematic users, the 
greater the difference is between the 2 models. Furthermore, comparing the difference 
between the baseline model and the model with deterrent effect reveals that the deterrent 
effect will also interact with the prevalence rate. Under the scenario of a 24% deterrent 
effect, the random drug testing model is more likely to be beneficial than the no testing 
model, when there is a higher prevalence of problematic users (Tables 7.7.5 to Table 
7.7.8). 
 
The proportion of pupils who have taken any drugs in the last month by age are used as 
the probability of positive results in the initial test (National Centre for Social Research, 
2007). In the sensitivity analysis, different proportions are used as the probability of 
problematic users, such as pupils who have taken any drugs in the last month, in the last 
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year and ever taken drugs. All probabilities vary according to age. Furthermore, the 
difference between no deterrent effect and a deterrent effect is compared. This shows that 
when there is a higher percentage of positive results for the initial test, the difference is 
greater between the non-testing model and the drug testing model. However, there is only 
very little difference between the different scenarios. The baseline model and the model 
with the deterrent effect are also compared, which shows that the deterrent effect is 
interacted with the prevalence of the positive result for the initial test (Tables 7.7.5 to 
Table 7.7.8). 
 
Finally, in terms of sensitivity analyses, different self-exclusion rates are used to compare 
the difference between outcomes. The self-exclusion rate is reduced until it gets to no 
self-exclusion. The sensitivity analysis shows that there is only very little difference of 
outcomes between the different self-exclusion rates (Tables 7.7.9 and 7.7.10). 
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Table 7.7.3 Sensitivity analysis: deterrent effect on number of pupils 
Deterrent 
effect 
Recreational user no. (non-
NEET) (no testing) 
Problematic user no. (non-
NEET) (no testing) 
Recreational user no. (non-NEET) 
(drug testing) 
Problematic user no. (non-NEET) 
(drug testing) 
0.00 120.0 10.0 120.0 10.0 
-0.19 120.0 10.0 97.2 8.1 
-0.24 120.0 10.0 91.8 7.7 
-0.28 120.0 10.0 86.4 7.2 
-0.30 120.0 10.0 84.0 7.0 
-0.40 120.0 10.0 72.0 6.0 
-0.45 120.0 10.0 66.0 5.5 
-0.453 120.0 10.0 65.7 5.5 
-0.50 120.0 10.0 60.0 5.0 
 
Table 7.7.4 Sensitivity analysis: deterrent effect on net benefits 
Deterrent 
effect 
Net 
benefit: no 
test ( C ) 
Net 
benefit: 
drug test 
(D) 
Net 
benefit: 
drug test 
(D') 
Difference 
(=D-C) 
Difference 
(=D'-C) 
Net benefit per 
pupil: no test 
(=C/500) 
Net benefit per 
pupil: drug test 
(=D/500) 
Net benefit per 
pupil: drug test 
(=D'/500) 
Difference 
(=(D-C)/500) 
Difference 
(=(D'-C)/500) 
0.00 -471200 -698300 -694400 -227100 -223200 -942 -1397 -1389 -454 -446 
-0.19 -471200 -602500 -599400 -131300 -128200 -942 -1205 -1199 -263 -256 
-0.24 -471200 -580300 -577300 -109100 -106100 -942 -1161 -1155 -218 -212 
-0.28 -471200 -557400 -554600 -86200 -83400 -942 -1115 -1109 -172 -167 
-0.30 -471200 -547400 -544600 -76200 -73400 -942 -1095 -1089 -152 -147 
-0.40 -471200 -497200 -494900 -26000 -23700 -942 -994 -990 -52 -47 
-0.45 -471200 -472100 -470000 -900 1200 -942 -944 -940 -2 2 
-0.453 -471200 -470600 -468500 600 2700 -942 -941 -937 1 5 
-0.50 -471200 -447000 -445100 24200 26100 -942 -894 -890 48 52 
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Table 7.7.5 Sensitivity analysis: number of pupils applied different prevalence with no deterrent effect  
Prevalence (no deterrent) Recreational user no. (non-
NEET) (no testing) 
Problematic user no. (non-
NEET) (no testing) 
Recreational user no. (non-
NEET) (drug testing) 
Problematic user no. (non-
NEET) (drug testing) 
problematic user=taken class A 
drugs in last month (0.02) 
120.0 10.0 120.0 10.0 
problematic user=taken class A 
drugs in last year (0.043) 
120.0 21.5 120.0 21.5 
problematic user=ever taken class A 
drugs (0.054) 
120.0 27.0 120.0 27.0 
Initial test positive= have taken any 
drugs in last month, by age 
120.0 10.0 120.0 10.0 
Initial test positive= have taken any 
drugs in last year, by age 
120.0 10.0 120.0 10.0 
Initial test positive=ever taken any 
drugs, by age 
120.0 10.0 120.0 10.0 
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Table 7.7.6 Sensitivity analysis: net benefits applied different prevalence with no deterrent effect  
Prevalence (no 
deterrent) 
Net 
benefit: no 
test ( C ) 
Net 
benefit: 
drug test 
(D) 
Net 
benefit: 
drug test 
(D') 
Difference 
(=D-C) 
Difference 
(=D'-C) 
Net benefit 
per pupil: no 
test (=C/500) 
Net benefit 
per pupil: 
drug test 
(=D/500) 
Net benefit 
per pupil: 
drug test 
(=D'/500) 
Difference 
(=(D-
C)/500) 
Difference 
(=(D'-
C)/500) 
problematic 
user=taken class A 
drugs in last month 
(0.02) 
-471200 -698300 -694400 -227100 -223200 -942 -1397 -1389 -454 -446 
problematic 
user=taken class A 
drugs in last year 
(0.043) 
-1002600 -1229700 -1225800 -227100 -223200 -2005 -2459 -2452 -454 -446 
problematic 
user=ever taken class 
A drugs (0.054) 
-1257000 -1484100 -1480200 -227100 -223200 -2514 -2968 -2960 -454 -446 
Initial test positive= 
have taken any drugs 
in last month, by age 
-471200 -698300 -694400 -227100 -223200 -942 -1397 -1389 -454 -446 
Initial test positive= 
have taken any drugs 
in last year, by age 
-471200 -723700 -716500 -252500 -245300 -942 -1447 -1433 -505 -491 
Initial test 
positive=ever taken 
any drugs, by age 
-471200 -750200 -739700 -279000 -268500 -942 -1500 -1479 -558 -537 
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Table 7.7.7 Sensitivity analysis: number of pupils applied different prevalence with 24% deterrent effect 
Prevalence (-24% deterrent effect) Recreational user no. (non-
NEET) (no testing) 
Problematic user no. (non-
NEET) (no testing) 
Recreational user no. (non-
NEET) (drug testing) 
Problematic user no. (non-
NEET) (drug testing) 
problematic user=taken class A 
drugs in last month (0.02) 
120.0 10.0 91.8 7.7 
problematic user=taken class A 
drugs in last year (0.043) 
120.0 21.5 91.8 16.5 
problematic user=ever taken class 
A drugs (0.054) 
120.0 27.0 91.8 20.7 
Initial test positive= have taken any 
drugs in last month, by age 
120.0 10.0 91.8 7.7 
Initial test positive= have taken any 
drugs in last year, by age 
120.0 10.0 91.8 7.7 
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Table 7.7.8 Sensitivity analysis: net benefits applied different prevalence with 24% deterrent effect 
Prevalence (-24% 
deterrent effect) 
Net 
benefit: no 
test ( C ) 
Net 
benefit: 
drug test 
(D) 
Net 
benefit: 
drug test 
(D') 
Difference 
(=D-C) 
Difference 
(=D'-C) 
Net benefit 
per pupil: no 
test (=C/500) 
Net benefit 
per pupil: 
drug test 
(=D/500) 
Net benefit 
per pupil: drug 
test (=D'/500) 
Difference 
(=(D-
C)/500) 
Difference 
(=(D'-
C)/500) 
problematic 
user=taken class A 
drugs in last month 
(0.02) 
-471200 -580300 -577300 -109100 -106100 -942 -1161 -1155 -218 -212 
problematic 
user=taken class A 
drugs in last year 
(0.043) 
-1002600 -986900 -983900 15700 18700 -2005 -1974 -1968 31 37 
problematic 
user=ever taken 
class A drugs 
(0.054) 
-1257000 -1181500 -1178500 75500 78500 -2514 -2363 -2357 151 157 
Initial test positive= 
have taken any 
drugs in last month, 
by age 
-471200 -580300 -577300 -109100 -106100 -942 -1161 -1155 -218 -212 
Initial test positive= 
have taken any 
drugs in last year, 
by age 
-471200 -599700 -594200 -128500 -123000 -942 -1199 -1188 -257 -246 
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Table 7.7.9 Sensitivity analysis: different self-exclusion rate with no deterrent effect 
Self-
exclusion 
rate ( = 1-
rate of 
initial test 
participate-
rate of 
refuse to 
participate) 
(Baseline) 
Total 
number 
of 
exclusion 
(NEET) 
Problematic 
user no. 
(non-
NEET) (no 
testing) 
Problematic 
user no. 
(non-
NEET) 
(drug 
testing) 
Net 
benefit: 
no test 
( C ) 
Net 
benefit: 
drug test 
(D) 
Net 
benefit: 
drug 
test (D') 
Difference 
(=D-C) 
Difference 
(=D'-C) 
Net 
benefit 
per 
pupil: 
no test 
( = 
C/500) 
Net 
benefit 
per 
pupil: 
drug 
test ( = 
D/500) 
Net 
benefit 
per 
pupil: 
drug test 
( = 
D'/500) 
Difference 
( = (D-
C)/500) 
Difference 
( = (D'-
C)/500) 
0.025 0.1 10.0 7.7 -471200 -580300 -577300 -109100 -106100 -942 -1161 -1155 -218 -212 
0.020 0.1 10.0 7.7 -471200 -571600 -568600 -100400 -97400 -942 -1143 -1137 -201 -195 
0.015 0.0 10.0 7.7 -471200 -563300 -560300 -92100 -89100 -942 -1127 -1121 -184 -178 
0.010 0.0 10.0 7.7 -471200 -555000 -552000 -83800 -80800 -942 -1110 -1104 -168 -162 
0.005 0.0 10.0 7.7 -471200 -546700 -543500 -75500 -72300 -942 -1093 -1087 -151 -145 
0 0.0 10.0 7.7 -471200 -538400 -535300 -67200 -64100 -942 -1077 -1071 -134 -128 
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Table 7.7.10 Sensitivity analysis: different self-exclusion rate with 24% deterrent effect 
Self-
exclusion 
rate ( = 1-
rate of 
initial test 
participate
-rate of 
refuse to 
participate
) (24% 
deterrent 
effect) 
Total 
number of 
exclusion 
(NEET) 
Problematic 
user no. 
(non-
NEET) (no 
testing) 
Problematic 
user no. 
(non-
NEET) 
(drug 
testing) 
Net 
benefit: 
no test 
( C ) 
Net 
benefit: 
drug test 
(D) 
Net 
benefit: 
drug test 
(D') 
Difference 
( = D-C) 
Difference 
( = D'-C) 
Net 
benefit 
per 
pupil: 
no test 
( = 
C/500) 
Net 
benefit 
per 
pupil: 
drug 
test ( = 
D/500) 
Net 
benefit 
per 
pupil: 
drug test 
( = 
D'/500) 
Difference 
( = (D-
C)/500) 
Difference 
( = (D'-
C)/500) 
0.025 0.1 10.0 10.0 -471200 -698300 -694400 -227100 -223200 -942 -1397 -1389 -454 -446 
0.020 0.1 10.0 10.0 -471200 -689600 -685700 -218400 -214500 -942 -1379 -1371 -437 -429 
0.015 0.0 10.0 10.0 -471200 -681300 -677400 -210100 -206200 -942 -1363 -1355 -420 -412 
0.010 0.0 10.0 10.0 -471200 -673000 -669100 -201800 -197900 -942 -1346 -1338 -404 -396 
0.005 0.0 10.0 10.0 -471200 -664700 -660800 -193500 -189600 -942 -1329 -1322 -387 -379 
0 0.0 10.0 10.0 -471200 -656500 -652500 -185300 -181300 -942 -1313 -1305 -371 -363 
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7.8 Conclusion and discussion 
 
The aim of the chapter has been to develop a drug testing in schools model to provide an 
example of a long-term drug misuse modelling study that considers a wide range of 
dimensions of the monetary outcome in order to comprehensively evaluate the intervention 
from the societal perspective. Having developed the model, it is worth briefly summarising 
its findings and examining the extent to which it overcomes the limitations of other 
modelling studies discussed in the previous chapter. 
 
The results of the model illustrate that although drug testing in schools may reduce the 
number of recreational and problematic users, the testing itself is very costly. The sensitivity 
analysis shows that even if there is a very large deterrent effect, the net benefit of the random 
drug testing model would still be lower than the model of no testing. The break even point, 
where the costs of drug testing are equal to the potential benefits, requires a 45.3% deterrent 
effect, well above any realistic rate. The sensitivity analysis also indicates that when there is 
higher prevalence of problematic users, the random drug testing model will be more 
beneficial. This indicates that the model is more likely to be cost-effective in those schools 
with greater drug problems. 
 
One of the main problems identified in the previous chapter with existing long-term drug 
misuse models was that there are very few longitudinal studies of drug misuse interventions 
from which data can be extracted. The drug testing in schools model attempted to overcome 
this problem by combining an intervention period of only 5 years with long-term estimates of 
costs and outcomes for drug users extracted from existing literature. This assumes, however, 
that all of the effects of the intervention will have materialised by the time the pupils are 16. 
Although this approach may be justified in the case of the drug testing in schools model it 
may not be applicable for other drug misuse models, which expect the effects of the 
intervention to continue for a longer period of time, as is the case with many drug misuse 
treatment models. 
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One of the other principal advantages of the drug testing in schools model is that it considers 
a wide range of dimensions of the monetary outcome. In chapter 4 it was shown that many 
drug misuse intervention studies do not consider a number of dimensions in both the 
resources saved and other value created domain which would influence the overall monetary 
impact on society, and this was also true of the modelling studies reviewed in chapter 6. By 
contrast, the drug testing in schools model considered the health care costs, crime costs, and 
social care services costs (especially those related to education costs) in the resources saved 
domain. In the other value created domain the model considered a wide range of relevant 
dimensions including the value to third parties from reduced drug related crime and the 
impact on productivity, both whether or not the pupils become NEET and the costs of 
parents’ time while accompanying the pupils for confirmatory tests. 
 
One of the limitations of considering such a wide range of costs, however, is that the model 
had to assume a number of estimates. For example, after introducing drug testing in schools 
more pupils may exclude themselves, which is an important cost to take into account. 
However, there is no real-world evidence to indicate the increased amount of self-exclusion 
from the programme, which would support the estimates used in the model. The model thus 
faces one of the major problems identified in the previous chapter, which is that there is often 
insufficient real-world data on which to base the estimates used in the model. 
 
The problem of there being insufficient real-world evidence is not only related to estimating 
costs, but also to setting the parameters for the model. As there is no evidence regarding the 
refusal rate for drug testing in schools in the UK, the model used refusal rates from a drug 
testing study among the UK young offender population (Matrix Research and Consultancy 
and Institute for Criminal Policy Research, 2007). Although random drug testing in schools 
may have a similar effect to mandatory drug testing, the refusal rate among school pupils 
might still be higher than among the arrestees who are supervised by a police officer. 
 
Another major limitation due to the lack of available information concerned the transition 
between drug free pupils, recreational users and problematic users. As there was no 
applicable real-world evidence regarding the transition between these states, the model 
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assumed that no transition occurred. However, in real life it is likely that there would be 
some transition between these states and random drug testing in schools may affect the 
pattern of this transition. Transition between states would be one of the most important 
parameters for the model, thus further research would be required before these parameters 
could be accurately estimated in order to make the model more realistic. 
 
The problem of setting parameters was further increased due to the complexity of the model 
as many simplifications had to be made. For example, in the no testing scenario it was 
assumed that recreational users will not be caught. Although in reality this may be unlikely, it 
would have been too complex to factor this into the model. Similarly, it was assumed that 
both recreational drug users and drug free pupils entering the model have the same 
probabilities of becoming problematic drug users at age 16, which does not take into account 
the possibility that recreational drug users might be more likely to start using hard drugs. 
Consequently, the model may underestimate the total costs and outcomes within the non drug 
testing in schools scenario. 
 
In addition to making simplifying assumptions, in some cases data had to be extracted from 
different sources as there were no available UK studies. Some of the probabilities from 
random drug testing studies in the USA were used to calculate the proportion of positive test 
results. These may underestimate the positive results in drug testing among young people in 
the UK. The proportion of recreational drug misuse may be higher in the UK because the 
general attitude of the public and the government is more open towards soft drugs, such as 
marijuana and other Class C drugs. The problem of having to use studies from different 
countries when there is insufficient data available from one country alone was encountered 
by models reviewed in the last chapter, and this model faces the same problem. 
 
The development of the drug testing in schools model has demonstrated that it is possible to 
consider a wide range of outcomes in the long-term. In doing so, the model has attempted to 
overcome 2 of the major limitations with many existing drug misuse intervention studies: that 
they do not consider a broad enough perspective and that they do not estimate the long-term 
outcomes of the intervention. However, in overcoming these problems, the model has proven 
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susceptible to a number of the other limitations with modelling studies identified in the 
previous chapter. Indeed this chapter has illustrated that in modelling a range of long-term 
outcomes, drug misuse models are likely to face more problems. This provides a 
performative example of one of the major problems with modelling. The more 
comprehensive a model attempts to be, the more complex it becomes and the more real-world 
data it requires. Consequently, the model has to make more simplifications and assumptions, 
and is more likely to encounter problems regarding the lack of real-world information on 
which the parameters and estimates of outcomes are based. 
 
The main advantage of developing a model is that it can hypothetically consider the long-
term outcomes of an intervention, when the time and resources would be unavailable to 
examine this in real life. However, the model is likely to be uncertain if there is no real-world 
data available, such as data from longitudinal studies in the case of drug misuse. This poses 
something of a dilemma for policy makers. If there is not the time and resources to invest in 
longitudinal studies that follow patients up over many years then modelling studies may 
prove the best way to estimate the long-term costs and outcomes of a given intervention. 
However, as the model has to make assumptions and set parameters based on estimates of 
what will happen in real life, the results of the model will be more uncertain and less reliable 
to the extent that there is a lack of real-world data that they can apply. The main problem 
with modelling studies, therefore, is one of limited data, which can only be rectified if the 
limitations with other drug misuse intervention studies examined throughout this thesis are 
addressed. 
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Chapter 8 Conclusion 
 
The purpose of this thesis has been to examine and evaluate the measurement of outcomes in 
economic evaluations of drug misuse interventions. The importance of economic evaluations 
is that they provide an analysis of the costs and effectiveness of different interventions, which 
policy makers can then take into account. 
 
It is important to know which outcomes should be measured in the economic evaluation, and 
which of these are the most significant. Economic evaluations of cost-effectiveness or cost 
utility design can only take into consideration one outcome at a time, such as QALYs. Policy 
makers usually take into consideration generic outcomes so that they can compare different 
policies across different fields. In contrast, cost benefit analysis involves measuring 
individual and social outcomes in monetary terms.  
 
This thesis has examined the different outcomes that have been taken into account in 
economic evaluations of drug misuse interventions, identified the rationales for choosing 
outcomes and addressed the problems of using generic outcomes to evaluate drug misuse 
interventions. The aim of this chapter is to summarise the main findings of the thesis, and to 
consider their limitations and the implications for future research and drug misuse policy. 
 
8.1 Summary of findings 
 
This thesis has examined 3 different aspects of measuring outcomes in the economic 
evaluation of drug misuse interventions. The first focused on non-monetary outcomes at the 
individual patient level, the second focused on monetary outcomes within studies using 
individual patient level data, and the third focused on long-term outcomes, either monetary or 
non-monetary. These aspects were each examined in turn. 
 
In chapters 2 and 3 the non-monetary individual patient level outcomes were evaluated. 
Within the UK, NICE (2008) requires that QALYs, a health utility measure, are used as the 
standard health measure for evaluating interventions and policy making. Furthermore, it 
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strongly recommends that the EQ-5D instrument with UK population values should be used 
to evaluate QALYs. However, EQ-5D is a generic measure and is not specifically designed 
to measure the outcomes of drug misuse patients. It is therefore important to know whether 
the results from using the EQ-5D measure are supported by the results of measures that are 
designed specifically for drug misuse patients, and whether they measure the same concepts 
as each other. For example, if the results from EQ-5D show that a patient’s QALYs have 
improved after receiving the treatment, it is important to know whether or not other specific 
outcomes such as the patient’s dependence have also improved. If the results from EQ-5D 
reveal the same trends as specific drug misuse measures then EQ-5D may be an adequate 
generic measure that policy makers can use, however, if it does not, this might suggest that 
policy makers need to consider specific drug misuse measures as well as, or instead of, EQ-
5D. 
 
Chapter 2 examined the evaluation studies that have considered both EQ-5D and other 
outcome measures together when evaluating drug misuse interventions. These studies each 
include an economic evaluation that uses EQ-5D to measure QALYs and also include other 
individual level patient outcomes, such as dependence. The chapter reviewed these 
evaluation studies to identify which outcomes have been measured and whether or not they 
have similar trends to EQ-5D. The review only identified 8 evaluation studies. However, in 
addition to EQ-5D, 16 relevant outcomes measures were identified over 3 different 
dimensions, which indicates that current researchers consider it important to take into 
account a wide range of outcomes to evaluate the effectiveness of any given intervention. 
 
As the outcome scores in the different studies were all presented differently, they were first 
standardised so that they could be compared with one another. With the exception of a few 
individual measures, the results revealed that EQ-5D generally did not reflect the same trends 
as most of the other measures across all 3 dimensions of non-monetary outcomes. Indeed 
there was a wide divergence of trends among the included studies, which reveals that it may 
be inappropriate to use any single measure to provide a comprehensive evaluation of drug 
misuse interventions. 
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Where chapter 2 was concerned with comparing the outcomes measured by EQ-5D and other 
specific drug misuse measures, chapter 3 was concerned with the concepts measured in the 
different outcomes. If EQ-5D does not cover the same concepts as the other outcome 
measures then any similarity between them may only be contingent. The chapter followed the 
WHO’s ICF guideline to categorise the different concepts that can be measured, such as the 
physical and psychological health of the patients. The guideline identified a wide range of 
different concepts across 4 different categories.  
 
EQ-5D only covers some of the concepts from 2 of the 4 categories. The other specific drug 
misuse measures cover some of the concepts from 3 of the categories, including the 2 that are 
covered by EQ-5D. All of the concepts that are covered in EQ-5D are also covered by most 
of the other outcome measures, even though there are many concepts covered by the other 
measures that EQ-5D does not cover. In the 2 categories that EQ-5D covers there is a large 
extent of content agreement with the other measures, even if they do not cover exactly the 
same concepts. However, there are also a large number of concepts in other categories that 
EQ-5D does not cover, which is a major limitation of using EQ-5D as a single outcome 
measure. In addition, even where EQ-5D and over measures cover the same concepts, it is 
not clear that patients respond consistently to questions within the same concept, which 
indicates a wide range of questionnaires may be necessary to capture all of the aspects of 
patients’ responses to any intervention. Taken together, chapters 2 and 3 thus expose the 
problems with using EQ-5D as a generic outcome measure for drug misuse intervention 
studies as NICE recommends.  
 
Having considered non-monetary outcomes in the previous two chapters, chapters 4 and 5 
turned to examine the individual level monetary outcome. One of the advantages of this 
approach is that a wide range of monetary dimensions can potentially be evaluated in 
commensurate units of measurement, which may allow policy makers to make informed 
decisions about the economic benefit to society. The aim of the chapters was to identify 
which monetary dimensions have been measured in drug misuse interventions and to 
evaluate the limitations of the existing studies. 
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The first aim of chapter 4 was simply to identify the drug misuse studies that have measured 
social outcomes and the monetary dimensions that have been measured. The chapter 
followed Godfrey (2006) in identifying the dimensions that it is important to measure for 
drug misuse policy, which were divided into 2 domains: resources saved and other value 
created. Given that drug misuse is associated with many social problems, it is important that 
a wide range of dimensions are included in economic evaluations, as otherwise the figures 
that policy makers work with might neglect some of the determining factors of the overall 
monetary impact on society. 
 
The review identified 46 drug misuse studies. Although most of the studies claimed to be 
conducted form a societal perspective, many of them only measured a limited number of 
monetary dimensions. Most of the studies considered the monetary dimensions related to the 
resources that patients use, especially those relating to health care and criminal justice 
resources. However, many studies neglected the social care resources, which drug misuse 
patients are likely to use, and only a few of the studies measured all of the dimensions in the 
resource use domain and any in the other value created domain. None of the studies 
measured all of the dimensions identified in both domains. This indicates a major limitation 
when policy makers base their decisions on existing studies, as they do not take into account 
all of the relevant factors that might impact on the overall monetary outcome of drug misuse 
interventions, thus the figure that the policy makers work with may be misleading. A further 
limitation was also identified in the chapter. It is not clear whether specific types of drug 
misuse patient use more of certain resources than other types of patients, which might 
influence how policy makers target their interventions.  
 
The aim of chapter 5 was to see whether or not a profile of different types of drug misuse 
patients could be developed. This would provide valuable information for policy makers as 
they would then be able to target different types of intervention at different types of drug 
misuse patient. The chapter used an existing data sample, RESULT (Raistrick et al, 2008), to 
attempt to develop this profile. The first step was to use a clustering technique to cluster the 
patients into different groups. These clusters could then be analysed to try to identify 
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relationships between different patient characteristics and different dimensions of the 
monetary outcome, or just between different monetary dimensions. 
 
The chapter failed, however, to identify any strong relationships between the different patient 
characteristics and the different monetary dimensions. It would therefore be difficult to 
develop a profile based on any single patient characteristic. The reason that this proved to be 
so difficult was that when the data sample was run through the clustering technique only very 
few characteristics and monetary dimensions that determined the different clusters were 
statistically significant. In addition, where there were statistically significant characteristics, 
they often varied between the different clusters, which meant that the clusters could not be 
compared with one another to determine the influence of any single patient characteristic. 
This indicates that the profile of different types of drug misuse patient might be more 
complicated than expected and very difficult to capture using economic evaluations of the 
monetary outcome. Although it would be beneficial if policy makers could target the 
interventions at particular groups of drug misuse patient, the chapter revealed the problems 
with estimating the monetary outcome for different groups, on which such decisions would 
have to be based. 
 
One problem with using clinical trials to estimate the individual level outcome is that they do 
not usually have the resources to follow the patients up over a period of more than 2 years. 
However, as drug misuse is usually considered to be a chronic condition it is important that 
policy makers are aware of the long-term effects of the interventions. This is a problem not 
just in drug misuse policy but in a wider range of health care problems. The only way to 
estimate the long-term outcomes is by economic modelling. The possibilities and limitations 
of doing this for drug misuse interventions were explored in chapters 6 and 7, by using the 
decision analytic model. The decision analytic model identifies the possible pathways of the 
patients who receive the intervention compared with the pathways of those who do not 
receive it. This suggests a possible range of outcomes for the patient based on the existing 
evidence that is entered into the model. The various endpoints of the model can then be 
compared to assess the effectiveness and the benefits of the intervention. 
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Chapter 6 reviewed the existing decision analytic models that have been conducted for drug 
misuse interventions. Having identified the relevant models, their quality was then assessed 
using the checklist of good practice developed by Phillips and colleagues (2004). This 
provided the basis for evaluating the limitations of using modelling for drug misuse 
interventions. 
 
The review identified 16 models and most met the standard of good practice for a decision 
analytic model in most dimensions. However, a number of limitations were also identified. 
One of the limitations was that there is a lack of detailed parameters, especially from 
longitudinal studies, which would render the estimates more plausible and reflect real-world 
experience. As there are no longitudinal studies available for drug misuse interventions, 
assumptions have to be based on trials that have only followed up the patients over a few 
years, which may not reflect their potential longer-term outcomes. Another limitation with 
the existing models is that the pathways are usually simplified to prevent the model from 
becoming overly complex, yet this may result in the model misjudging the outcomes and the 
costs involved. One of the most significant limitations is that although many studies claim to 
be estimating societal outcomes they do not include a wide range of dimensions of the 
monetary outcome, for instance none of the models reviewed took into account the social 
care services cost. 
 
Given the limitations identified with modelling studies in chapter 6, the aim of chapter 7 was 
to indicate how some of these might be overcome by building a model illustrating the 
possible outcomes of a drug misuse intervention, while also taking into account the 
limitations of existing drug misuse studies identified throughout the thesis. To this extent 
chapter 7 explored the limitations of trying to address the problems highlighted throughout 
the thesis within a single intervention study. To do this a drug testing in schools model was 
built, which aimed to examine the potential pathways and benefits to society, by following a 
hypothetical population of 1000 pupils over the course of their secondary school education. 
At the endpoint the real life estimates that had been extracted from the literature for drug free, 
recreational and problematic drug users aged 16 were entered into the model to estimate the 
long-term outcomes of the drug testing in schools intervention. 
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To some extent the model proved successful. The model took into account the most 
important individual level outcomes for the pupils, including their education outcomes and 
their drug misuse outcomes. By combining the model with real life estimates of the monetary 
outcome, the study was able to estimate the long-term monetary outcome of the intervention, 
even though the intervention was only followed over 5 years. This indicates one way of 
estimating long-term outcomes even when there are no longitudinal studies of drug misuse 
interventions available. 
 
The drug testing in schools model therefore offers one way of addressing the limitations of 
existing drug misuse models; however, there were further limitations with doing so. As the 
drug testing in schools model attempted to take into account a wide range of outcomes it 
necessarily became more complex. The more complex a model becomes, the more 
assumptions and simplifications have to be made, which increases the level of uncertainty. 
The drug testing in schools model also faced one of the mains problems encountered by other 
drug misuse models, which is that there was insufficient real-world evidence to support the 
parameters and estimates used in the model. A more general problem with drug misuse 
models was thus revealed. Such models are developed as the resources to follow patients up 
over a long period of time are rarely available. However, if there is a lack of real-world 
evidence to support the models then the extent to which their results will reflect real life 
experiences is uncertain. This problem can only be rectified if the limitations with existing 
drug misuse intervention studies discussed in earlier chapters are addressed, yet this would 
require a great deal of time and resources. 
 
8.2 Limitations of research and implications for future research 
 
Although this thesis has attempted to conduct a comprehensive analysis of different 
economic evaluations of drug misuse interventions, there are a number of limitations to the 
findings. In many cases these were due to having to work with existing drug misuse 
intervention studies, which were not always concerned with the same objectives as this thesis. 
It is worth summarising these limitations by chapter, as they also indicate where future 
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research should be conducted, before considering a couple of general limitations of the 
research taken as a whole. 
 
In chapter 2 the focus was on EQ-5D as it is the recommended measure of QALYs by NICE 
in the UK. However, it is important to recognise that EQ-5D is not the only measure of 
QALYs and a more comprehensive review should take into account other measures of 
QALYs, which may well lead to different results. In addition, only studies that measured 
both EQ-5D and other individual level outcome measures were included in the review, as the 
objective was to compare EQ-5D with those measures. However, there are many outcome 
measures that have not been studied alongside EQ-5D and the results of the chapter therefore 
do not indicate whether or not EQ-5D has similar trends to these outcome measures. A final 
limitation was that the standardised mean score that was used to examine the trends of EQ-
5D was extracted from existing research. As a result, it was impossible to calculate the 
variance across the data, which means there could have been a lot of outlying results that 
were not taken into account. It would have been better to use the Z score, which takes into 
account standard deviation, but this was not possible as the individual patient scores were 
unavailable. 
 
In chapter 3 the WHO’s ICF was used to map the concepts between EQ-5D and other 
outcome measures. ICF is a generic outline developed for any concepts related to individual 
well-being, however, there had not previously been an ICF mapping study for drug misuse 
specific outcome measures and so this had to be conducted for the first time. Future research 
should try to identify the concepts in drug misuse specific outcome measures to map onto 
ICF, which could then be compared with the mapping exercise conducted in the chapter. 
 
The mapping found that most of the concepts covered by EQ-5D were also covered by other 
drug misuse specific outcome measures but not vice versa. There are 2 limitations that follow 
from this. The first is that even where there are overlapping concepts, this only indicates a 
probable cause of the correlation. However, greater analysis would be required to prove that 
the correlation was certainly not contingent. In addition, a more sophisticated analysis, such 
as factor analysis, might be required to examine the relationship between the non-overlapping 
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concepts; those covered by other outcome measures but not EQ-5D. A final limitation of 
chapter 3 was that where in other fields a content comparison of the outcome measures used 
a gold standard, this is not available for drug misuse studies. There is therefore no accepted 
standard with which the content of EQ-5D and other outcome measures can be compared. 
 
In chapter 4 the guideline by Godfrey (2006) was used to identify the different dimensions of 
the monetary outcome that should be measured in economic evaluations of drug misuse 
interventions. However, there is no common agreement about how the individual dimensions 
are calculated. For example, for health care resource saved, some studies might take into 
account the costs of the prescriptions whereas other might not. This could distort the overall 
monetary outcome when comparing interventions. It is also worth stressing that although 
studies were reviewed from different countries, it proves difficult to compare these with one 
another as the drug misuse policies vary between countries and thus the societal cost will be 
different for the same type of drug misuse patient in different countries. 
 
In chapter 5 a clustering technique was used to cluster the patients into different groups based 
on the available characteristics from the RESULT sample used. However, the clustering 
results would have varied greatly if different characteristics had been taken into consideration. 
The results therefore rested on assumptions about which characteristics might prove to be the 
most important. A further limitation of the RESULT sample is that it is an original data set, 
which only considers the intervention over a 6 month follow-up period and the patients do 
not begin receiving the intervention at the same time. All these factors might have 
contributed to the complexity of patients’ characteristics and the difficulty of identifying 
statistically significant characteristics across the clusters. 
 
One of the limitations of chapter 6 was simply the lack of modelling studies identified by the 
review, which made it difficult to assess whether modelling is a satisfactory approach for 
drug misuse intervention studies. Although the checklist designed by Phillips and colleagues 
(2004) was used to assess the quality of the decision analytic models reviewed, it remains 
difficult to conclude whether or not models are realistic as there is no empirical data of real-
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world experience with which they can be compared. If the model is not realistic then policy 
makers may be misled by the findings of the modelling study. 
 
There are a number of limitations with the drug testing in schools model that was developed 
in chapter 7. These were discussed in detail in the chapter and some of the problems have 
been summarised in section 8.1. However, there were also limitations with the implications 
of the modelling study for the objectives of the thesis. The drug testing in schools model was 
developed to try to overcome the limitations within existing drug misuse interventions 
studies identified throughout the thesis. However, the problems that were addressed in the 
drug testing in schools model would probably not be of application to other drug misuse 
intervention studies, especially treatment studies. Prevention studies are primarily concerned 
with preventing individuals from becoming drug users, whereas treatment studies are aimed 
at changing the behaviour of existing drug misuse patients. Where the deterrent effect of drug 
testing in schools will only apply during the period of the intervention, treatment studies 
would expect to affect the behaviour and health status of the drug misuse patient beyond the 
duration of the intervention. Such interventions would therefore not be able to use real-world 
estimates to predict the long-term societal costs at the end of the intervention period. Even 
though the drug testing in schools model overcomes some of the shortcomings identified with 
existing studies, it therefore fails to provide a model that could suitably be adopted for other 
drug misuse intervention studies. 
 
In addition to the limitations of the individual chapters, there are more general limitations of 
the thesis as a whole that are worth indicating. This thesis has only examined economic 
evaluation studies and has focused on individual level interventions rather than population 
level interventions, such as drug legalisation. In addition, there are other considerations that 
policy makers might want to consider when framing policy that are not covered by economic 
evaluations, such as ethical considerations. 
 
8.3 Conclusions, discussion and the implications for policy makers 
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This thesis has provided an overview of the existing methods of economic evaluation of drug 
misuse interventions and identified many of the shortcomings and limitations within existing 
studies. The main problems highlighted in the thesis may be broadly summarised in two 
points. The first is simply that only a relatively small number of economic evaluations of 
drug misuse interventions have been carried out to date. The second is that these studies have 
many limitations, especially regarding the lack of studies that follow patients up over a long 
period of time. It is important to recognise that the limitations of these studies are not simply 
criticisms of them, but rather that they reflect the complexity and difficulty of conducting 
economic evaluations in this field. 
 
Given the wide range of effects that drug misuse has on society many different outcomes 
should be measured in economic evaluations, and furthermore there are many dimensions 
that may determine the monetary outcome. However, this being the case, to provide a 
comprehensive evaluation of the benefits and drawbacks of any given intervention proves 
particularly difficult, as not only the benefits to the individual drug user but also the wider 
impact on society must be considered. It is often simply unfeasible to take into account all of 
these considerations in any given study. In addition, the outcomes for drug misuse patients 
prove especially impractical to measure. Drug misuse is considered to be a chronic condition, 
however, given the characteristics of drug misuse patients it is often unfeasible to follow 
them up over a long enough period of time that would be necessary to estimate the realistic 
societal outcomes. 
 
In the studies that have been examined different perspectives have been adopted and it is 
important to recognise that these may be in tension with one another, for example research 
can be conducted from the perspective of the health care system or the societal perspective. 
This is especially important to bear in mind in states like the UK where the priorities are 
often set by the NHS, as it cannot be assumed that the NHS priorities reflect the best 
outcomes when considered from the wider societal perspective. 
 
In addition to identifying the limitations with existing research, this thesis has attempted to 
draw out recommendations for policy makers and future research. However, there has only 
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been mixed success in doing this. One of the strongest conclusions relates to the use of EQ-
5D as a generic outcome measure as recommended by NICE in the UK. Chapters 2 and 3 
have demonstrated that in many respects EQ-5D is inadequate at reflecting the trends and 
measuring the concepts of other drug misuse specific measures. If EQ-5D is used as the only 
outcome measure in drug misuse intervention studies then many important drug-related 
outcomes may be neglected. However, other chapters were unable to arrive at such strong 
conclusions. For example, the attempt to develop a patient characteristic profile of the 
different monetary outcomes in chapter 5 proved largely unsuccessful. Although it would be 
beneficial for policy makers to target interventions at specific types of drug misuse patient, 
the findings have only highlighted the difficulties with identifying the relevant characteristics 
and indicate the complexity of characteristics among drug misuse patients. 
 
If there is a lesson to be drawn for policy makers from this thesis, it is to approach the 
existing studies with caution. In many cases there is insufficient evidence or data to provide a 
comprehensive economic evaluation of the different drug misuse interventions, and if policy 
makers adopt the results from these without bearing in mind the limitations they may be 
misled. The importance of this thesis, then, is primarily in highlighting those limitations. In 
addition, policy makers need to be able to justify their priorities when considering drug 
misuse interventions. In some cases the intervention might have different effects on different 
individual level outcomes. This is well illustrated in the drug testing in schools model, where 
it was estimated that if the programme was adopted then the drug population among 16 year 
olds would decrease, but the school drop-out rate would increase. In such circumstances 
policy makers have to decide which outcome they want to prioritise. This is indicative of a 
wider problem that different outcomes might conflict with one another, and the intervention 
that is in the best interest of the individual drug misuse patient might not be considered to be 
in the best interest of society more generally. 
 
This thesis has exposed many of the limitations of measuring outcomes in economic 
evaluations of drug misuse interventions and identified the problems with conducting such 
studies. It is important that policy makers are aware of these limitations when framing drug 
policy. The thesis has attempted to identify relationships between different types of outcome 
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measures that might help to overcome the existing limitations. However, at best the 
relationships identified have proved tentative, and at worst no such relationships have been 
identified. This only goes to indicate further the complexity of designing adequate drug 
misuse interventions and the problems that face future research. It is certainly important to be 
aware of the limitations of existing studies, however, the somewhat disquieting conclusion of 
this thesis, is that even when the limitations are known it still proves very difficult to design 
evaluations and interventions that can take them into account. 
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Appendices  
 
Appendix 1 Description of outcome measure 
 
Brief Symptom Inventory (BSI) 
BSI, a shorter version of the Symptom Checklist-90, was developed by Derogatis and 
Melisaratos (1983). It is a validated questionnaire and includes 53 items that assess 
individuals’ psychological status. It consists of 9 dimensions: somatisation, obsessive-
compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid 
ideation, and psychoticism. The rating of the individuals’ psychological status ranges 
between 0 and 4, where 4 is the worst status. It produces 3 global indices: global severity 
index, positive symptom distress index, and positive symptom total. The global severity 
index is the average rating of all of the 53 items. The positive symptom distress index is the 
average rating of all of the symptoms complained of (items rated higher than 0). The positive 
symptom total is the number of symptoms complained about regarding individuals’ 
psychological status. 
 
Composite International Diagnostic Interview (CIDI) 
Developed by WHO (WHO, 1990), CIDI is an outcome measure that covert 41 different 
dimensions related to individuals’ well-being, such as depression, mania, panic disorder, 
phobia, anxiety disorder, suicidality, personality, alcohol and illegal substance use, chronic 
conditions, tobacco use, eating disorders, obsessive compulsive disorder, psychosis, 
employment, finances, and childhood. Each dimension covers questions related to the 
specific life area of the participants. Only the illegal substance use dimension of CIDI is used 
in the included studies for this thesis. The CIDI illegal substance use section consists of 65 
questions related to individuals’ past and current severity of addiction, functioning status 
related to substance misuse problems and consumption of substance. Individuals need to 
answer the questions to indicate their history regarding the specific substance misuse related 
problems, the severity of the problems and the frequency of the problems.  
 
Clinical Outcomes in Routine Evaluation (CORE) 
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The outcome measure, CORE, discussed in this thesis is CORE Outcome Measure (CORE-
OM). CORE-OM is a validated self-completed outcome measure which was developed in 
1998 (Barkham et al, 1998; Evans et al, 2000; Evans et al, 2002). It consists of 34 items 
related to individuals’ psychological health status in 4 dimensions: well-being, symptoms, 
functioning, and risk. The score ranges from 0 to 4, where 4 indicates that individuals 
experience the specified psychological problems all of the time. To calculate the overall 
CORE score of the individuals the mean item score is multiplied by 10.  
 
European Addiction Severity Index (EuropASI) 
EuropASI, developed by Kokkevi and Hartgers (1995), is the modified version of the original 
ASI (McLellan et al, 1980). EuropASI is a validated semi-structured interview among the 
substance misuse population in Europe. It covers a wide range of dimensions related to 
individuals’ current problems regarding substance misuse: medical, employment and 
education, alcohol use, drug use, family and social relations, forensic and legal, and 
psychiatric (Koeter and Hartgers, 1997). The composite scores from each domain are derived 
from the key questionnaire items related to recent problems and severity. The composite 
score ranges from 0 to 1, where the higher score indicates more problems and greater severity.  
 
Hospital Anxiety and Depression scale (HADS) 
Developed by Zigmond and Snaith (1983), HADS is a specific validated questionnaire that 
assesses individuals’ psychological health status during their hospitalisation. Individuals are 
asked how often they have experienced the 14 different specified states of depression and 
anxiety. The overall score ranges from 0 to 42. Individuals who scored 0-7 are classified as 
non-cases and those who scored 8-10 are classified as borderline cases. Individuals who 
scored more than 11 are classified as cases with depression and anxiety.  
 
Injecting Drug User Quality of Life Scale (IDUQoL) 
IDUQoL (Brogly et al, 2003; Hubley, Russell and Palepu, 2005) is a validated questionnaire 
designed to assess both the health and non-health related quality of life of injecting drug 
users. Based on the WHO-QoL definition of quality of life, it consists of 21 life area 
questions: being useful, drugs, drug treatment, education, family, feeling good, friends, harm 
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reduction, health, health care, housing, independence, leisure activities, money, 
neighbourhood safety, partners, resources in the community, sex, spirituality, transportation 
and treatment by others. Each question is presented on a picture card with a description. Each 
area is given a score weighting its importance by the participant by placing small plastic 
chips. The score ranges from 0 to 3, where 0 is not at all important. It also measures the 
satisfaction score for each area given by the participant and the score ranges from 1 to 7, 
where 7 means very satisfied. The overall quality of life score is estimated based on the 
importance weighting and the satisfaction score of each area. 
 
Injecting Risk Questionnaire (IRQ) 
Developed by Stimson and colleagues (1998), IRQ consists of 18 questions and is a validated 
questionnaire that assesses individuals’ retrospective (last 4 weeks) injecting behaviour and 
sharing risk. Individuals are asked how often they have experienced the specified risky 
injecting behaviours, such as sharing equipment or the number of people they share 
equipment with, based on a 4-point scale.  
 
Leeds Dependence Questionnaire (LDQ) 
LDQ, developed by Raistrick and colleagues (1994), is a 10-item validated questionnaire that 
is designed to assess individuals’ substance dependence status. Individuals are asked about 
how frequently they have experienced the specified description related to drug misuse, based 
on a 4-point scale. The overall LDQ score ranges from 0 to 30, where 30 represents those 
who have the highest dependence severity. 
 
Manchester Short Assessment of Quality of Life (MANSA) 
MANSA, derived from the Lancashire Quality of Life Profile (Oliver, 1991-1992), is a 16-
item validated questionnaire designed to assess quality of life among patients with mental 
illness (Priebe et al, 1999). It is a shorter and modified version of the Lancashire Quality of 
Life Profile. It consists of 4 YES/NO questions about relationships with friends and criminal 
activity, and 12 questions about satisfaction of life, job, financial situation, friendships, 
leisure activities, accommodation, personal safety, people lived with, sex life, family 
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relationships, physical health, and mental health. The score for satisfaction ranges from 1 to 7, 
where 1 represents the worst state. 
 
Maudsley Addiction Profile (MAP) 
MAP, developed by Marsden and colleagues (1998), is a validated questionnaire to assess the 
outcomes for substance misuse patients. It consists of 4 dimensions: substance use, high risk 
behaviour, physical and psychological health, and personal/ social functioning. In the 
substance use domain, the results are presented as frequency of substance use in the past 
month, and as the total amount of substance consumed across the day. In the high risk 
behaviour domain, the results are presented as the frequency of risky injecting behaviour and 
risky sexual behaviour. The physical and psychological health domain measures the 
frequency of problems experienced in 10 items related to physical health problems and 10 
items related to anxiety and depression. The total composite score of physical and 
psychological health each ranges from 0 to 40, where 40 represents the worst health status. 
The personal/social functioning domain measures the frequency of contacts and conflicts 
with family and friends, days of being in employment/unemployment, and the estimated 
frequency of crime committed.  
 
Opiate Treatment Index (OTI) 
Developed by Darke and colleagues (1991b), OTI is a validated structured interview 
designed to measure the effectiveness of drug treatments. OTI consists of a wide range of 
dimensions: drug use, HIV risk-taking behaviour, social functioning, criminality, health 
status and psychological functioning. Drug use measure is derived from the calculation of a 
quantity/frequency estimate of drug use (Q score), and the higher score indicates greater drug 
use consumption. OTI produces the composite scores in the other dimensions, based on the 
questions about frequency of the specified incidents. In the dimensions of HIV risk-taking 
behaviour, social functioning dimension, criminality and psychological function, the 
maximum scores are 55, 48, 16 and 28, respectively. The higher scores indicate that 
individuals have more problems in these areas. In the health status domain, the composite 
score is derived from individuals’ responses to the questions about whether or not they have 
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the listed symptoms/diseases or not. The highest score for a female is 50 and 48 for a male 
and the higher score indicates the worse health status. 
 
HIV Risk-Taking Behaviour Scale (RTBS) 
Developed by Darke and colleagues (1991a), RTBS is a validated questionnaire to measure 
the HIV risk behaviours in 2 dimensions: injecting risk and sexual risk. The highest 
composite score attainable for injecting risk behaviour is 30, and for sexual risk behaviour it 
is 25. The highest overall score is 55, and a higher score indicates a higher incidence of risk 
behaviour. 
 
Symptom Checklist-90 (SCL-90) 
SCL-90, developed by Derogatis and Cleary (1977), is a 90-item validated self-completed 
questionnaire that assesses the individuals’ psychological health status. As with the shorter 
version, BSI, SCL-90 consists of 9 dimensions of psychological symptoms. The rating scale 
for each item is from 0 to 4, where 4 represents the worst status. It produces the same 3 
global indices as BSI, where the global severity index is the average rating of all 90 items. 
 
Severity of Dependence Scale (SDS) 
Developed by Gossop and colleagues (1995), SDS is a validated 5-item questionnaire 
designed to assess the degree of drug dependence of individuals. The rating scale of each 
item is from 0 to 3 and the total score ranges from 0 to 15. The highest scores indicate the 
highest levels of dependence severity. 
 
SF-12 and SF-36 
SF-36 (Ware et al, 1993; Ware, Kosinski and Keller, 1994) is a validated questionnaire that 
assesses individuals’ health-related quality of life. It consists of 8 dimensions: physical 
functioning, role-physical, bodily pain, general health, vitality, social functioning, role-
emotional and mental health. It produces 2 composite scores: MCS (mental component 
summary) and PCS (physical component summary) and the scores of MCS and PCS each 
range from 0 to 100. Similarly, SF-12, the shorter version of SF-36, also consists of questions 
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within the 8 dimensions and produces the MCS and PCS scores (Ware, Kosinski and Keller, 
1995 and 1996). 
 
Social Satisfaction Questionnaire (SSQ) 
SSQ (Raistrick et al, 2007; Tober et al, 2000) is a validated questionnaire, which is designed 
to assess individuals’ satisfaction towards different areas related to social integrations, such 
as employment and social relationships. SSQ consist of 8 questions and individuals are asked 
about their degree of satisfaction towards to the specified area. SSQ scores range from 0 to 
24, where 24 represents that the individuals have the highest degree of satisfaction towards 
the specified areas of social integration.  
 
Timeline Follow Back (TLFB) 
TLFB (Sobell and Sobell, 1996; Sobell et al, 1996) is a validated questionnaire designed to 
estimate individuals’ consumption of different substances. The overall scores are presented 
as the percentage of days being abstinent of the specific drugs (PDA).  
 
WHO’s Disability Assessment Schedules II (WHODAS II) 
WHODAS II (WHO, 2000), is a validated questionnaire designed to assess individuals’ 
health status. The version discussed in this thesis is the 12-item WHODAS II. It consists of 
questions from 6 dimensions: understanding and communicating, getting around, self care, 
getting along with people, life activities, and participation in society. The score of each item 
ranges from 1 to 5, where 1 indicates that individuals do not experience any difficulty for the 
specified health-related motilities and social functioning 
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Appendix 2 Kappa coefficient of inter-observer agreement 
 
Appendix 2.1 Kappa coefficient of inter-observer agreement in the outcome measures 
included in chapter 2 
 component Chapter 1st level 2nd level 3rd level 4th level 
EQ-5D 1.00** 1.00** 0.79**   
BSI 0.27** 0.93** 0.80** 1.00** 1.00 
CIDI 0.92** 0.96** 0.99** 0.95**  
EuropASI 0.60** 0.95** 0.98** 1.00**  
HADS 0.62 ** 1.00** 0.55** 0.33  
IDUQoL 0.71** 0.94** 0.94** 1.00**  
IRQ 1.00 ** 0.04 0.40   
MANSA 0.61** 1.00** 0.86** 1.00**  
MAP 0.46** 1.00** 0.81** 0.80** 1.00* 
OTI 0.60** 0.81** 0.73** 1.00** 1.00 
RTBS 1.00 ** 0.46** 1.00** 1.00**  
SCL-90 0.26** 0.78** 0.78** 0.95** 1.00* 
SDS 1.00** 1.00 ** 1.00** 0.71*  
SF-12 0.89** 1.00** 1.00** 1.00*  
SF-36 0.91** 1.00** 0.95** 1.00**  
TLFB 0.85** 1.00** 1.00** 1.00**  
WHODAS II 0.66** 0.94** 0.87** 1.00**  
Overall 0.75** 0.89** 0.91** 0.97** 1.00** 
*: p < 0.05 
**: p< 0.001 
 
Appendix 2.2 Kappa coefficient of inter-observer agreement in RESULT 
 component Chapter 1st level 2nd level 3rd level 4th level 
CORE 0.35** 0.86** 0.61** 0.77*  
EQ-5D 1.00** 1.00** 0.79**   
LDQ 0.51** 0.44* 0.69* 1.00  
SCL 1.00** 1.00** 1.00** 0.79** 1.00* 
SSQ 0.64* 1.00** 0.77** 0.84*  
Overall 0.61** 0.90** 0.81** 0.80** 1.00* 
*: p < 0.05 
**: p< 0.001 
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Appendix 3 ICF mapping results 
 
Appendix 3.1 ICF mapping results for outcome measures in the continuation of illegal substance use and abuse dimension 
 
Appendix 3.1.1 ICF mapping results for outcome measures in the continuation of illegal substance use and abuse dimension: body 
functions component 
ICF category EQ-5D CIDI EuropASI 
EuropASI 
Drug IDUQoL IRQ OTI 
OTI-
drug RTBS SDS 
TLFB-
cannabis 
TLFB-heroin, 
methadone 
b126 Temperament and 
personality functions   1    1      
b1262 
Conscientiousness       1      
b1263 Psychic stability       3      
b1265 Optimism       1      
b1266 Confidence     1  2      
b1267 Trustworthiness       2      
b1300 Energy level       1      
b1303 Craving  3        1   
b1304 Impulse control  6 1       2   
b134 Sleep functions   1 1         
b1340 Amount of sleep   1 1   1      
b1342 Maintenance of 
sleep       1      
b140 Attention functions   2          
b1442 Retrieval of 
memory  4 2          
b152 Emotional 
functions 1 3 9 1   3   2   
b156 Perceptual   1          
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functions 
b160 Thought functions   9 1         
b1603 Control of 
thought   1          
b164 High-level 
cognitive function   6 1         
b280 Sensation of pain 1            
b28010 Pain in head and 
neck       2      
b5500 Body temperature       1      
Total ICF concepts 2 16 34 5 1 0 19 0 0 5 0 0 
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Appendix 3.1.2 ICF mapping results for outcome measures in the continuation of illegal substance use and abuse dimension: activities 
and participation component 
ICF category EQ-5D CIDI EuropASI 
EuropASI 
Drug IDUQoL IRQ OTI 
OTI-
drug RTBS SDS 
TLFB-
cannabis 
TLFB-
heroin, 
methadone 
d177 Making decisions     1  1      
d2102 Undertaking a 
single task independently     1        
d2202 Undertaking 
multiple tasks 
independently 
    1        
d230 Carrying out daily 
routine 1 2     1      
d240 Handling stress and 
other psychological 
demands 
      1      
d2400 Handling 
responsibilities  1     2      
d2401 Handling stress       1      
d350 Conversation  4           
d355 Discussion  1           
d4 Mobility 1            
d450 Walking 1            
d470 Using transportation     1        
d475 Driving   1          
d4750 Driving human-
powered transportation  1           
d4751 Driving motorized 
vehicles  1 2          
d498 Mobility, other 
specified-confined to bed 1            
d5 Self-care 2            
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d510 Washing oneself 1            
d540 Dressing 1            
d550 Eating   1          
d570 Looking after one’s 
health  1 1          
d5702 Maintaining one's 
health   3 3  12   9    
d620 Acquisition of goods 
and services   1 1       1 2 
d6200 Shopping  1           
d640 Doing housework 1 1           
d6402 Cleaning living 
area  1           
d660 Assisting others   1          
d710 Basic interpersonal 
interactions   2  1        
d720 Complex 
interpersonal interactions   2  1 4 1      
d7200 Forming 
relationships  1           
d730 Relating with 
strangers   1          
d740 Formal relationships   1          
d750 Informal social 
relationships  1 4          
d7500 Informal 
relationships with friends   3          
d7501 Informal 
relationships with 
neighbours 
  1          
d7503 Informal 
relationships with co-
inhabitants 
  3          
d760 Family relationships 1 2 5  1        
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d7600 Parent-child 
relationships  1 2  1        
d7601 Child-parent 
relationships  1 4  1        
d7602 Sibling 
relationships  1 2  1        
d7603 Extended family 
relationships   1          
d770 Intimate 
relationships   3          
d7701 Spousal 
relationships   3  1        
d7702 Sexual 
relationships   2  1 1   5    
d779 Particular 
interpersonal 
relationships, other 
specified and unspecified 
  1   1       
d810 Informal education     1        
d820 School education  1 1  1        
d830 Higher education   1          
d839 Education, other 
specified and unspecified-
study 
1  1  1        
d850 Remunerative 
employment 1 4 7  1        
d855 Non-remunerative 
employment   2  1        
d860 Basic economic 
transactions   2    1      
d865 Complex economic 
transactions   1    1      
d870 Economic self-
sufficiency     1        
  215 
d8700 Personal economic 
resources   7          
d8701 Public economic 
entitlements   5          
d910 Community life  1           
d920 Recreation and 
leisure 1    1        
d9201 Sports  1           
d9205 Socializing  1 2          
d930 Religion and 
spirituality     1        
d940 Human rights     1        
Total ICF concepts 13 29 79 4 21 18 9 0 14 0 1 2 
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Appendix 3.1.3 ICF mapping results for outcome measures in the continuation of illegal substance use and abuse dimension: 
environmental factors component 
ICF category EQ-5D CIDI EuropASI 
EuropASI 
Drug IDUQoL IRQ OTI 
OTI-
drug RTBS SDS 
TLFB-
cannabis 
TLFB-heroin, 
methadone 
e1100 Food   17 13   5 5     
e1101 Drugs  72 45 37 1  51 50  3 3 7 
e165 Assets   1    1      
e1651 Tangible assets     1        
e310 Immediate family   7          
e315 Extended family   3          
e320 Friends   3  1 1       
e325 Acquaintances, 
peers, colleagues, 
neighbours and 
community 
members 
  2   1       
e345 Strangers      1       
e355 Health professionals  4           
e540 Transportation 
services, systems and 
policies 
    1        
e5458 Civil protection 
services, systems and 
policies, other specified 
  8    4      
e5500 Legal services   12          
e570 Social security 
services, systems and 
policies 
  1          
e5700 Social security 
services   1  1        
e5750 General social 
support services  2 2          
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e5800 Health services  5 11 5 1        
e590 Labour and 
employment services, 
systems and policies 
  2          
Total ICF concepts 0 83 115 55 6 3 61 55 0 3 3 7 
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Appendix 3.1.4 ICF mapping results for outcome measures in the continuation of illegal substance use and abuse dimension: concepts 
not covered in ICF 
ICF category EQ-5D CIDI EuropASI 
EuropASI 
Drug IDUQoL IRQ OTI 
OTI-
drug RTBS SDS 
TLFB-
cannabis 
TLFB-heroin, 
methadone 
hc-AIDS   1          
hc-chronic medical 
problems   1          
hc-health problems   1          
hc-hepatitis B   1          
hc-hepatitis-C   1          
hc-HIV   2          
hc-medical problems   4          
hc-medical problems 
(o.d.’s, d.t.’s)   1          
hc-pelvic 
inflammatory disease   1          
hc-tuberculosis   1          
hc-venereal diseases   1          
nc-abuse   3          
nc-conflict   1          
nc- neighbourhood 
safety     1        
nc-physical abuse   1          
nc-sexual abuse   1          
nc-suicide   4    4      
nd-gh     1  2      
nd-mh   5  1        
nd-period of 
consumption       11 11     
nd-QoL   1          
nd-satisfaction   3    1      
Total ICF concepts 0 0 34 0 3 0 18 11 0 0 0 0 
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Appendix 3.2 ICF mapping results for outcome measures in the improvement of medical conditions dimension 
 
Appendix 3.2.1 ICF mapping results for outcome measures in the improvement of medical conditions dimension: body functions 
component  
ICF category EQ-5D BSI 
EuropASI 
Medical 
EuropASI 
Psychiatric HADS IDUQoL MANSA 
MAP-
HSS 
OTI- 
psychological 
health 
SCL-
90 
SF-
12 
SF-
36 WHODASII 
b1 Mental 
functions             1 
b126 
Temperament and 
personality 
functions 
   1     1 1    
b1262 
Conscientiousness         1     
b1263 Psychic 
stability  2   3    3 3  1  
b1265 Optimism         1 1    
b1266 Confidence  1    1   2 1    
b1267 
Trustworthiness  1       2 1    
b1300 Energy 
level     1    1 1 1 4 2 
b1301 Motivation  1        1    
b1302 Appetite  1   1   1  1    
b1304 Impulse 
control  3  1      3    
b1340 Amount of 
sleep         1 1    
b1341 Onset of 
sleep  1        1    
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b1342 
Maintenance of 
sleep 
    1    1     
b1343 Quality of 
sleep     1     1    
b140 Attention 
functions  1  2      1    
b1400 Sustaining 
attention  1        1   1 
b1442 Retrieval 
of memory  1  2      1    
b152 Emotional 
functions 1 18  5 5    3 29 4 7 1 
b156 Perceptual 
functions    1          
b1560 Auditory 
perception          1    
b160 Thought 
functions  2 1 4 1     1    
b1602 Content of 
thought  3        4    
b1603 Control of 
thought  1  1 1     6    
b164 High-level 
cognitive function   1 1          
b2401 Dizziness  1        2    
b265 Touch 
function  1      1  1    
b280 Sensation of 
pain 1          1 2 1 
b2800 
Generalized pain        1      
b28010 Pain in 
head and neck         2 1    
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b28011 Pain in 
chest  1      1  1    
b28012 Pain in 
stomach or 
abdomen 
       1      
b28013 Pain in 
back          1    
b28016 Pain in 
joints        1      
b340 Alternative 
vocalization 
functions 
         1    
b4100 Heart rate          1    
b4101 Heart 
rhythm     1         
b440 Respiration 
functions        1      
b4401 
Respiratory 
rhythm 
 1        1    
b4552 
Fatiguability        1      
b460 Sensations 
associated with 
cardiovascular 
and respiratory 
functions 
         1    
b5350 Sensation 
of nausea  1      1  1    
b5500 Body 
temperature  1       1 1    
b640 Sexual 
functions          1    
b6400 Functions          1    
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of sexual arousal 
phase 
b730 Muscle 
power functions  1        1    
b7301 Power of 
muscles of one 
limb 
         1    
b7651 Tremor        1  1    
b780 Sensations 
related to muscles 
and movement 
functions 
         1    
Total ICF 
concepts 2 44 2 18 15 1 0 10 19 78 6 14 6 
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Appendix 3.2.2 ICF mapping results for outcome measures in the improvement of medical conditions dimension: activities and 
participation component  
ICF category EQ-5D BSI 
EuropASI 
Medical 
EuropASI 
Psychiatric HADS IDUQoL MANSA 
MAP-
HSS 
OTI- 
psychological 
health 
SCL-
90 
SF-
12 
SF-
36 WHODASII 
d Activities 
and 
Participation 
          1   
d155 
Acquiring 
skills 
            1 
d177 Making 
decisions  1    1   1 1    
d2 General 
tasks and 
demands 
         2    
d2102 
Undertaking a 
single task 
independently 
     1        
d2202 
Undertaking 
multiple tasks 
independently 
     1        
d230 Carrying 
out daily 
routine 
1    1    1  2 3 5 
d2303 
Managing 
one's own 
activity level 
            2 
d240 Handling 
stress and         1 2    
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other 
psychological 
demands 
d2400 
Handling 
responsibilities 
        2     
d2401 
Handling 
stress 
        1     
d355 
Discussion  1        1    
d4 Mobility 1             
d4102 
Kneeling            1  
d4104 
Standing             1 
d4105 
Bending            1  
d4154 
Maintaining a 
standing 
position 
            1 
d430 Lifting 
and carrying 
objects 
          1 2  
d4300 Lifting            1  
d4451 Pushing           1   
d4454 
Throwing          1    
d450 Walking 1             
d4500 
Walking short 
distances 
           2  
d4501            1 1 
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Walking long 
distances 
d4551 
Climbing           1 2  
d4552 
Running            1  
d470 Using 
transportation      1    1    
d498 Mobility, 
other 
specified-
confined to 
bed 
1             
d5 Self-care 2             
d510 Washing 
oneself 1           1  
d5101 
Washing 
whole body 
            1 
d540 Dressing 1           1 1 
d550 Eating    1      2    
d560 Drinking          1    
d570 Looking 
after one’s 
health 
         2   1 
d5702 
Maintaining 
one's health 
            1 
d6200 
Shopping          1  1  
d640 Doing 
housework 1          1 2 1 
d660 Assisting 
others            1  
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d710 Basic 
interpersonal 
interactions 
     1        
d7100 Respect 
and warmth in 
relationships 
 2        2    
d7102 
Tolerance in 
relationships 
 1        1    
d7103 
Criticism in 
relationships 
 1        2    
d7105 
Physical 
contact in 
relationships 
 1        1    
d720 Complex 
interpersonal 
interactions 
 2    1    3    
d7203 
Interacting 
according to 
social rules 
 1        1    
d730 Relating 
with strangers             1 
d7500 
Informal 
relationships 
with friends 
      1      1 
d7503 
Informal 
relationships 
with co-
inhabitants 
      3       
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d760 Family 
relationships 1     1 1       
d7600 Parent-
child 
relationships 
     1 1       
d7601 Child-
parent 
relationships 
     1        
d7602 Sibling 
relationships      1        
d7701 Spousal 
relationships      1        
d7702 Sexual 
relationships      1 1       
d810 Informal 
education      1        
d820 School 
education      1        
d839 
Education, 
other specified 
and 
unspecified-
study 
1     1 1       
d840 
Apprenticeship 
(work 
preparation) 
      1       
d850 
Remunerative 
employment 
1     1 1    3 4  
d855 Non-
remunerative 
employment 
     1 1       
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d859 Work 
and 
employment, 
other specified 
and 
unspecified 
            2 
d870 
Economic self-
sufficiency 
     1 1       
d8701 Public 
economic 
entitlements 
   1   1       
d9 
Community, 
social and 
civic life 
    1         
d910 
Community 
life 
            1 
d920 
Recreation and 
leisure 
1     1 1    1 1 1 
d9201 Sports           1 2  
d9202 Arts 
and culture          1  1  
d9204 Hobbies            1  
d9205 
Socializing       1    1 2  
d930 Religion 
and spirituality      1       1 
d940 Human 
rights      1        
Total ICF 
concepts 13 10 0 2 2 21 15 0 6 25 13 31 23 
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Appendix 3.2.3 ICF mapping results for outcome measures in the improvement of medical conditions dimension: environmental 
factors component 
ICF category EQ-5D BSI 
EuropASI 
Medical 
EuropASI 
Psychiatric HADS IDUQoL MANSA 
MAP-
HSS 
OTI- 
psychological 
health 
SCL-
90 
SF-
12 
SF-
36 WHODASII 
e1100 Food    1         1 
e1101 Drugs   1 1  1       1 
e1200 General 
products and 
technology for 
personal 
indoor and 
outdoor 
mobility and 
transportation 
         1    
e1650 
Financial 
assets 
      1       
e1651 
Tangible 
assets 
     1 2       
e320 Friends      1 1       
e540 
Transportation 
services, 
systems and 
policies 
     1        
e570 Social 
security 
services, 
systems and 
policies 
   1          
e5700 Social   1   1        
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security 
services 
e5800 Health 
services   4 2  1        
Total ICF 
concepts 0 0 6 5 0 6 4 0 0 1 0 0 2 
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Appendix 3.2.4 ICF mapping results for outcome measures in the improvement of medical conditions dimension: concepts not covered 
in ICF 
ICF category EQ-5D BSI 
EuropASI 
Medical 
EuropASI 
Psychiatric HADS IDUQoL MANSA 
MAP-
HSS 
OTI- 
psychological 
health 
SCL-
90 
SF-
12 
SF-
36 WHODASII 
hc            1  
hc-AIDS   1           
hc-chronic 
medical 
problems 
  1           
hc-health 
problems   1           
hc-hepatitis B   1           
hc-hepatitis-C   1           
hc-HIV   2           
hc-medical 
problems   4           
hc-medical 
problems 
(o.d.’s, d.t.’s) 
  1           
hc-pelvic 
inflammatory 
disease 
  1           
hc-
tuberculosis   1           
hc-venereal 
diseases   1           
nc-life             2 
nc- 
neighbourhood 
safety 
     1        
nc-physical    1          
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abuse 
nc-safety       1       
nc-sexual 
abuse    1          
nc-suicide  2  4 1    4 2    
nc-violence       1       
nd-blame 
oneself          1    
nd-blame 
others          1    
nd-gh      1 1  2  3 8 2 
nd-guilt  1            
nd-mh    4  1 1       
nd-moderate 
activities            1  
nd-QoL   1    1       
nd-satisfaction       1  1     
nd-vigorous 
activities            1  
pf-crime       1       
Total ICF 
concepts 0 3 16 10 1 3 7 0 7 4 3 11 4 
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Appendix 3.3 ICF mapping results for outcome measures in the social integration dimension 
 
Appendix 3.3.1 ICF mapping results for outcome measures in the social integration dimension: body functions component  
ICF category EQ-5D CIDI 
EuropASI 
Employment 
EuropASI 
Family/Other 
EuropASI 
Legal IDUQoL MANSA 
MAP-
crime 
OTI-
crime 
b1266 Confidence      1    
b1303 Craving  3        
b1304 Impulse control  6        
b1442 Retrieval of 
memory  4        
b152 Emotional 
functions 1 3  3      
b160 Thought functions   1 1 1     
b164 High-level 
cognitive function   1 1 1     
b280 Sensation of pain 1         
Total ICF concepts 2 16 2 5 2 1 0 0 0 
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Appendix 3.3.2 ICF mapping results for outcome measures in the social integration dimension: activities and participation component 
ICF category EQ-5D CIDI 
EuropASI 
Employment 
EuropASI 
Family/Other 
EuropASI 
Legal IDUQoL MANSA 
MAP-
crime 
OTI-
crime 
d177 Making decisions      1    
d2102 Undertaking a single task 
independently      1    
d2202 Undertaking multiple tasks 
independently      1    
d230 Carrying out daily routine 1 2        
d2400 Handling responsibilities  1        
d350 Conversation  4        
d355 Discussion  1        
d4 Mobility 1         
d450 Walking 1         
d470 Using transportation      1    
d475 Driving   1       
d4750 Driving human-powered 
transportation  1        
d4751 Driving motorized vehicles  1   2     
d498 Mobility, other specified-
confined to bed 1         
d5 Self-care 2         
d510 Washing oneself 1         
d540 Dressing 1         
d570 Looking after one’s health  1 1       
d6200 Shopping  1        
d640 Doing housework 1 1        
d6402 Cleaning living area  1        
d660 Assisting others   1       
d710 Basic interpersonal 
interactions    2  1    
d720 Complex interpersonal 
interactions    1 1 1   1 
  235 
d7200 Forming relationships  1        
d730 Relating with strangers    1      
d740 Formal relationships    1      
d750 Informal social relationships  1  4      
d7500 Informal relationships with 
friends    3   1   
d7501 Informal relationships with 
neighbours    1      
d7503 Informal relationships with 
co-inhabitants    3   3   
d760 Family relationships 1 2  5  1 1   
d7600 Parent-child relationships  1  2  1 1   
d7601 Child-parent relationships  1  4  1    
d7602 Sibling relationships  1  2  1    
d7603 Extended family 
relationships    1      
d770 Intimate relationships    3      
d7701 Spousal relationships    3  1    
d7702 Sexual relationships   1  1 1 1   
d779 Particular interpersonal 
relationships, other specified and 
unspecified 
   1      
d810 Informal education      1    
d820 School education  1 1   1    
d830 Higher education   1       
d839 Education, other specified 
and unspecified-study 1  1   1 1   
d840 Apprenticeship (work 
preparation)       1   
d850 Remunerative employment 1 4 7   1 1   
d855 Non-remunerative 
employment   2   1 1   
d860 Basic economic transactions     2    1 
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d865 Complex economic 
transactions     1   1 1 
d870 Economic self-sufficiency      1 1   
d8700 Personal economic 
resources   7       
d8701 Public economic 
entitlements   4    1   
d910 Community life  1        
d920 Recreation and leisure 1     1 1   
d9201 Sports  1        
d9205 Socializing  1  2   1   
d930 Religion and spirituality      1    
d940 Human rights      1    
Total ICF concepts 13 29 27 39 7 21 15 1 3 
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Appendix 3.3.3 ICF mapping results for outcome measures in the social integration dimension: environmental factors component 
ICF category EQ-5D CIDI 
EuropASI 
Employment 
EuropASI 
Family/Other 
EuropASI 
Legal IDUQoL MANSA 
MAP-
crime 
OTI-
crime 
e1100 Food    3      
e1101 Drugs  72  3 3 1  1 1 
e165 Assets     1   4 1 
e1650 Financial assets       1   
e1651 Tangible assets      1 2   
e310 Immediate family   1 6      
e315 Extended family   1 2      
e320 Friends   1 2  1 1   
e325 Acquaintances, peers, 
colleagues, neighbours and 
community 
members 
   2      
e355 Health professionals  4        
e540 Transportation 
services, systems and 
policies 
     1    
e5452 Civil protection 
policies        5  
e5458 Civil protection 
services, systems and 
policies, other specified 
  2 1 5    4 
e5500 Legal services     12     
e5700 Social security 
services      1    
e5750 General social 
support services  2  2      
e5800 Health services  5    1    
e590 Labour and 
employment services, 
systems and policies 
  2       
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Total ICF concepts 0 83 7 21 21 6 4 10 6 
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Appendix 3.3.4 ICF mapping results for outcome measures in the social integration dimension: concepts not covered in ICF 
ICF category EQ-5D CIDI 
EuropASI 
Employment 
EuropASI 
Family/Other 
EuropASI 
Legal IDUQoL MANSA 
MAP-
crime 
OTI-
crime 
nc-abuse    3      
nc-conflict    1      
nc- neighbourhood 
safety      1    
nc-safety       1   
nc-violence       1   
nd-gh      1 1   
nd-mh    1  1 1   
nd-QoL       1   
nd-satisfaction    3   1   
pf-crime       1   
Total ICF concepts 0 0 0 8 0 3 7 0 0 
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Appendix 3.4 ICF mapping results for outcome measures in RESULT 
 
Appendix 3.4.1 ICF mapping results for outcome measures in RESULT: body functions 
component 
ICF category EQ-5D CORE LDQ SCL (MAP-HSS) SSQ 
b1263 Psychic stability  2    
b1265 Optimism  2    
b1266 Confidence  1    
b1300 Energy level  1    
b1302 Appetite    1  
b1303 Craving   3   
b1304 Impulse control   1   
b1341 Onset of sleep  1    
b1342 Maintenance of sleep  1    
b1442 Retrieval of memory  1    
b152 Emotional functions 1 11    
b1602 Content of thought  2    
b1603 Control of thought   1   
b1645 Judgement   1   
b265 Touch function    1  
b280 Sensation of pain 1 1    
b2800 Generalized pain    1  
b28011 Pain in chest    1  
b28012 Pain in stomach or abdomen    1  
b28016 Pain in joints    1  
b440 Respiration functions    1  
b4552 Fatiguability    1  
b5350 Sensation of nausea    1  
b7651 Tremor    1  
Total ICF concepts 2 23 6 10 0 
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Appendix 3.4.2 ICF mapping results for outcome measures in RESULT: activities and 
participation component 
ICF category EQ-5D CORE LDQ SCL (MAP-HSS) SSQ 
d175 Solving problems  1    
d177 Making decisions   2   
d230 Carrying out daily routine 1  2   
d240 Handling stress and other 
psychological demands  1    
d2400 Handling responsibilities  1    
d2401 Handling stress   1   
d4 Mobility 1     
d450 Walking 1     
d498 Mobility, other specified-
confined to bed 1     
d5 Self-care 2     
d510 Washing oneself 1     
d540 Dressing 1     
d560 Drinking   1   
d610 Acquiring a place to live     1 
d640 Doing housework 1     
d710 Basic interpersonal interactions  2    
d7100 Respect and warmth in 
relationships  1    
d7101 Appreciation in relationships  1    
d7103 Criticism in relationships  1    
d7202 Regulating behaviours within 
interactions  1    
d7500 Informal relationships with 
friends     1 
d7503 Informal relationships with co-
inhabitants     1 
d760 Family relationships 1    2 
d7600 Parent-child relationships     1 
d7601 Child-parent relationships     1 
d770 Intimate relationships     1 
d7700 Romantic relationships     1 
d7701 Spousal relationships     1 
d839 Education, other specified and 
unspecified-study 1     
d850 Remunerative employment 1    1 
d855 Non-remunerative employment     1 
d870 Economic self-sufficiency     1 
d920 Recreation and leisure 1    1 
d9205 Socializing     1 
Total ICF concepts 13 9 6 0 15 
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Appendix 3.4.3 ICF mapping results for outcome measures in RESULT: environmental 
factors component 
ICF category EQ-5D CORE LDQ SCL (MAP-HSS) SSQ 
e1101 Drugs   1   
e3 Support and relationships  1    
e320 Friends  1    
Total ICF concepts 0 2 1 0 0 
 
Appendix 3.4.4 ICF mapping results for outcome measures in RESULT: concepts not 
covered in ICF 
ICF category EQ-5D LDQ SSQ CORE SCL (MAP-HSS) 
nc-achievement    1  
nc-hurt oneself    1  
nc-suicide    2  
Total ICF concepts 0 0 0 4 0 
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Appendix 4 Description of the outcome measures for the included human capital approach studies in chapter 4 
Study, country Population Intervention Benefit outcome measures and cost-benefit outcomes 
Abou-Saleh et al, 2003; 
Abou-Saleh et al, 2008 
(HEPC), UK 
33 injecting drug users 
(IDUs), recruited from 
drug treatment centres 
Trial enhanced HIV 
prevention counselling 
intervention 
-Stay Safe Therapy (SST; 4 
sessions) 
-Simple Educational 
Counselling (SEC; 1 
session) 
Monetary outcomes converted from Service Use 
Questionnaire (SUQ) 
 
Resource saved 
-Health care costs: costs of A&E (visit and 
overnight), emergency ambulance, inpatient stay, 
day care patient, GP(surgery visit and home visit), 
practice nurse (surgery visit and home visit), CPN 
home, NHS direct, walk-in centre, prescriptions, 
outpatient and inpatient drug services, counselling, 
residential treatment, after-care hostel, other 
agency, street agency, needle-exchange scheme and 
day programme 
-Criminal justice costs: costs of crime arrests (drug 
possession/drug offences, drink driving, other 
motoring, prostitution, other sex offences) and costs 
per offences (violence/assault, robbery, burglary, 
shoplifting, vehicle theft, criminal damage) 
-Social care costs: costs of housing benefit advisor, 
social worker, occupational therapist, citizens 
advice, RELATE counselling, alternative medical 
practitioner, debt advisor, homeless person agency 
and employment advisor 
 
Cost-benefit outcome 
-Changes of resource use between baseline and 
follow-up for SST group and SEC group are £5,239 
and £-3,968 per patient, respectively 
Ates et al, 2005, Germany 57 drug misuse patients Three groups: 
-Specialised integration 
project (Mudra e.V.) 
-Standard work projects 
Resource saved 
-Health care costs: costs of hospital stays, inpatient 
and outpatient detoxification and substitution 
-Criminal justice costs: costs of law enforcement,  
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-Graduates of work projects criminal justice system, probation and prison 
-Social care costs: cost of unemployment social 
assistance 
 
Other value created 
-Increased productivity 
 
Cost-benefit outcome 
-Net benefit of Mudra e.V. at 1 year follow-up is 
EUR4,446.39 
Avants et al, 1999, USA 291 opioid dependent 
patients 
Two groups 
-Day treatment 
-Enhanced standard 
methadone maintenance 
programme 
Resource saved 
-Health care costs: costs of medical primary care, 
medical hospitalisation, emergency room, mental 
health services, psychiatric/drug hospitalisation and 
transfer payment (administrative costs) 
-Criminal justice costs: costs of incarceration 
-Social care costs: cost of vocational counselling and 
legal counselling 
 
Other value created 
-Increased productivity 
 
Cost-benefit outcome 
-Mean difference of total societal costs at 6 month 
between two groups is $661 per patient 
Barnett et al, 2006, USA 126 IDUs Patients in methadone 
treatment 
-Group 1: usual care 
-Group 2: case management 
-Group 3: voucher for free 
substance treatment 
-Group 4: case management 
plus voucher 
Resource saved 
-Health care costs: costs of case management, long-
term methadone maintenance, methadone 
detoxification, residential substance abuse 
treatment, other substance abuse treatment, 
outpatient mental health care, inpatient mental 
health care, hospital care, emergency department 
care and outpatient medical care 
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Cost-benefit outcome 
-Total resource use for group 1-4 are $5,620, $7,400, 
$13,087, $10,411 per patient, respectively 
Berg, 1997, Norway 61 patients who have used 
several substance (heroin, 
amphetamine, hashish, 
painkillers, 
benzodiazepines and/or 
alcohol) 
Residential detoxification 
and counselling for 3 weeks 
-Completer 
-Non-completer 
Resource saved 
-Health care costs: decline in costs of future 
detoxifications and reduction in necessary treatment 
sessions (GP and hospital) 
 
Other value created 
-Increased productivity: increased taxes from taxable 
income 
 
Cost-benefit outcome 
-Net benefit of completer and non-completer are 
NKR 19,000 ($2,920) and NKR 69,000 per patient, 
respectively 
Berger, 2003, USA 3.9 million pregnant 
women 
Universal substance misuse 
screening 
Resource saved 
-Health care costs: reduced substance abuse and 
reduced need for medical/ health care services 
(hospital costs of drug exposed new born, hospital 
costs of boarder babies, health care costs of 
postnatal exposure, avoided infant lives saved) 
 
Cost-benefit outcome 
-Assuming 5.6% CPS (child protective services) 
reporting rate, net benefit of the universal substance 
misuse screening is from $-44.09 to $-126.89 per 
pregnant woman 
-Assuming 4.1% CPS reporting rate, net benefit of 
the programme is from $40.98 to $50.03 
Bishai et al, 2008, USA 241 heroin addicts Before entering a methadone 
maintenance treatment 
Cost-benefit outcome 
-Estimated programme costs is $82 per week 
-Patients are willing to pay for a median weekly fee 
from $7.3 (3 months heroin-free effects) to $17.11 
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(24 months heroin-free effects) 
-Median WTP of case management is $5.64 per 
week 
Borisova and Goodman, 
2003 and 2004, USA 
303 substance misuse 
patients 
Methadone maintenance 
treatment 
Cost-benefit outcome 
-Mean WTP and willingness-to-accept (WTA) of the  
travel time required to obtain methadone  
maintenance treatment are $7.32 and $8.65 per 
hour, respectively 
-Median wage of the employed patients is $10.04 per 
hour 
-Average value of travel time is $5.49 per hour 
Conover et al, 2006, USA 1,138 patients with 
HIV/AIDS, chronic mental 
illness and substance 
misuse 
Two groups: 
-Employed 
-Unemployed 
Resource saved 
-Social care costs: unemployment/ workers 
compensation, public assistance/ AFDC/ welfare, 
child support/ alimony and pension/ benefits/ social 
security 
 
Other value created 
-Increased productivity: income 
 
Cost-benefit outcome 
-Average societal costs related to income is $447 
-Average societal costs of employed patients and 
unemployed patients are $247 and $479, 
respectively 
Daley et al, 2000, USA 439 pregnant substance 
misuse patients 
Public funded treatment 
-Group 1: detoxification 
-Group 2: methadone 
-Group 3: residential 
-Group 4: outpatient 
-Group 5: residential/ 
outpatient 
Resource saved 
-Criminal justice costs: costs of police investigation, 
illegal earnings, stolen property, other crime,  
incarceration, adjudication and parole 
 
Other value created 
-Victim costs 
 
Cost-benefit outcome 
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-Avoided crime costs for group 1-5 are $2,151,  
$1,867, $5,184, $983, $1, 692, $2,642 per patient,  
respectively 
-Benefit-cost ratio for group 1-5 are 1.14, 1.54, 2.11,  
1.72, 2.10, 1.54, respectively 
Davies et al, 2009 (Drug 
treatment outcomes 
research study; DTORS), 
UK 
1,545 drug misuse patients Patients received structured 
drug misuse treatment: 
community-based 
drug treatment or residential 
drug 
treatment 
Resource saved 
-Health care costs: costs of GP visits, community 
nurse, social worker, other professional services, 
A&E, Day hospital, general medical and surgical, 
other services, psychiatry, non-psychiatric, 
psychiatric services, substance misuse treatment, 
other unstructured drug treatment services, needle 
exchange and dug related advice services 
-Criminal justice costs: costs of offending behaviour 
(shoplifting, begging, buying and selling stolen 
goods, drug dealing, prostitution, theft of vehicle, 
theft from vehicle, house burglary, business 
burglary, violent theft, bag snatch, other stealing, 
cheque or credit card fraud, benefit fraud, and other 
violent crime) 
-Social care costs: costs of children in care,  
accommodation (hostel, night-time drop-in centres) 
 
Other value created 
-Victim costs 
 
Cost-benefit outcome 
-Average net benefit of drug misuse treatment is 
£7,301 
-Benefit-cost ratio is 2.5:1 
Dijkgraaf et al, 2005, 
Netherlands 
430 Heroin addicts Two groups: 
-Methadone plus heroin 
-Methadone alone 
Monetary outcomes converted from the European 
version of Addiction Severity Index (EuropASI) 
 
Resource saved 
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-Health care costs: costs of GP, physiotherapist, 
psychiatrist/ psychologist/ therapist, company 
physician, alternative/ traditional medicine, other 
addiction care programmes, general hospital 
(outpatient and inpatient), psychiatric hospital 
(outpatient and inpatient), regional agency for 
mental health care, crisis intervention centre 
(outpatient and inpatient) and addiction care centre 
(physical and psychiatric) 
-Criminal justice costs: police arrests and official 
report, conviction (prosecution and adjudication), 
imprisonment and probation 
 
Other value created 
-Victim costs: company (theft and burglary) and 
civilian 
 
Cost-benefit outcome 
-Benefit of methadone plus heroin and methadone  
are EUR 19,533 and EUR 49,002, respectively 
-Net benefit difference between methadone plus  
heroin and methadone is EUR -12,793 
Dismuke et al, 2004 
(PETS; The Persistent 
Effects of Treatment 
Study), USA 
1,326 substance misuse 
patients from PETS 
Substance misuse 
programmes from Chicago 
Target Cities Project 
Monetary outcomes converted from Addiction 
Severity Index (ASI) 
 
Resource saved 
-Health care costs: days experience medical problem, 
days in inpatient medical treatment, emergency 
room visits, clinic or physician visits, days 
experience psychological problems, days in 
inpatient psychiatric treatment and days in 
outpatient psychiatric treatment 
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-Criminal justice costs: drug offence, forgery,  
burglary, robbery, assault, arson, rape, homicide,  
prostitution, drug deal, illegal gambling, vehicle  
theft and receiving/selling stole property 
 
Other value created 
-Increased productivity: income received from 
employment 
 
Cost-benefit outcome 
-Total societal costs are $18,187, $9,051, $7,402, 
$3,319, $3,726 per patient at baseline, 6, 24, 36, 48 
months follow-up, respectively 
Drummond et al, 2004; 
Drummond, C. et al, 2005 
(UKCBTMM), UK 
60 opiate addicts, recruited 
from 10 community based 
clinics 
Two groups: 
-Cognitive behaviour therapy 
(CBT) plus methadone 
maintenance treatment 
(MMT) 
-MMT alone 
Monetary outcomes converted from Service Use 
Questionnaire (SUQ) 
 
Resource saved 
-Health care costs: costs of A&E (visit and 
overnight), emergency ambulance, inpatient stay, 
outpatient visit, day care patient, GP(surgery visit 
and home visit), practice nurse, CPN, NHS direct, 
walk-in centre, prescriptions, inpatient drug 
services, residential treatment, after-care hostel, 
street agency, day care programme and residential 
drug care 
-Criminal justice costs: costs of crime arrests (drug 
possession/drug supply), costs per offences 
(violence/assault, robbery, burglary, shoplifting, 
prostitution and other criminal offence) 
-Social care costs: benefit advisor, social worker,  
occupational therapist, citizens advice, RELATE  
counselling, alternative medical practitioner, debt 
advisor, homeless person agency, employment 
advisor and other advice 
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Cost-benefit outcome 
-Changes of resource use between baseline and 
12-month follow-up for MMT&CBT group and 
MMT group are £-9,028.45 and £-2,064.68 per 
patient, respectively 
Ettner et al, 2006 
(CalTOP; California 
Treatment Outcome 
Project), USA 
2,567 drug misuse patients 43 drug misuse treatment for 
CalTOP 
Monetary outcomes converted from ASI 
 
Resource saved 
-Health care costs: costs of hospital nights for 
medical problems, emergency room visits and 
inpatient and outpatient mental health services 
-Criminal justice costs: costs of criminal activities  
and incarceration 
-Social care costs: unemployment,  
disability/retirement and other services 
 
Other value created 
-Increased productivity: money received from 
employment 
-Victim cost 
 
Cost-benefit outcome 
-Average net benefit is $9,903 per patient. 
-Benefit-cost ratio is 7:1 
Fals-Stewart, O'Farrell 
and Birchler, 1997, USA 
80 substance misuse male 
patients from married or 
cohabiting couple 
Two groups: 
-Behavioural couples therapy 
(BCT) 
-Individual-based substance 
misuse treatment (IBT) 
Resource saved 
-Health care costs: outpatient counselling 
programmes and intensive ambulatory care, 
hospital-based programmes (28-day inpatient and 
detoxification) and long-term residential facilities 
(halfway houses, sober houses and therapeutic 
communities) 
-Criminal justice costs: costs of crime arrests,  
incarceration, legal supervision (parole and 
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probation) and illegal income (trafficking, robbery 
and selling stolen property) 
-Social care costs: cost of general cash assistance 
and food stamps 
 
Cost-benefit outcome 
-Net benefit of BCT and IBT are $4,856.01 and 
$544.95 per patient, respectively 
-Benefit-cost ratio of BCT and IBT are 5.01 and  
1.37, respectively 
Finigan, 1996, USA 1,267 substance misuse 
patients 
Two groups: 
-Substance misuse treatment 
(outpatient, residential and 
methadone) 
-No treatment 
Resource saved 
-Health care costs: costs of inpatient and outpatient 
medical care, emergency medical care, inpatient 
and outpatient mental health care 
-Criminal justice costs: costs of police protection 
services, prosecution, adjudication, public defence  
and correction (incarceration, parole and probation) 
-Social care costs: food stamps, emergency  
assistance, public disability payment and other  
public assistance 
 
Other value created 
-Victim cost: victim expenditures on medical care, 
repairs of damaged property, lost time from work 
that results from predatory crimes and value of 
property or money stolen during a crime 
 
Cost-benefit outcome 
-Total net benefit of substance misuse treatment is 
$83,147 
Finigan, Carey and Cox, 
2007, USA 
11,102 offenders Two groups: 
-Drug court 
-Traditional court 
Resource saved 
-Criminal justice costs: costs of arrests, bookings, 
court, imprisonment, probation 
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Other value created 
-Victim cost 
 
Cost-benefit outcome 
-Cost-benefit ratio of drug court is 1: 2.63 
Flynn et al, 1999 
(DATOS; Drug Abuse 
Treatment Outcome 
Studies), USA 
502 cocaine dependent 
patients 
Two groups: 
-Long-term residential  
treatment (LTR) 
-Outpatient drug-free  
treatment (ODF) 
Resource saved 
-Criminal justice costs: costs of criminal justice 
system (aggravated assault, burglary, theft, robbery, 
forgery, fencing, gambling, prostitution and drug 
lay violation) 
 
Other value created 
-Increased productivity: crime career/productivity 
loss 
-Victim cost (aggravated assault, burglary, theft, and 
robbery) 
 
Cost-benefit outcome 
-Cost of crime of LTR group is from $18,461 to 
$30,092 and cost of crime of ODF group is from 
$1,891 to $4,638 
-Benefit-cost ratio of LTR is from 1.68 to 2.73 and 
benefit-cost ratio of ODF is from 1.33 to 3.26 
French et al, 2000, USA 263 addiction treatment 
patient 
Two groups: 
-Outpatient substance misuse 
treatment (PC) 
-Residential substance 
misuse treatment (FC) 
Monetary outcomes converted from ASI 
 
Resource saved 
-Health care costs: costs of days experiencing 
medical problems, overnight hospitalisation, 
emergency room visits, clinic or physician visits, 
days experiencing psychological problems, 
inpatient and outpatient psychiatric treatment and 
hospital outpatient psychiatric treatment 
-Criminal justice costs: costs of criminal activities 
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Other value created 
-Increased productivity: income received from  
employment 
 
Cost-benefit outcome 
-Net benefit of PC and FC are $11,173 and $17,833, 
respectively 
-Benefit-cost ratio of PC and FC are 23.33 and 9.70, 
respectively 
French et al, 2002a 
(PAAM; Pregnant 
Addicts/Addicted 
Mothers), USA 
121 pregnant substance 
misuse patients 
Two groups: 
-Specialty residential  
treatment 
-Standard residential 
treatment 
Monetary outcomes converted from ASI 
 
Resource saved 
-Health care costs: costs of days experiencing 
medical problems, overnight hospitalisation, 
emergency room visits, clinic or physician visits, 
days experiencing psychological problems, 
inpatient and outpatient psychiatric treatment and 
hospital outpatient psychiatric treatment 
-Criminal justice costs: costs of criminal activities 
 
Other value created 
-Increased productivity: income received from  
employment 
 
Cost-benefit outcome 
-Net benefit of specialty residential treatment and 
standard residential treatment are $17,143 and 
$8,090, respectively 
-Benefit-cost ratio of specialty residential treatment 
and standard residential treatment are 3.1 and 6.5, 
respectively 
French et al, 2002b, USA 186 patients from 
homeless shelters and 
psychiatric hospitals 
Two groups: 
-Treatment-as-usual (TAU) 
-Modified therapeutic 
Resource saved 
-Health care costs: costs of other therapeutic 
community treatment, emergency room visits, 
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community treatment (TC) hospital detoxification, shor0term residential 
treatment, non-residential treatment, outpatient 
treatment, individual psychotherapy, methadone 
maintenance treatment, outpatient and inpatient 
psychological treatment 
-Criminal justice costs: costs of criminal justice  
system (alcohol offence, drug law violation, 
forgery/ fraud, fencing, gambling/ running numbers, 
prostitution/ pimping, burglary/ GTA, other theft, 
robbery, violent assault, and other/ miscellaneous) 
 
Other value created 
-Increased productivity: income 
-Victim costs 
 
Cost-benefit outcome 
-Net benefit of TAU and TC are $85,257 and 
$253,337, respectively 
-Benefit-cost ratio of TAU and TC are 5.19 and 
13.44, respectively 
French et al, 2002c, USA 178 substance misuse 
patients 
3 outpatient drug-free 
programmes 
Monetary outcomes converted from ASI 
 
Resource saved 
-Health care costs: costs of inpatient medical care, 
inpatient psychiatric care, and inpatient addiction 
treatment, days of experiencing medical problems 
and days of experiencing psychiatric problems 
-Criminal justice costs: costs of criminal activities 
 
Other value created 
-Increased productivity: income received from 
employment 
 
Cost-benefit outcome 
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-Average net benefit is from $1,939 to $14,307 
-Average benefit-cost ratio is from 9 to 56 
French, Salome, and 
Carney, 2002, USA 
222 substance misuse 
patients 
9 adult substance residential 
treatments 
Monetary outcomes converted from ASI 
 
Resource saved 
-Health care costs: costs of inpatient medical care, 
inpatient psychiatric care, and inpatient addiction 
treatment, days of experiencing medical problems 
and days of experiencing psychiatric problems 
-Criminal justice costs: costs of criminal activities 
 
Other value created 
-Increased productivity: income received from 
employment 
 
Cost-benefit outcome 
-Average net benefit is from $4,673 to $90,839 
-Average benefit-cost ratio is from 1.63 to 25.89 
French et al, 2003, USA 600 adolescent cannabis 
users aged 12 to 18 
5 programmes of CYT study 
(Cannabis Youth Treatment): 
-Motivational enhancement  
treatment/cognitive  
behaviour therapy 
(MET/CBT) 5 sessions 
-MET/CBT 12 sessions 
-Family support network 
(FSN) 
-Adolescent community  
reinforcement approach  
(ACRA) 
-Multidimensional family 
therapy (MDFT) 
Resource saved 
-Health care costs: costs of inpatient hospital days, 
emergency room visit, outpatient clinic/ doctor’s 
office visit, days bothered by health/ medical 
problems, days bothered by psychological 
problems, detoxification programmes, inpatient 
substance abuse treatment, long-term residential 
programmes, intensive and regular outpatient 
substance abuse programmes 
-Criminal justice costs: costs of crime arrests,  
probation, parole, prison/jail, juvenile detention 
-Social care costs: costs of schools truancy, lost  
income for stressful days of parents 
 
Cost-benefit outcome 
-Net benefit of MET/CBT5, MET/CBT12, FSN, 
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ACRA and MDFT are $1,113, $1,185, $3,246, 
$1,408 and $2,012, respectively 
French, Fang and Fretz, 
2010, USA 
571 criminal offenders Two groups: 
-Pre-release substance 
treatment 
-No treatment 
Resource saved 
-Criminal justice costs: costs of arrests, convictions, 
incarceration 
 
Other value created 
-Increased productivity: wage loss 
-Victim costs 
 
Cost-benefit outcome 
-Total cost of crime for treatment group and control 
group are $7,678 and $11,985, respectively 
Godfrey, Stewart and 
Gossop, 2004 (NTORS; 
National Treatment 
Outcome Research 
Study), UK 
549 substance misuse 
patients 
Patient from 54 residential 
and community treatment 
programmes 
Resource saved 
-Health care costs: costs of substitute prescribing, 
substance misuse hospital inpatient, residential 
rehabilitation, medical inpatient hospital, A&E, GP, 
psychiatric inpatient hospital, community 
psychiatric care and street agency 
-Criminal justice costs: costs of criminal justice  
system (shoplifting, burglary, robbery, fraud and  
drug offences) 
-Social care costs: costs of social care services 
 
Other value created 
-Victim costs 
 
Cost-benefit outcome 
-Average benefit-cost ratio is from 9.5:1 to 18:1 
Harris, Gospodarevskaya 
and Ritter, 2005, 
Australia 
139 heroin dependent 
patients 
Two groups: 
-Buprenorphine 
-Methadone 
Resource saved 
-Health care costs: costs of other prescription drugs, 
over-the-counter drugs, prescribe visits, inpatient 
hospital, outpatient and emergency services, 
ambulance, psychiatric counselling, Allied Health 
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and pathology 
-Criminal justice costs: costs of criminal activities 
(property crime, fraud, credit card fraud and violent 
crime) and police investigation 
 
Cost-benefit outcome 
-Total societal costs of buprenorphine group and 
methadone group are AUD16,614 and AUD10,131, 
respectively 
Hartz et al, 1999, USA 102 opioid-addicted 
patients 
Two groups: 
-Methadone treatment with  
contingency contracting 
-Methadone treatment  
(control group) 
Resource saved 
-Health care costs: costs of medications (analgesics, 
antibiotics, cardiac, cold/ respiratory, psychotropic 
and miscellaneous) and procedures (minor surgery, 
radiology, laboratory analysis), emergency room 
visit, outpatient visit and inpatient hospitalisation 
 
Cost-benefit outcome 
-Total health care resource use of treatment group 
and control group are $397.51 and $1329.69, 
respectively 
-Benefit-cost ratio is 4.87:1 between two groups 
Harwood et al, 1988 
(TOPS; Treatment 
Outcome Prospective 
Study), USA 
11,000 drug users from 
TOPS 
41 drug misuse treatment of 
outpatient methadone, 
residential and outpatient 
drug-free programme 
Resource saved 
-Criminal justice costs: costs of criminal justice 
system (police protection services, prosecution, 
adjudication, public defence and correction 
services) 
 
Other value created 
-Increased productivity: crime career/ productivity  
loss and legal earnings 
-Victim costs: medical services, property destruction 
and lost work and household productivity 
 
Cost-benefit outcome 
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-Benefit-cost ratio of residential treatment, 
methadone treatment and drug-free treatment are 
2.01, 0.92 and 4.28, respectively (benefits in 
reduced costs to society) 
-Benefit-cost ratio of residential treatment, 
methadone treatment and drug-free treatment are 
3.84, 4.04 and 1.28, respectively (benefits in 
reduced costs to law-abiding citizens) 
Healey et al, 1998, 
(NTORS), UK 
1,075 substance misuse 
patients 
Patient from 54 residential 
and community treatment 
programmes 
Resource saved 
-Health care costs: costs of general medical inpatient, 
psychiatric inpatient, A&E, GP visits, community 
mental health/ outpatient, drug dependency 
inpatient treatment, residential rehabilitation, 
methadone treatment provided in hospitals or by 
community drug teams or by GP, Alcoholics and 
Narcotics Anonymous and street agency 
-Criminal justice costs: costs of criminal justice  
system (burglary, robbery, shoplifting and vehicle  
theft, drug possession, drug supply, fraud, soliciting  
and other) 
-Social care costs: costs of social care services 
 
Other value created 
-Victim costs 
 
Cost-benefit outcome 
-Total societal cost is £12.2 million over 1 year and 
the average total societal cost is £11,404 per patient 
Koenig et al, 2005 
(PETS), USA 
595 substance misuse 
patients 
Substance misuse 
programme (methadone, 
residential rehabilitation, 
intensive overnight, 
outpatient) 
Resource saved 
-Health care costs: costs of doctor’s office visits, 
emergency room visit and psychiatric hospital 
-Criminal justice costs: police enforcement,  
adjudication, prosecution and corrections 
-Social care costs: costs of unemployment  
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compensation, government assistance, supplemental 
security income, disability pay and food stamps 
 
Other value created 
-Increased productivity: income 
-Victim costs 
 
Cost-benefit outcome 
-Average benefit-cost ratio of single treatment and 
multiple treatment admission at 30 month is 9.9 and 
2.9, respectively 
-Average benefit-cost ratio of the sample is 4.1 
Levine, Stoloff and 
Spruill, 1976, USA 
15,000 substance misuse 
patients 
45 public drug misuse 
treatment programmes 
Other value created 
-Victim costs of property crime 
 
Cost-benefit outcome 
-Benefits to victims of reduced crime is $129,430 per 
year 
Logan et al, 2004, USA 745 offenders Three groups of drug court 
programme: 
-Graduated clients 
-Terminated clients 
-Assessed clients 
Resource saved 
-Health care costs: costs of inpatient and outpatient 
mental health care and accidents 
-Criminal justice costs: costs of prison, jail, parole,  
probation, convictions, charges 
-Social care costs: costs of child support services 
 
Other value created 
-Increased productivity: income 
 
Cost-benefit outcome 
-Benefit-cost ratio at 12 months for graduated clients 
and terminated clients are 3.81 and 1.13, 
respectively 
-Average benefit-cost ratio at 12 months for all 
clients is 2.71 
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Longshore et al, 2006 
(SACPA; The California 
Substance Abuse and 
Crime Prevention Act), 
USA 
130,152 offenders Two groups: 
-Probation with drug misuse  
treatment 
-Incarceration/ probation  
without treatment 
Resource saved 
-Health care costs: costs of medical care services and 
addiction services 
-Criminal justice costs: costs of prison, jail, parole,  
probation, arrests and convictions 
 
Other value created 
-Increased productivity: income and sale taxes 
 
Cost-benefit outcome 
-First year of SACPA: average benefit-cost ratio at 
30 months is 2.44:1 
-Second year of SACPA: average benefit-cost ratio 
at 12 month is 2.3:1 
-Benefit-cost ratio of treatment completer at 30 
months is 4:1 
Mark et al, 2001, USA 600,000 heroin addicts Cost-of-illness of heroin 
dependence 
Resource saved 
-Health care costs: costs of general hospital inpatient 
and outpatient, emergency room, physician office, 
medical complications from heroin addiction 
(AIDS, tuberculosis, hepatitis B, hepatitis C, 
pregnancy problems), health insurance 
administration, heroin addiction treatment and 
specialty substance misuse facilities 
-Criminal justice costs: costs of incarceration,  
policing, legal 
-Social care costs: costs of social welfare costs 
 
Other value created 
-Increased productivity: productivity due to 
premature mortality and income 
-Victim costs 
 
Cost-benefit outcome 
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-Total societal costs is $21, 872 
Masson et al, 2002, USA 3,147 opioid dependent 
patients 
Two groups: 
-Opioid dependent patients 
-General patient population 
Resource saved 
-Health care costs: costs of ambulatory care visits, 
emergency department visits and inpatient 
admissions 
 
Cost-benefit outcome 
-Average health care resource use of opioid 
dependent patients and general patient population 
are $13,393 and $5,440, respectively 
Mauser, VanStelle and 
Moberg, 1994 (TAP; 
Treatment Alternative 
Program), USA 
25 patients Treatment alternative 
programmes 
Resource saved 
-Health care costs: costs of doctor visits,  
hospitalisation and psychologist 
-Criminal justice costs: costs of police services, jail, 
probation, parole and courts 
 
Other value created 
-Increased productivity 
-Victim costs (medical care expenses and property  
damage losses) 
 
Cost-benefit outcome 
-Average societal costs is from $58 to $81 at  
baseline, and from $47 to $50 at 6 months 
-Benefit-cost ratio is from 1.4:1 to 3.3:1 
McCollister et al, 2009, 
USA 
119 young       offenders 
aged 12 to 17 
Four groups: 
-Family court with  
community services (FC) 
-Drug court with community 
services (DC) 
-Drug court with evidence-
based treatment (DC/MST) 
-Drug court with evidence-
based treatment enhanced 
Resource saved 
-Criminal justice costs: costs of criminal activities 
(public disorder, theft and crimes against persons) 
and crime career costs 
 
Other value created 
-Victim costs and intangible costs associated with  
victims’ pain and suffering 
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with contingency 
management 
(DC/MST/CM) 
Cost-benefit outcome 
-Average total crime-related societal costs at  
baseline, 4 months and 12 months are $86,477,  
$67,444 and $54,099, respectively 
McGlothlin and Anglin, 
1981, USA 
187 substance misuse 
patients 
Two groups: 
-Patients from a closed down  
methadone treatment clinic 
(Bakersfield) 
-Patients from a continuing  
methadone treatment  
(Tulare) 
Resource saved 
-Criminal justice costs: costs of crime arrests, court 
processing, incarceration, legal supervision, 
property crime 
-Social care cost: costs of welfare income 
 
Cost-benefit outcome 
-Average societal costs of patients at Bakersfield 
before, during and after methadone are $120, $61  
and $52 per year, respectively 
-Average societal costs of patients at Tulare before,  
during and after methadone are $176, $82 and $56  
per year, respectively 
Miller and Hendrie, 2009, 
USA 
0.4-1.1 million young drug 
users aged 12 to 14 
Substance misuse prevention Resource saved 
-Health care costs: costs of speciality treatment and 
prevention services, treatment of medical 
consequences 
-Criminal justice costs: costs of criminal justice 
system and criminal activities 
-Social care costs: costs of education 
 
Other value created 
-Increased productivity: productivity loss due to  
premature death, illness related to substance or  
incarceration and criminal careers 
-Victim costs 
 
Cost-benefit outcome 
-Total societal costs is $151.4 billion 
-Benefit-cost ratio is from $7.7:1 to $36:1 
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Neale et al, 2006, UK 75 injecting drug users Patients recruited from 
existing needle exchange 
programmes in large city, 
small town, and medium 
town 
Monetary outcomes converted from Service Use 
Questionnaire (SUQ) 
 
Resource saved 
-Health care costs: costs of A&E, emergency 
ambulance, inpatient and patient hospital, day care, 
GP, practice nurse, CPN, NHS direct, NHS walk-in 
centre, prescription, psychologist, psychiatrist, 
methadone, addiction problem treatment in hospital, 
key worker, social worker, addiction residential 
treatment, after care hostel, other addiction 
treatment facility, street agency, needle exchange 
and addiction day programme 
-Criminal justice costs: costs of arrests, probation,  
magistrates court, crown court and prison 
-Social care costs: cost of benefit advisor, social  
worker, occupational therapist, citizens advice,  
RELATE, alternative medical practitioner, debt or  
legal advisor, homeless persons agency,  
employment advisor and other advice 
 
Cost-benefit outcome 
-Total resource use in Large city, small town and 
medium town are £6,299, £8,170 and £3,563 per 
patient, respectively 
Robertson, Grimes and 
Rogers, 2001, USA 
293 young offenders aged 
11 to 17 
Two groups: 
-Community-based intensive  
supervision and monitoring  
(ISM) 
-Cognitive behavioural 
intervention (CB) 
Resource saved 
-Criminal justice costs: costs of criminal justice 
systems 
 
Cost-benefit outcome 
-Average net benefit is $1,435 per offender at 18  
months 
-Benefit-cost ratio is 1.96 
Salome et al, 2003, USA 2,665 addiction patients Addiction treatment from 19 Monetary outcomes converted from ASI 
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treatment facilities  
Resource saved 
-Health care costs: costs of days experiencing 
medical problems, inpatient medical treatment, 
emergency room visits, clinic or physician visits, 
days experiencing psychological problems, 
inpatient and outpatient psychiatric treatments 
-Criminal justice costs: costs of criminal activities  
(drug offence, forgery, burglary, robbery, assault,  
arson, rape, homicide, prostitution, drug deal,  
illegal gambling, vehicle theft and receiving/ selling  
stolen property) 
 
Other value created 
-Increased productivity: income 
-Victim costs 
 
Cost-benefit outcome 
-Average net benefit is $6,325 
-Average benefit-cost ratio is 4.26 
Scanlon, 1976, USA 37,184 drug misuse 
patients 
Drug misuse treatment from 
6 facilities 
Resource saved 
-Health care costs: costs of opiate addiction and non-
opiate addiction 
-Social care costs: costs of welfare 
 
Other value created 
-Increased productivity: income 
 
Cost-benefit outcome 
-Average benefit-cost ratio is 17:1 
Sirotnik and Bailey, 
1975, USA 
285 heroin addicts 5 community drug misuse 
treatment programmes 
Resource saved 
-Health care costs: costs of health care services 
-Criminal justice costs: costs of arrests, court and 
incarceration 
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-Social care costs: costs of unemployment and  
welfare 
 
Other value created 
-Increased productivity: productivity loss 
 
Cost-benefit outcome 
-Net benefit is $3,359,919 
Sweeney et al, 2009, 
Australia 
393 IDUs Treatment for injecting-
related injuries and diseases 
Resource saved 
-Health care costs: costs of community based 
treatment, public hospital emergency departments, 
hospital admissions 
 
Cost-benefit outcome 
-Total health care resource use is between AUD 16.3 
million and AUD 27.6 million 
Tang et al, 2007, Taiwan 1,817 members of general 
public 
Drug misuse treatment Cost-benefit outcome 
-General public are willing to pay from NT$81 to  
NT$95 per month for a drug misuse treatment,  
while the benefits of the treatment are estimated  
around NT$12.8-15.0 billion 
Yu et al, 1991, USA 123 substance misuse 
patients 
Substance misuse treatment 
in workplaces 
Resource saved 
-Health care costs: costs of medical care services 
 
Cost-benefit outcome 
-Net benefits for patients with drug misuse and with 
alcohol and drug misuse are $1,097 and $95, 
respectively 
Zarkin, Cates and Bala, 
2000, USA 
393 members of general 
public 
Drug misuse treatment Cost-benefit outcome 
-General public are willing to pay $37.12 or $30.90  
when 100 or 500 drug users are successfully treated 
-General public are willing to pay $40.56 or $41.42 
when 100 or 500 women drug users are 
successfully treated 
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Appendix 5 Decision tree of drug testing in schools model 
 
Appendix 5.1 Decision tree of drug testing in schools model part 1 
□: decision node; ○: chance node; △: terminal node 
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Appendix 5.2 Decision tree of drug testing in schools model part 2 
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Appendix 5.3 Decision tree of drug testing in schools model part 3 
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